{
  "0": {
    "score": 3.0,
    "explanation": "3: The model answer provides a detailed and accurate mechanism for dopamine receptor agonists but does not directly identify the broader pharmacologic class \"adrenergic agonists\" as in the reference; it covers most key facts but misses the general class linkage."
  },
  "1": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant elaboration, and contains no inaccuracies or omissions. It appropriately emphasizes the risks, lack of benefit, and the primacy of supportive care in this scenario."
  },
  "2": {
    "score": 2.0,
    "explanation": "2: The model answer focuses on dopamine synthesis and iron’s role in neurotransmission, which is relevant to RLS but does not address the reference answer’s key point about electrolyte activity and neuronal/muscular excitability. It omits the direct physiologic process specified (electrolyte balance), constituting a moderate omission."
  },
  "3": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional explanations, and contains no inaccuracies or omissions."
  },
  "4": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies ergosterol binding and membrane disruption as the drug's mechanism, but does not specify inhibition of ergosterol synthesis as in the reference; this is a related but distinct process, covering most key facts but missing the precise molecular target."
  },
  "5": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly states that adjuvant radiotherapy is routinely indicated for all patients with R1/R2 margins regardless of prior chemotherapy, whereas the reference clarifies that its use is not routine and should be individualized; this is a moderate factual error, though the answer is otherwise detailed and relevant."
  },
  "6": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts but incorrectly asserts that radiological N3 alone is sufficient to define stage IIIB/C and guide treatment, whereas the reference emphasizes the necessity of pathological confirmation before upstaging and altering management. This represents a moderate factual inaccuracy regarding staging and treatment decision-making."
  },
  "7": {
    "score": 3.0,
    "explanation": "3: The model answer accurately describes the mechanism of pyrantel pamoate (nAChR agonism and depolarization), but the reference specifically requires cholinesterase inhibition as the primary mechanism. Thus, the model omits the key fact of cholinesterase inhibition and instead describes a different, though related, mechanism."
  },
  "8": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies the clinical context and mechanism of action but incorrectly names SSTR2 as the primary receptor, whereas the reference specifies somatostatin receptor type 5; the explanation is thorough but contains this moderate factual error."
  },
  "9": {
    "score": 4.0,
    "explanation": "4: The model answer covers nearly all key facts, correctly states that adjuvant systemic therapy is indicated regardless of age if comorbidities are well-compensated, and provides relevant detail on individualization and current evidence. However, it introduces nuanced recommendations about radiation and immunotherapy that, while accurate, slightly overcomplicate the reference's clear stance and could be seen as a minor omission in not stating as directly that age alone is not a contraindication."
  },
  "10": {
    "score": 2.0,
    "explanation": "2: The model answer provides plausible mechanisms (MMP inhibition, cytokine suppression, antimicrobial effects), but these are not definitively established and overstate the current scientific consensus; it omits the key fact that the precise molecular mechanism is not fully understood, which is central to the reference answer."
  },
  "11": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly states that selpercatinib or pralsetinib remain \"first-line\" after initial chemotherapy, which contradicts the reference answer and guidelines; while it provides relevant rationale and cites data, it misses the key point that these agents become subsequent-line therapy if chemotherapy was already started, constituting a moderate factual error."
  },
  "12": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies the IL-6 receptor as the target and provides accurate, relevant clinical context and mechanism, but does not specify the \"soluble interleukin-6 receptor subunit alpha (IL-6Rα)\" as precisely as the reference answer, representing a minor omission in specificity."
  },
  "13": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate, guideline-based rationale, and adds relevant, correct details without any inaccuracies or omissions."
  },
  "14": {
    "score": 2.0,
    "explanation": "2: The model answer covers the general rationale for adjuvant trastuzumab in HER2-positive, node-positive breast cancer but omits the key fact that metaplastic histology is an exception to standard recommendations; it incorrectly asserts that histology does not affect eligibility, which is a moderate factual error."
  },
  "15": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly asserts that EGFR status is irrelevant and that ceritinib can be used regardless of EGFR status, omitting the key fact that ALK inhibitor therapy presumes EGFR negativity; this is a moderate factual error, though the rest of the content is mostly accurate."
  },
  "16": {
    "score": 0.0,
    "explanation": "0: The model answer incorrectly identifies anticholinergic agents instead of serotonin antagonists as the relevant drug class, which is a major factual error and fails to address the key fact in the reference answer."
  },
  "17": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately details the surveillance intervals for both treatment modalities, and provides clinically relevant rationale for the differences, with no inaccuracies or omissions."
  },
  "18": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly identifies CYP3A4 instead of CYP2C8, which is the key enzyme induced by the relevant Nrf2-activating therapy (omaveloxolone) for Friedreich ataxia, not PKAN. While the explanation is detailed, it contains a moderate factual error regarding both the diagnosis and the pharmacologic target, covering less than 70% of key facts."
  },
  "19": {
    "score": 4.0,
    "explanation": "4: The model answer covers nearly all key facts, correctly noting that adjuvant chemo/trastuzumab is generally recommended for tumors 0.6–1.0 cm and may be considered for smaller tumors with high-risk features, but slightly overstates guideline support for routine use below 0.6 cm; the reference more clearly states that <0.6 cm is not routinely recommended, making this a minor wording inaccuracy."
  },
  "20": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, correctly identifies hydralazine, and accurately describes its mechanistic classification as having an incompletely understood molecular mechanism, matching the reference answer without inaccuracies or omissions."
  },
  "21": {
    "score": 3.0,
    "explanation": "3: The model answer provides a strong rationale for switching to ALK inhibitor therapy and cites guidelines, but it incorrectly states that immediate switch is the only standard, omitting that completing the current regimen is also guideline-endorsed; this is a moderate factual omission."
  },
  "22": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides additional correct and clinically relevant explanations, and cites guidelines without any inaccuracies or omissions."
  },
  "23": {
    "score": 4.0,
    "explanation": "4: The model answer covers over 90% of key facts, correctly prioritizing re-resection plus systemic therapy when feasible and noting chemoradiation as an alternative, with accurate references and rationale. However, it overstates the evidence for the superiority of re-resection over chemoradiation (the reference says there is no definitive evidence of superiority), which is a minor wording inaccuracy."
  },
  "24": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies lipoxygenases (specifically 5-LOX) as the enzyme class, accurately explains the leukotriene pathway, and provides relevant clinical context without inaccuracies or omissions."
  },
  "25": {
    "score": 3.0,
    "explanation": "3: The model answer provides a strong rationale for immediate initiation of crizotinib and includes relevant, up-to-date information, but it omits that both completing current therapy or switching are valid options and that the decision should be individualized; this is a moderate omission compared to the reference."
  },
  "26": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies DNA-dependent RNA polymerase as the molecular target, matching the reference answer with no omissions or inaccuracies."
  },
  "27": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the pharmacological class as organic nitrates (nitric oxide donors), thoroughly explains the mechanism, and provides relevant clinical context without inaccuracies or omissions."
  },
  "28": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately emphasizing that broad molecular profiling is not routinely indicated, PD-L1 testing is standard, and broader testing may be considered in select subgroups. Additional content is correct, clinically relevant, and there are no inaccuracies or omissions."
  },
  "29": {
    "score": 3.0,
    "explanation": "3: The model answer provides a detailed and accurate account of the proposed mechanism of nitroimidazoles, but it fails to emphasize that the precise molecular target is still unknown, as required by the reference; this constitutes a moderate omission."
  },
  "30": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, including the need for individual evaluation and staging of each lesion, the shift in management strategy, and the importance of distinguishing between synchronous primaries and metastases. Additional content is accurate and clinically relevant, with no omissions or inaccuracies."
  },
  "31": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains that amivantamab-vmjw use is not contingent on broad profiling, and provides additional clinically relevant context without inaccuracies or omissions."
  },
  "32": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the molecular target as the interleukin-6 receptor alpha subunit, explains the mechanism of action, and provides clinically relevant context without inaccuracies or omissions."
  },
  "33": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional detail, and contains no inaccuracies or omissions."
  },
  "34": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly states that adjuvant trastuzumab plus pertuzumab is required regardless of initial nodal status, whereas the reference specifies it is only required if the initial staging was node-positive; this is a moderate factual error, though the rest of the content is detailed and relevant."
  },
  "35": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key facts from the reference (mu-opioid receptor agonism), adds correct and clinically relevant mechanistic detail, and contains no inaccuracies or omissions."
  },
  "36": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant elaboration, and contains no inaccuracies or omissions."
  },
  "37": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly explains the restriction of the osimertinib/pemetrexed/platinum regimen to nonsquamous histology, emphasizes the appropriateness of osimertinib monotherapy, and provides accurate, relevant additional details without inaccuracies or omissions."
  },
  "38": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly states that the presence of other actionable driver mutations does not affect the indication for NTRK-targeted therapy, directly contradicting the key clinical fact that NTRK inhibitors are reserved for cases without other approved actionable mutations; while it provides some relevant background, this is a moderate factual error."
  },
  "39": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies VEGF as the primary molecular target and provides relevant clinical context and mechanism, but does not specify VEGF-A, which is the precise isoform referenced; this is a minor omission."
  },
  "40": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies the clinical context and the mechanism of glucocorticoids inhibiting PLA₂, but it does not directly name \"lipoxygenase inhibitors\" as the enzyme class targeted for anti-leukotriene effects, which is the specific focus of the reference answer. The explanation is accurate but misses the precise enzyme class required by the question."
  },
  "41": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the staging, surgical indications, and relevant considerations, with additional correct and clinically relevant details and no inaccuracies or omissions."
  },
  "42": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly identifies FXR as the primary target instead of PPAR-delta, which is the key fact in the reference. While the FXR mechanism is described accurately and is relevant to PBC, this represents a moderate factual error regarding the specific molecular target."
  },
  "43": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies papaverine and notes that its precise mechanism is incompletely understood, matching the reference. It provides accurate, relevant extra detail about possible mechanisms, but the explicit statement that the mechanism is \"unknown\" or \"not defined\" per current references is less direct than the reference, constituting a minor wording inaccuracy."
  },
  "44": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately identifies the mechanism (inhibition of PABA utilization via DHPS), and provides correct, relevant additional explanation without inaccuracies or omissions."
  },
  "45": {
    "score": 3.0,
    "explanation": "3: The model answer correctly includes the Fibroblast Growth Factor Receptor family but adds PDGFR and VEGFR, which, while factually correct for nintedanib, are not asked for in the question and may distract from the reference answer's focus; the key fact (FGFR) is present, but the answer is less concise and focused than required."
  },
  "46": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, including alectinib's superiority over crizotinib in CNS efficacy and overall outcomes, and provides additional, accurate, and clinically relevant details from guidelines and clinical trials without any inaccuracies or omissions."
  },
  "47": {
    "score": 4.0,
    "explanation": "4: The model answer covers all key steps in the glucocorticoid mechanism, including annexin-1 induction, PLA₂ inhibition, and reduced leukotriene synthesis, but does not directly state \"inhibition of lipoxygenase pathways\" as in the reference; this is a minor omission in wording, though the mechanistic pathway is clearly described."
  },
  "48": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the serotonin (5-HT₂C) receptor as the primary target, thoroughly explains the mechanism, and provides relevant clinical context without inaccuracies or omissions."
  },
  "49": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies competitive inhibition as the class of enzyme inhibition and explains the clinical context and mechanism, but it does not specifically name \"cytochrome P450 17A1 inhibitors\" as required by the reference answer, and instead focuses on the general mechanism and multiple CYP enzymes, which is less precise than the reference."
  },
  "50": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies that SERMs are not always required, and explains that cytotoxic chemotherapy is indicated in visceral crisis. It provides additional, accurate, and clinically relevant detail about current preferred regimens (CDK4/6 inhibitor + AI + OFS), without any inaccuracies or omissions."
  },
  "51": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies the dual serotonin-norepinephrine reuptake inhibition mechanism and provides relevant clinical context, but the reference answer focuses specifically on serotonin uptake inhibitors, and the model's emphasis on SNRIs introduces ambiguity and minor inaccuracy regarding the most accurate pharmacologic class for the described mechanism."
  },
  "52": {
    "score": 3.0,
    "explanation": "3: The model answer provides a detailed and accurate description of metronidazole’s known actions but does not directly state that the mechanism is \"unknown cellular or molecular interaction\" as required; instead, it classifies the mechanism as \"cytotoxic,\" which, while informative, does not fully align with the reference answer’s emphasis on the mechanism being unknown."
  },
  "53": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies CYP3A4 induction as the mechanism, explains the pharmacokinetic effect on contraceptive hormones, and provides relevant clinical context without inaccuracies or omissions."
  },
  "54": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional details, and contains no inaccuracies or omissions."
  },
  "55": {
    "score": 1.0,
    "explanation": "1: The model answer directly contradicts the reference by recommending immediate initiation of alectinib rather than completing current systemic therapy, which is a major inaccuracy and could lead to inappropriate clinical management."
  },
  "56": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains that prior multifocality or ineligibility for local therapy does not preclude concurrent chemoradiation, and provides relevant, correct additional details without any inaccuracies or omissions."
  },
  "57": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies disruption of disulfide bonds as the principal pharmacodynamic effect, thoroughly explains the mechanism, and accurately distinguishes this from secondary antioxidant effects, fully matching the reference answer with no errors or omissions."
  },
  "58": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies the mechanism (50S ribosomal binding, inhibition of translocation), the clinical context (Legionella), and the specific class (macrolides), which is a more specific subset of the reference answer (\"protein synthesis inhibitors\"). The only minor omission is not explicitly stating the broader class, but all key facts are present and correct."
  },
  "59": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional detail, and contains no inaccuracies or omissions."
  },
  "60": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately clarifies that palliative chemotherapy does not assume absence of metastases, and provides relevant, correct elaboration on the necessity and implications of staging imaging, with no inaccuracies or omissions."
  },
  "61": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate, guideline-based rationale, and includes relevant, correct additional details without any inaccuracies or omissions."
  },
  "62": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately prioritizing systemic therapy, appropriately discussing the role of local therapy for brain and thoracic lesions, and providing relevant, guideline-based rationale without inaccuracies or omissions."
  },
  "63": {
    "score": 3.0,
    "explanation": "3: The model answer overstates the routine indication for adjuvant chemotherapy with trastuzumab in T1bN0 HER2+ tumors, whereas guidelines suggest it may be considered but is not universally recommended; this represents a moderate factual inaccuracy, though most key facts are otherwise covered."
  },
  "64": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant guideline citations, and offers additional correct rationale without any inaccuracies or omissions."
  },
  "65": {
    "score": 1.0,
    "explanation": "1: The model answer directly contradicts the reference by recommending immediate switch to EGFR TKI and dismissing maintenance therapy, which is not standard for squamous histology and disregards the reference's emphasis on completing planned systemic therapy before targeted therapy; this is a major inaccuracy with potentially unsafe implications."
  },
  "66": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately states that adjuvant radiotherapy is an acceptable alternative with category 2B evidence, and provides additional relevant, correct, and detailed information without inaccuracies or omissions."
  },
  "67": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately prioritizing fam-trastuzumab deruxtecan-nxki and correctly positioning ado-trastuzumab emtansine as an alternative; additional details are factually correct and clinically relevant, with no inaccuracies or omissions."
  },
  "68": {
    "score": 4.0,
    "explanation": "4: The model answer covers nearly all key facts, correctly identifying CD20 targeting, B-cell depletion, and the inhibition of B-cell-mediated antigen presentation, with accurate mechanistic and clinical context. However, it does not explicitly mention \"antibody-dependent cytotoxicity\" (ADCC) as the direct effector mechanism, which is a minor omission."
  },
  "69": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key facts from the reference, accurately emphasizes the mechanism is unknown, and provides clinically relevant, correct additional context without inaccuracies or omissions."
  },
  "70": {
    "score": 2.0,
    "explanation": "2: The model answer focuses on P-glycoprotein (P-gp) inhibitors and HCV protease inhibitors, missing the key fact that BCRP (not P-gp) inhibition by NS5A inhibitors like velpatasvir is the principal concern in this context; this is a moderate factual omission."
  },
  "71": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies interleukin-1β as the target, provides accurate clinical context, explains the mechanism of action, and distinguishes from other cytokines, fully matching the reference answer with no errors or omissions."
  },
  "72": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly emphasizes the need for more intensive surveillance due to positive margins, and provides evidence-based recommendations without inaccuracies or omissions."
  },
  "73": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale for comprehensive molecular profiling, addresses guideline requirements, and highlights the clinical implications of co-occurring alterations, with no inaccuracies or omissions."
  },
  "74": {
    "score": 3.0,
    "explanation": "3: The model answer covers the mechanism of fluoroquinolones and mentions both DNA gyrase and topoisomerase IV, but the reference specifically asks for the directly inhibited enzyme in S. pneumoniae, which is topoisomerase IV; listing both is a minor inaccuracy in this context."
  },
  "75": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies benzimidazole therapy and discusses hepatic enzyme induction, but incorrectly states that CYP3A4 is the primary enzyme induced, whereas the reference specifies CYP1A. The explanation is detailed but contains a moderate factual error regarding the main enzyme class, covering about 70-89% of key facts."
  },
  "76": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately lists required mutations, emphasizes the necessity of broad profiling regardless of prior radiotherapy, and provides correct, clinically relevant elaboration without inaccuracies or omissions."
  },
  "77": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional detail, and contains no inaccuracies or omissions."
  },
  "78": {
    "score": 2.0,
    "explanation": "2: The model answer provides a detailed and accurate mechanism for oral vancomycin, but the reference answer states that the precise mechanism (for metronidazole) is not clearly defined; thus, the model answer addresses the wrong drug and does not align with the reference, constituting a moderate factual error and significant omission."
  },
  "79": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies cyclooxygenase (COX) as the molecular target and accurately describes its role in prostaglandin synthesis and inflammation, but it does not specify COX-2 (prostaglandin G/H synthase 2) as in the reference answer, representing a minor omission."
  },
  "80": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides correct and clinically relevant additional detail, and contains no inaccuracies or omissions."
  },
  "81": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly prioritizing bisphosphonate/denosumab in asymptomatic, non-impending fracture cases, and accurately defers radiotherapy to symptomatic or high-risk situations; all additional content is factually correct and clinically relevant."
  },
  "82": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly identifies the primary mechanism as direct muscarinic agonism (pilocarpine), whereas the question describes a cholinesterase inhibitor (e.g., physostigmine); this is a moderate factual error, though the explanation is otherwise relevant."
  },
  "83": {
    "score": 3.0,
    "explanation": "3: The model answer provides a plausible agent (gentian violet) and discusses its possible mechanisms, but the reference answer emphasizes that the mechanism is unknown; thus, the model overstates current knowledge and does not align with the reference's key point, covering about 70-89% of the required facts."
  },
  "84": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides correct and clinically relevant rationale, and includes no inaccuracies or omissions. Additional details are accurate and enhance understanding."
  },
  "85": {
    "score": 4.0,
    "explanation": "4: The answer correctly identifies enzyme inhibition as the key mechanism and provides accurate, relevant details about microtubule inhibition and metabolic disruption, but includes some extraneous detail about drug classes and alternative therapies that, while correct, is not strictly necessary; there are no major omissions or inaccuracies."
  },
  "86": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate, guideline-based rationale, and includes relevant, correct additional details without any inaccuracies or omissions."
  },
  "87": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies the drug class as \"interleukin-1 (IL-1) inhibitors\" and provides accurate, relevant clinical reasoning, but it does not use the more specific term \"interleukin 1 receptor antagonists\" as in the reference; this is a minor wording inaccuracy that does not alter the clinical meaning."
  },
  "88": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides additional clinically relevant detail about SABR's advantages, limitations, and considerations in restrictive lung disease, and contains no inaccuracies or omissions."
  },
  "89": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the insulin receptor as the molecular target, provides accurate and clinically relevant mechanistic details, and appropriately contrasts with other agents; there are no omissions or inaccuracies."
  },
  "90": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional details, and contains no inaccuracies or omissions."
  },
  "91": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides additional correct and clinically relevant details, and contains no inaccuracies or omissions."
  },
  "92": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, correctly identifies direct ROS scavenging as the most relevant property, and provides accurate, clinically relevant explanations without any inaccuracies or omissions."
  },
  "93": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies the mechanism as antimetabolites and thoroughly explains methotrexate’s action, which is factually accurate and clinically relevant. However, it does not explicitly use the broader class term \"nucleic acid synthesis inhibitors\" as in the reference, which is a minor wording inaccuracy."
  },
  "94": {
    "score": 3.0,
    "explanation": "3: The model answer covers the mechanism described but incorrectly identifies \"interferons\" as the class, rather than the broader and correct \"biological response modifiers\" per the reference. It provides relevant mechanistic reasoning but misses the key fact of the correct class, constituting a moderate factual error."
  },
  "95": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate staging details, and offers clinically relevant explanations without any inaccuracies or omissions."
  },
  "96": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly stating that surgery is appropriate for N0–1 but not for N2 disease, which shifts management to chemoradiation. Additional content is accurate, relevant, and expands on guidelines and evidence without introducing errors or omissions."
  },
  "97": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies the activin type II receptor (ActRIIA/IIB) as the target and provides accurate, relevant mechanistic and clinical context, but does not specify ACVR2A by gene/protein name as in the reference, which is a minor omission."
  },
  "98": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately identifies the pharmacologic class and mechanism, and provides additional correct and clinically relevant details without any inaccuracies or omissions."
  },
  "99": {
    "score": 4.0,
    "explanation": "4: The model answer covers all key clinical facts, accurately emphasizing that systemic therapy is generally not recommended but not categorically excluded, and details the rare circumstances where single-agent chemotherapy may be considered. It provides correct, relevant elaboration without inaccuracies, but is slightly more expansive than necessary, which could be seen as a minor deviation from the concise reference answer."
  },
  "100": {
    "score": 4.0,
    "explanation": "4: The model answer covers nearly all key facts, correctly emphasizing passive transfer of neutralizing antibodies and mentioning Fc-mediated effects (ADCC, complement), but does not explicitly mention \"modulation of immune responses via Fc receptor engagement\" as in the reference; otherwise, it is thorough and accurate."
  },
  "101": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional detail, and contains no inaccuracies or omissions."
  },
  "102": {
    "score": 3.0,
    "explanation": "3: The model answer provides a detailed and mostly accurate explanation of the clinical context and mechanism, but it does not use the reference term \"Enzyme Activators\" and instead introduces \"Coagulation Cascade Cofactor Therapy,\" which, while related, is not the standard general pharmacological class asked for. This represents a moderate omission in terminology, though the mechanistic explanation is otherwise correct."
  },
  "103": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the demulcent/barrier-forming property, and provides relevant, correct mechanistic detail without inaccuracies or omissions."
  },
  "104": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant elaboration, and contains no inaccuracies or omissions."
  },
  "105": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies the drug class as TNF inhibitors and provides accurate, relevant details about mechanism, subclass, and examples, but it omits the broader class term \"Biological Response Modifiers\" used in the reference, which is a minor omission."
  },
  "106": {
    "score": 3.0,
    "explanation": "3: The model answer accurately identifies the drug, its binding site, and describes the known aspects of its mechanism, but it does not explicitly state that the full cellular or molecular interaction is unknown or incompletely characterized, which is the key fact in the reference answer."
  },
  "107": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, including eligibility for BRAF-targeted therapy regardless of prior radiotherapy or palliative needs, addresses toxicity concerns, and emphasizes integration with palliative care; all additional content is accurate and clinically relevant."
  },
  "108": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, including prioritization of brain metastasis treatment, rationale for neurological urgency, and subsequent thoracic management. Additional content is accurate, relevant, and evidence-based, with no inaccuracies or omissions."
  },
  "109": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately stating that the surveillance protocol does not change with adjuvant radiotherapy and providing correct, relevant guideline-based rationale without any inaccuracies or omissions."
  },
  "110": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional detail, and contains no inaccuracies or omissions."
  },
  "111": {
    "score": 4.0,
    "explanation": "4: The model answer covers nearly all key facts, correctly explaining that classifying as two primaries leads to curative-intent treatment for each lesion if feasible, and clarifies the distinction from metastatic disease; however, the initial \"No\" is somewhat misleading and could cause confusion, representing a minor wording inaccuracy."
  },
  "112": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale for endocrine therapy, and provides relevant, correct elaboration without any inaccuracies or omissions."
  },
  "113": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies the biological contradiction, and provides accurate, guideline-based recommendations for both HER2-positive and triple-negative scenarios, with no inaccuracies or omissions."
  },
  "114": {
    "score": 1.0,
    "explanation": "1: The model answer directly contradicts the reference by stating that imaging alone is sufficient for stage III-specific treatment, which is a major inaccuracy and could lead to inappropriate management; this is a clinically unsafe recommendation."
  },
  "115": {
    "score": 2.0,
    "explanation": "2: The answer incorrectly identifies IL-8 receptor antagonism as the primary mechanism, which is not established for sulfasalazine; it omits the key fact that the drug acts by inhibiting PABA utilization in folate synthesis, as required by the reference. While some relevant context is provided, the main mechanism is inaccurately described."
  },
  "116": {
    "score": 2.0,
    "explanation": "2: The model answer provides a detailed and accurate summary of the proposed mechanisms of ursodeoxycholic acid, but it does not align with the reference answer, which emphasizes that the cellular or molecular interaction is unknown; thus, the model overreaches by presenting speculative mechanisms rather than focusing on the lack of established knowledge."
  },
  "117": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly states that adjuvant chemotherapy is routinely required for all resected stage IIA (T2bN0) NSCLC patients, omitting that observation alone is an appropriate option per guidelines; this is a moderate factual error, though the answer is otherwise detailed and not unsafe."
  },
  "118": {
    "score": 2.0,
    "explanation": "2: The model answer provides a thorough and accurate explanation of imiquimod’s mechanism (TLR7 agonism), but it does not identify RNA replicase as the most directly inhibited molecular target, which is the key fact in the reference answer; thus, it omits the required direct molecular target and focuses on the drug’s immune modulation rather than viral replication machinery."
  },
  "119": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies tetracyclines as the class and provides accurate mechanistic and clinical context, but it omits the broader pharmacologic class \"protein synthesis inhibitors\" specified in the reference answer, which is a key fact."
  },
  "120": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately lists relevant high-risk features, and provides additional correct, clinically relevant context from guidelines and evidence without any inaccuracies or omissions."
  },
  "121": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts and emphasizes the importance of exhausting non-invasive and invasive staging, but it incorrectly states that it is acceptable to proceed with treatment based solely on imaging if biopsy is infeasible, which contradicts the reference's insistence on pathological confirmation and may lead to over-treatment; this represents a moderate omission."
  },
  "122": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly states that ROS1-targeted therapy is recommended regardless of squamous histology, contradicting current guidelines that generally exclude squamous histology except in rare, well-validated cases. While it provides supporting evidence and rationale, it omits the key fact that squamous histology is typically an exclusion criterion, representing a moderate factual error."
  },
  "123": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies the specific class (beta-lactam antibiotics) and provides accurate, relevant mechanistic and clinical context, but it does not directly answer the general pharmacological class asked for in the question (\"enzyme inhibitors\"), omitting the broader classification required by the reference answer."
  },
  "124": {
    "score": 3.0,
    "explanation": "3: The model answer provides a detailed and accurate explanation of nintedanib’s mechanism and clinical use, but it does not directly name \"protein kinase inhibitors\" as the drug class responsible for inhibiting fibrotic remodeling, which is the key fact in the reference answer; instead, it emphasizes \"antifibrotic agents,\" which is a therapeutic category, not the mechanistic drug class asked for."
  },
  "125": {
    "score": 3.0,
    "explanation": "3: The model answer accurately describes the genomic actions of vitamin A via retinoic acid receptors and their relevance to epithelial integrity, but it omits the key reference fact—antioxidant (free radical scavenging) activity—thus missing the primary mechanism requested."
  },
  "126": {
    "score": 3.0,
    "explanation": "3: The model answer covers the uncertainty of the exact mechanism and notes the lack of a single defined target, but it overemphasizes amiodarone’s multi-class actions rather than directly stating the mechanism is unknown, as in the reference; this introduces minor inaccuracy and partial omission of the key fact."
  },
  "127": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies the specific class (beta-lactam antibiotics) and provides accurate, relevant reasoning, but it omits the broader pharmacological class \"enzyme inhibitors\" as specified in the reference answer, thus missing a key fact."
  },
  "128": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides detailed, up-to-date evidence (including LAURA and PACIFIC trial data), and clearly explains why osimertinib is preferred over durvalumab in this setting, with no inaccuracies or omissions."
  },
  "129": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies that surveillance frequency differs between stage II and stage III NSCLC, provides accurate NCCN guideline details for both, and clearly explains the rationale for the difference; all key clinical facts from the reference are included with no inaccuracies or omissions."
  },
  "130": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies \"inhibition of protein synthesis\" as the broad pharmacological mechanism, covers all key clinical facts, and provides accurate, relevant explanations without any errors or omissions."
  },
  "131": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key facts from the reference, clearly stating that the precise cellular or molecular mechanism is unknown, while accurately describing the current understanding of cyclobenzaprine’s central actions and their relevance to symptom relief in inflammatory myopathies, with no inaccuracies or omissions."
  },
  "132": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, correctly identifies topoisomerase IV as the primary target for decatenation, and provides accurate, relevant mechanistic details without any inaccuracies or omissions."
  },
  "133": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly recommends annual surveillance rather than the guideline-supported 3–6 month interval for the first 3 years, omitting the key fact that more frequent imaging is standard in this period; while the rationale is well-argued and evidence-based, this represents a moderate factual error."
  },
  "134": {
    "score": 3.0,
    "explanation": "3: The answer correctly identifies PDE5 as the molecular target and explains its role in cGMP hydrolysis, but introduces \"cimicoxib\" (which is not a standard NSAID for humans and is not known for PDE5 inhibition), and overstates the clinical relevance of PDE5 inhibition in osteoarthritis, which is not established; these inaccuracies and overextensions lower the score."
  },
  "135": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate, guideline-based rationale, and adds relevant supporting evidence without inaccuracies or irrelevant content."
  },
  "136": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale, cites relevant trials, and provides correct, clinically relevant additional detail without any inaccuracies or omissions."
  },
  "137": {
    "score": 5.0,
    "explanation": "5: The model answer accurately identifies D2 dopamine receptor antagonism as the key mechanism, thoroughly explains the CTZ's role, and correctly distinguishes it from other antiemetic classes, with no inaccuracies or omissions."
  },
  "138": {
    "score": 3.0,
    "explanation": "3: The model answer provides a detailed and accurate explanation of EGFR as a molecular target in actinic keratosis, but it does not identify HER2/neu (erbB-2), which is the specific receptor named in the reference answer; thus, it omits the key fact required for full credit."
  },
  "139": {
    "score": 3.0,
    "explanation": "3: The model answer correctly explains the downstream effects of ACTH (increased cortisol and its immunosuppressive actions) but omits the key fact that the primary pharmacological mechanism is direct agonism of the ACTH (pituitary hormone) receptor; thus, it covers the majority but not all key facts."
  },
  "140": {
    "score": 1.0,
    "explanation": "1: The model answer directly contradicts the reference by recommending immediate initiation of targeted therapy rather than completing planned systemic therapy first, which is a major inaccuracy and could lead to inappropriate clinical management."
  },
  "141": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly identifies TNF-α as the molecular target, whereas the reference specifies interleukin-1 beta; while the explanation is detailed and relevant to JIA management, this constitutes a moderate factual error regarding the specific cytokine inhibited."
  },
  "142": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies the drug (hydroxyurea), its mechanism (ribonucleotide reductase inhibition), and its effect, and classifies it as an antimetabolite, which is accurate. However, the reference answer uses the broader and more precise class \"nucleic acid synthesis inhibitors,\" which is more directly tied to the mechanism described; \"antimetabolite\" is correct but less specific, representing a minor wording inaccuracy."
  },
  "143": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, including the rationale for preferring osimertinib, relevant trial data (PACIFIC and LAURA), and the lack of benefit and potential risks of durvalumab in EGFR-mutant patients, with no inaccuracies or omissions."
  },
  "144": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the drug class as thyroid hormone receptor beta agonists, explains the nuclear receptor mechanism, details the effects on hepatic fatty acid oxidation and lipogenesis, and appropriately distinguishes from other classes; all key clinical facts are covered with no inaccuracies or omissions."
  },
  "145": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies beta-lactam antibiotics as the class and thoroughly explains their mechanism, but it does not explicitly state \"enzyme inhibitors\" as requested by the reference answer, missing the key classification term. The rest of the content is accurate and relevant."
  },
  "146": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale, references supporting evidence and guidelines, and contains no inaccuracies or omissions."
  },
  "147": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts, including indications for SRS and surgery, but equivocates on SRS use in mildly symptomatic patients, whereas the reference clearly states surgery is preferred if symptoms are present. The model's nuanced approach introduces ambiguity and does not fully align with the reference's clear recommendation, constituting a minor but clinically relevant omission."
  },
  "148": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, correctly identifies the drug class as DNA polymerase inhibitors, explains the mechanism, and provides relevant additional details without inaccuracies or omissions."
  },
  "149": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts, correctly explaining the staging and the distinction between metastatic disease and synchronous primaries, and appropriately discusses aggressive treatment for oligometastatic disease. However, it incorrectly states that it is \"not appropriate\" to treat the lesions as distinct primaries without acknowledging that, in practice, if both are potentially curable, they may be managed as separate primaries, as per the reference answer—this is a moderate omission."
  },
  "150": {
    "score": 2.0,
    "explanation": "2: The model answer contradicts the reference by stating it is reasonable to proceed with SRS without pathologic confirmation, whereas the reference emphasizes the necessity of biopsy whenever feasible. While the model provides relevant caveats and guideline citations, it omits the key fact that pathologic confirmation is generally required before definitive local therapy, constituting a moderate omission."
  },
  "151": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional explanations, and contains no inaccuracies or omissions."
  },
  "152": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides a detailed and accurate molecular mechanism, and includes only relevant, correct additional information without any inaccuracies or omissions."
  },
  "153": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately prioritizing immediate SVC stenting for symptomatic obstruction, explaining the rationale, and noting that chemoradiation should follow; all additional details are correct and clinically relevant."
  },
  "154": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies dopamine partial agonists (specifically aripiprazole) and explains their action as partial agonists at postsynaptic dopamine D₂ receptors, covering the key mechanism. However, it introduces more detail than required and slightly overcomplicates the mechanism, but there are no clinically significant errors or omissions."
  },
  "155": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately contrasts surveillance schedules, provides rationale, and cites relevant guidelines without inaccuracies or omissions."
  },
  "156": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies cyclooxygenase (COX) as the primary target and provides accurate, relevant clinical context, but does not specify the COX-2 isoform (prostaglandin G/H synthase 2) as in the reference answer, representing a minor omission."
  },
  "157": {
    "score": 1.0,
    "explanation": "1: The model answer incorrectly asserts significant differences in surveillance protocols, including more intensive imaging and use of PET-CT and brain MRI, which is not supported by guidelines; this constitutes a major inaccuracy and could lead to confusion or inappropriate management."
  },
  "158": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides additional relevant and accurate detail, and contains no inaccuracies or omissions."
  },
  "159": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the glucocorticoid receptor as the molecular target, covers all key clinical facts, and provides relevant, accurate additional context without any inaccuracies or omissions."
  },
  "160": {
    "score": 1.0,
    "explanation": "1: The model answer incorrectly states that EGFR TKI therapy is not appropriate in the presence of a concurrent KRAS mutation, directly contradicting guidelines and the reference answer; it also provides detailed but misleading rationale, constituting a major inaccuracy."
  },
  "161": {
    "score": 4.0,
    "explanation": "4: The model answer covers nearly all key facts, correctly identifies the supplement's role in the extracellular matrix, and provides relevant mechanistic detail, but uses \"incorporation into the extracellular matrix\" rather than the broader \"biological macromolecular activity\" as the principal category, which is a minor wording inaccuracy."
  },
  "162": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional details (including specific drugs, guideline recommendations, and rationale), and contains no inaccuracies or omissions."
  },
  "163": {
    "score": 2.0,
    "explanation": "2: The model answer covers some relevant considerations about the need for comprehensive molecular profiling and alternative actionable mutations, but it incorrectly states that amivantamab-lazertinib is not appropriate without full profiling, which contradicts the reference answer and current approvals. This represents a moderate factual error and omits the key fact that confirmed EGFR mutation alone is sufficient for this therapy."
  },
  "164": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale, and provides relevant, up-to-date guideline and trial support. There are no inaccuracies or omissions."
  },
  "165": {
    "score": 3.0,
    "explanation": "3: The model answer provides a detailed and accurate description of bismuth’s urease inhibition and additional actions, but it omits the key reference point of acid-base modulation and mucosal protection as the primary mechanism, instead emphasizing urease inhibition, which is less central per the reference."
  },
  "166": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies the clinical context and mechanism of nintedanib, but incorrectly names PDGFR as the receptor whose inhibition directly reduces fibroblast activity, whereas the reference specifies VEGFR; otherwise, the explanation is accurate and relevant."
  },
  "167": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly states that chemotherapy is indicated for a recurrence score of 25, whereas guidelines and the reference answer specify that chemotherapy is generally not recommended below a score of 26; this is a moderate factual error, despite the otherwise thorough and relevant discussion."
  },
  "168": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies COX-2 as the primary molecular target, accurately explains the mechanism, rationale for switching, and clinical relevance, with no inaccuracies or omissions."
  },
  "169": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional explanations, and contains no inaccuracies or omissions."
  },
  "170": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the sufficiency of low-dose non-contrast CT for surveillance, addresses guideline support, CKD contraindication, and practical considerations, with no inaccuracies or omissions."
  },
  "171": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional details (trial data, regimen options, contraindications), and clearly justifies regimen selection without any inaccuracies or omissions."
  },
  "172": {
    "score": 2.0,
    "explanation": "2: The model answer identifies the IL-22 receptor complex instead of the interferon alpha receptor complex, which is a moderate factual error; while the mechanistic reasoning is detailed and relevant, it does not address the specific target named in the reference answer."
  },
  "173": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, adds accurate and clinically relevant detail regarding patient selection, guidelines, and supporting evidence, and contains no inaccuracies or omissions."
  },
  "174": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate, clinically relevant additional details (guideline citations, efficacy data, safety, and practical considerations), and contains no inaccuracies or omissions."
  },
  "175": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly recommends immediate transition to afatinib without completing the current systemic therapy, which contradicts the reference's standard approach of finishing the planned regimen first; while the answer is detailed and evidence-based, this represents a moderate factual error regarding sequencing, despite otherwise relevant and accurate content."
  },
  "176": {
    "score": 1.0,
    "explanation": "1: The model answer incorrectly states that contrast-enhanced brain MRI is mandatory despite renal impairment, contradicting the reference, which allows for non-contrast MRI or CT if contrast is contraindicated. This is a major inaccuracy that could lead to unsafe recommendations."
  },
  "177": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies cyclooxygenase (COX) as the inhibited enzyme and explains its role in prostaglandin synthesis and uric acid handling, but does not specify the COX-2 isoform (prostaglandin G/H synthase 2) as in the reference, which is a minor omission."
  },
  "178": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly states that broad molecular profiling is indicated regardless of squamous histology, and provides accurate, relevant guideline-based rationale without any inaccuracies or omissions."
  },
  "179": {
    "score": 4.0,
    "explanation": "4: The model answer correctly explains that a separate pulmonary nodule in the same lobe is classified as T3 and that T3N0M0 is stage IIB, with clear reference to AJCC guidelines and distinctions between lobe locations. However, it omits that T3 with N1 disease would be stage IIIA, a minor omission given the question's focus on N0, so a score of 4 is appropriate."
  },
  "180": {
    "score": 2.0,
    "explanation": "2: The model answer covers some relevant considerations and guideline nuances but omits the key fact that 21-gene RT-PCR testing is strongly recommended for ER-positive, HER2-negative, node-negative tumors >0.5 cm in premenopausal women, as per major guidelines; it incorrectly downplays the recommendation strength and introduces ambiguity not present in the reference."
  },
  "181": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly identifies phospholipase A₂ inhibitors as the most direct class, whereas the reference specifies lipoxygenase inhibitors; while the mechanistic explanation is detailed and mostly accurate, it omits the key fact required by the question and thus contains a moderate factual error."
  },
  "182": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly emphasizes that HER2-positive status in cT1cN0 tumors justifies neoadjuvant therapy, and provides additional accurate, relevant explanations and guideline references without inaccuracies or omissions."
  },
  "183": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant elaboration, and contains no inaccuracies or omissions."
  },
  "184": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies botulinum toxin and its mechanism but does not explicitly use the drug class \"acetylcholine release inhibitors\" as in the reference; it instead uses \"neurotoxins,\" which is less specific. The explanation is accurate and relevant but misses the precise terminology required."
  },
  "185": {
    "score": 2.0,
    "explanation": "2: The model answer provides a detailed and plausible mechanism (AhR activation), but fails to emphasize that the precise molecular mechanism is unknown, which is the key fact in the reference answer; this is a moderate omission."
  },
  "186": {
    "score": 2.0,
    "explanation": "2: The model answer provides a detailed and accurate description of chlorhexidine’s known antibacterial mechanisms, but it fails to directly address the reference answer’s key point—that the precise cellular or molecular interaction in periodontal disease management is unknown. This constitutes a moderate omission relative to the question’s focus."
  },
  "187": {
    "score": 2.0,
    "explanation": "2: The model answer focuses on JAK1/JAK2 as the primary molecular target, rather than VEGF-A, which is the key fact in the reference answer. While it provides relevant mechanistic context, it omits the direct identification of VEGF-A as the main mediator of anti-angiogenic effects, constituting a moderate factual omission."
  },
  "188": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies the mechanism as inhibition of transpeptidase enzymes (penicillin-binding proteins), which matches the reference answer, and provides accurate, relevant clinical context. However, the final answer given is \"Beta-lactam antibiotics\" rather than the precise class of molecular action, \"Transpeptidase inhibitors,\" representing a minor wording inaccuracy."
  },
  "189": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale, cites guidelines, and adds relevant, correct details about mutation frequency, clinical impact, and PD-L1 testing, with no inaccuracies or omissions."
  },
  "190": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies medium-chain triglycerides and their absorption pathway, naming fatty acid transporters and relevant mechanisms, but it omits the key fact that the structural macromolecules (cellular membrane components) themselves are the direct molecular targets, as specified in the reference. The focus on transporters is accurate but not as directly aligned with the reference answer’s emphasis."
  },
  "191": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies AR-V7 as the relevant target and provides accurate, detailed mechanistic context, but it does not mention AR-V3, which is the specific variant in the reference answer; this constitutes a minor omission, as AR-V7 is the more clinically recognized variant but not the one specified in the reference."
  },
  "192": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies tubulin as the principal pharmacologic target, provides accurate and clinically relevant context about FMF and colchicine’s mechanism, and contains no inaccuracies or omissions."
  },
  "193": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately stating that concurrent chemoradiation is appropriate and re-resection is not mandatory, while providing relevant guideline-based details and rationale without any inaccuracies or omissions."
  },
  "194": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly states that omission of further axillary surgery is appropriate after mastectomy if axillary radiotherapy is planned, and that this is not limited to breast-conserving surgery; all additional content is accurate, relevant, and well-supported by evidence and guidelines."
  },
  "195": {
    "score": 2.0,
    "explanation": "2: The model answer does not mention free radical scavenging or neutralization of reactive oxygen species, which is the key mechanism in the reference. Instead, it focuses on HIF-1α suppression, which is not the primary or most clinically relevant molecular mechanism in this context. While the explanation is detailed and not unsafe, it omits the main fact required."
  },
  "196": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies topoisomerase IV as the principal target, explains its role in decatenation, accurately describes the mechanism of fluoroquinolones, and provides relevant clinical context without any inaccuracies or omissions."
  },
  "197": {
    "score": 2.0,
    "explanation": "2: The model answer does not mention the principal mechanism of free radical scavenging (antioxidant activity) as stated in the reference, instead focusing on nuclear receptor-mediated gene regulation and epithelial differentiation. While these are correct and relevant secondary mechanisms of vitamin A, omission of the key antioxidant mechanism constitutes a moderate factual omission."
  },
  "198": {
    "score": 3.0,
    "explanation": "3: The model answer covers the majority of key facts, including binding of bile acids and interruption of enterohepatic circulation, but incorrectly identifies \"upregulation of hepatic LDL receptor expression\" as the primary mechanism, rather than the direct binding of bile acids; this is a minor but important inaccuracy in the context of the question."
  },
  "199": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the need for more intensive surveillance after radiotherapy, provides correct guideline-based intervals, and offers relevant rationale without inaccuracies or omissions."
  },
  "200": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional detail, and contains no inaccuracies or omissions."
  },
  "201": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant guideline details, and contains no inaccuracies or omissions."
  },
  "202": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts, emphasizing the need for quantitative assessment and risk stratification, but it overstates the appropriateness of standard therapy by implying surgery is generally suitable if ppo values are above certain thresholds, whereas the reference stresses that moderate restriction may itself require modification or contraindicate surgery. This represents a minor but clinically meaningful overstatement."
  },
  "203": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly states that histologic subtype does not affect eligibility, directly contradicting the reference answer, which specifies that metaplastic carcinoma is not included among eligible subtypes. While the answer is well-argued and references guidelines, it omits the key fact that metaplastic carcinoma is excluded, constituting a moderate factual error."
  },
  "204": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts in the reference, accurately describes when ALND is required versus when SLNB alone is sufficient, and provides relevant, up-to-date evidence and technical considerations without inaccuracies or omissions."
  },
  "205": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies cyclooxygenase (COX) as the molecular target and provides a thorough, accurate explanation, but it does not specify COX-1 (prostaglandin G/H synthase 1) as in the reference; this is a minor omission since NSAIDs inhibit both COX-1 and COX-2, but the reference specifically names COX-1."
  },
  "206": {
    "score": 3.0,
    "explanation": "3: The model answer explains the physical and chemical mechanisms of sunscreens and their clinical relevance, but it does not explicitly state the general class mechanism as \"physiochemical activity,\" which is the key fact in the reference answer. The answer is otherwise accurate and relevant."
  },
  "207": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant elaboration, and contains no inaccuracies or omissions. It clearly explains the necessity of confirming M0 status with brain MRI and FDG-PET/CT before perioperative therapy, aligning fully with the reference answer."
  },
  "208": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, correctly identifies sulfonamides as PABA inhibitors, thoroughly explains the mechanism, and provides relevant clinical context without inaccuracies or omissions."
  },
  "209": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts in the reference (\"enzyme interactions\") by specifying PDE3 inhibition and its downstream effects, with additional correct and clinically relevant detail; there are no inaccuracies or omissions."
  },
  "210": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the glucocorticoid receptor, thoroughly explains its cytoplasmic localization, mechanism of gene transcription modulation, and clinical relevance, with no inaccuracies or omissions."
  },
  "211": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly explains why surgery is contraindicated, and provides additional, accurate, and clinically relevant details about non-surgical options and their limitations in this context, with no inaccuracies or omissions."
  },
  "212": {
    "score": 4.0,
    "explanation": "4: The model answer covers all key facts (rasburicase, enzymatic degradation/activation, allantoin formation, increased solubility, clinical context) and provides relevant extra detail; however, it does not explicitly use the term \"enzyme activation\" as in the reference, which is a minor wording inaccuracy."
  },
  "213": {
    "score": 1.0,
    "explanation": "1: The model answer incorrectly states that durvalumab is contraindicated in EGFR-mutant patients, which is not supported by guidelines; while osimertinib is preferred, durvalumab is not excluded, making this a major inaccuracy that could mislead clinical care."
  },
  "214": {
    "score": 3.0,
    "explanation": "3: The model answer incorrectly states that squamous cell carcinoma is a subtype of non-squamous NSCLC, which is a moderate factual error, but otherwise covers most key facts, including the need for broad molecular profiling, rationale, and relevant actionable mutations. The rest of the content is accurate and clinically relevant, but the classification error lowers the score."
  },
  "215": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale for not proceeding directly to surveillance, and provides relevant, correct details about standard management and the need for concurrent chemoradiation; there are no inaccuracies or omissions."
  },
  "216": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly explains the need for more intensive surveillance post-radiotherapy, details the recommended schedule, and provides rationale and guideline sources. There are no inaccuracies or omissions."
  },
  "217": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies the drug as an anticoagulant and explains its mechanism, but it omits the key reference term \"enzyme activators\" and does not explicitly state that the drug acts by activating an enzyme (protein C), which is the central pharmacological class in the reference answer."
  },
  "218": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies the organism, drug, and general mechanism (persistent depolarization via nAChRs), but it does not specify cholinesterase inhibition as the mechanism of spastic paralysis, which is the key fact in the reference answer; instead, it attributes the effect to direct cholinergic agonism, which is inaccurate for the described mechanism."
  },
  "219": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies cyclooxygenase (COX) as the inhibited enzyme and provides a thorough, accurate explanation, but it does not specify COX-1 (prostaglandin G/H synthase 1) as in the reference, representing a minor omission in precision."
  },
  "220": {
    "score": 2.0,
    "explanation": "2: The model answer misses the key reference point that surgery is inherently excluded if definitive local therapy is not possible, instead arguing that surgery may still be considered. While it provides relevant considerations, it contradicts the reference's core clinical fact and introduces moderate factual inaccuracy."
  },
  "221": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides correct and clinically relevant additional explanations, cites guidelines, and contains no inaccuracies or omissions."
  },
  "222": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides additional correct and clinically relevant explanations, and contains no inaccuracies or omissions."
  },
  "223": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, thoroughly explaining zinc’s role as a metalloenzyme cofactor and its relevance to tissue repair, with no inaccuracies or omissions."
  },
  "224": {
    "score": 3.0,
    "explanation": "3: The model answer correctly explains the mechanism of corticosteroids and their inhibition of phospholipase A2, but it does not identify lipoxygenase enzymes as the primary enzyme system responsible for the lipid mediators in question, missing the key fact required by the reference answer."
  },
  "225": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately states that MET-targeted therapy is preferred over chemotherapy, and provides additional, correct, and clinically relevant details about efficacy, guidelines, and practical considerations without any inaccuracies or omissions."
  },
  "226": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies the 5-HT1B/1D receptors as the drug target and provides accurate, relevant clinical and mechanistic details, but the reference specifically asks for the 1B receptor (the direct mediator of vasoconstriction), so including 1D as equally direct is a minor inaccuracy in wording."
  },
  "227": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant rationale, cites major guidelines, and contains no inaccuracies or omissions."
  },
  "228": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides detailed, accurate, and guideline-supported explanations, and contains no inaccuracies or omissions."
  },
  "229": {
    "score": 3.0,
    "explanation": "3: The model answer overstates the requirement by calling brain MRI \"mandatory\" for stage II, whereas guidelines recommend but do not strictly require it; otherwise, it covers most key facts and provides relevant rationale, but this moderate factual inaccuracy lowers the score."
  },
  "230": {
    "score": 2.0,
    "explanation": "2: The model answer provides a detailed and accurate description of the retinoid receptor-mediated mechanism but omits the reference answer’s key fact: the primary cytoprotective effect in this context is free radical scavenging (antioxidant activity). The mechanistic explanation is correct but does not address the main molecular mechanism specified in the reference."
  },
  "231": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale, cites relevant guidelines and trials, and correctly identifies osimertinib as the preferred consolidation therapy; there are no inaccuracies or omissions."
  },
  "232": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies cytochrome P450 enzymes as the relevant class and provides detailed, accurate pharmacokinetic reasoning, but incorrectly emphasizes CYP3A4 rather than the CYP1A subfamily specified in the reference, which is a moderate factual inaccuracy."
  },
  "233": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly identifies the molecular complex as the thrombopoietin receptor (c-MPL) homodimer rather than the interferon alpha receptor complex, which is the reference answer. While the explanation is detailed and relevant to ITP, it centers on the wrong biologic mechanism, constituting a moderate factual error."
  },
  "234": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate, clinically relevant elaboration, and contains no inaccuracies or omissions."
  },
  "235": {
    "score": 3.0,
    "explanation": "3: The model answer provides a detailed and mostly accurate explanation, correctly identifying the clinical scenario and the mechanism of increased presynaptic dopamine release, but it does not explicitly state \"ion channel interactions\" as the primary pharmacological interaction, which is the key fact in the reference answer."
  },
  "236": {
    "score": 2.0,
    "explanation": "2: The model answer provides a detailed and accurate description of corticosteroid mechanisms but fails to directly state that the precise cellular or molecular interaction in cutaneous TB is unknown, as required by the reference; this is a moderate omission."
  },
  "237": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly states that EBRT is appropriate regardless of pulmonary function, directly contradicting the key reference point that severely compromised pulmonary function may preclude safe radiotherapy. While the answer is detailed and mostly accurate regarding stenting, it omits the crucial risk consideration for EBRT, constituting a moderate factual error."
  },
  "238": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies polyene antifungals and their mechanism—binding to ergosterol and disrupting membrane integrity—but does not specify inhibition of ergosterol synthesis, which is the pathway asked about in the question and given in the reference. It covers most key facts but misses the precise molecular pathway."
  },
  "239": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate, guideline-based rationale, and includes relevant, correct additional details without any inaccuracies or omissions."
  },
  "240": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly identifies both the drug (celecoxib) and the phosphodiesterase isozyme (PDE4 instead of cGMP-specific PDE), missing the key fact that the relevant target is cGMP-specific 3',5'-cyclic phosphodiesterase; while the mechanistic explanation is detailed, it is not relevant to the reference answer and contains moderate factual errors."
  },
  "241": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies the clinical scenario, mechanism, and pharmacological class (antifolate agents/DHFR inhibitors), and explains the link to nucleic acid synthesis inhibition. However, it does not explicitly use the reference term \"Nucleic Acid Synthesis Inhibitors\" as the best pharmacological class, which is a minor wording inaccuracy."
  },
  "242": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant elaboration, and contains no inaccuracies or omissions."
  },
  "243": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies fluoroquinolones and DNA gyrase as a target, but fails to specify topoisomerase IV as the most direct molecular target in this clinical context (otitis media pathogens are often gram-positive), omitting the key fact required by the question. The rest of the explanation is accurate and relevant."
  },
  "244": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale for prioritizing immunotherapy first-line in high PD-L1 NSCLC with KRAS G12C, and correctly places KRAS inhibitors as second-line; additional details are clinically relevant and there are no inaccuracies or omissions."
  },
  "245": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies SNRIs and provides a detailed, accurate explanation, but the reference answer specifically asks for \"serotonin uptake inhibitors,\" and the model's focus on SNRIs (which also inhibit norepinephrine) introduces a minor mismatch in terminology and emphasis, covering most but not all key facts."
  },
  "246": {
    "score": 3.0,
    "explanation": "3: The model answer accurately states that concurrent chemoradiation is preferred and provides detailed rationale, but incorrectly excludes chemotherapy alone or sequential chemoradiation as acceptable alternatives, which the reference answer explicitly allows; this is a moderate omission."
  },
  "247": {
    "score": 2.0,
    "explanation": "2: The model answer focuses on chloride channel activation and fluid secretion (mechanism of lubiprostone), but the reference answer specifies stool bulking as the key property. The model omits this direct effect, instead emphasizing a different mechanism, which is a moderate factual omission."
  },
  "248": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly identifies methylxanthines (adenosine receptor antagonists) rather than adenosine receptor agonists as the drug class sharing the primary molecular target, which is a moderate factual error; while the mechanistic explanation is accurate, the main answer does not match the reference."
  },
  "249": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, including guideline recommendations, rationale for testing in non-smokers with squamous histology, stage-specific considerations, and the importance of comprehensive molecular profiling; all additional content is accurate and clinically relevant."
  },
  "250": {
    "score": 2.0,
    "explanation": "2: The model answer covers some key facts (initial nodal status, post-neoadjuvant findings, guideline references) but incorrectly states that ALND is required, missing the nuance that ALND can be omitted if adjuvant radiotherapy is planned to cover the axilla. This is a moderate factual error and omits the option of omitting ALND with appropriate radiotherapy, as supported by current practice."
  },
  "251": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional detail, and contains no inaccuracies or omissions."
  },
  "252": {
    "score": 4.0,
    "explanation": "4: The model answer covers all key facts, correctly identifies amantadine, and details both NMDA antagonism and dopaminergic effects, but slightly overemphasizes NMDA antagonism as the \"primary\" mechanism rather than equally highlighting dopamine release enhancement, which is a minor wording inaccuracy."
  },
  "253": {
    "score": 2.0,
    "explanation": "2: The answer provides some relevant information about TMP-SMX's anti-inflammatory effects but incorrectly downplays the central role of folate synthesis inhibition (via PABA antagonism) as the therapeutic mechanism referenced in the question, and introduces moderate factual inaccuracies regarding the primary mechanism in this context."
  },
  "254": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies Janus kinase (JAK) as the molecular target and provides relevant mechanistic and clinical context, but it does not specify JAK1 as in the reference answer, representing a minor omission."
  },
  "255": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, thoroughly explaining the need for comprehensive clinicopathological assessment before classifying lesions as synchronous primaries, and accurately details the implications for management. There are no inaccuracies or omissions."
  },
  "256": {
    "score": 3.0,
    "explanation": "3: The model answer provides a detailed and accurate summary of the leading hypotheses regarding flecainide’s antiarrhythmic mechanisms, but it does not explicitly state that the exact cellular or molecular interaction is unknown, as required by the reference answer; instead, it elaborates on possible mechanisms, which, while correct, constitutes a minor omission of the key fact that the mechanism is not definitively established."
  },
  "257": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly explains that non-contrast CT is appropriate regardless of mild CKD, and adds accurate, clinically relevant detail about surveillance frequency and imaging alternatives without any inaccuracies or omissions."
  },
  "258": {
    "score": 3.0,
    "explanation": "3: The model answer covers the uncertainty about the mechanism but goes beyond the reference by asserting mitochondrial disruption and ROS generation as the \"best-characterized\" mechanism, which is not definitively established and may overstate current knowledge; this introduces minor factual inaccuracies, though most key facts are present."
  },
  "259": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies cyclooxygenase (COX)/prostaglandin H2 synthase as the molecular target and provides a thorough, accurate explanation, but it does not specify COX-1 (prostaglandin G/H synthase 1) as in the reference answer; this is a minor omission since most NSAIDs inhibit both COX-1 and COX-2, but the reference specifically names COX-1."
  },
  "260": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly identifies azithromycin as the antibiotic, misattributes its mechanism, and fails to name topoisomerase IV as the enzyme inhibited by the drug described in the question. While it provides some relevant information, it contains moderate factual errors and omits the key fact required."
  },
  "261": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, adds relevant and accurate detail about oligoprogression, management sequencing, and supporting evidence, and contains no inaccuracies or omissions."
  },
  "262": {
    "score": 1.0,
    "explanation": "1: The model answer incorrectly states that observation alone is unacceptable and that additional therapy is mandatory, directly contradicting the reference answer, which allows observation as an acceptable option. This is a major inaccuracy and could lead to overtreatment."
  },
  "263": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, including the prioritization of local ablative therapy in selected oligometastatic NSCLC patients, the importance of patient selection, and the continued role of systemic therapy. Additional details provided are accurate, clinically relevant, and enhance the answer without introducing errors or omissions."
  },
  "264": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies phosphodiesterase (PDE) as the enzyme class and explains the mechanism, but it does not specify cGMP-specific PDE (as in the reference), and includes both cAMP and cGMP, which is less precise; overall, it covers most key facts but lacks the required specificity."
  },
  "265": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional details, and contains no inaccuracies or omissions."
  },
  "266": {
    "score": 2.0,
    "explanation": "2: The model answer misidentifies the drug as pentoxifylline rather than papaverine, which is the agent referenced in the question and reference answer. While it discusses the uncertainty of the mechanism, this moderate factual error and focus on the wrong drug results in a significant omission of key facts."
  },
  "267": {
    "score": 2.0,
    "explanation": "2: The model answer correctly identifies the biologic as pegylated interferon-alpha and thoroughly explains its mechanism, but it incorrectly states that \"interferons\" are the class with the most similar mechanism, rather than \"RNA replicase inhibitors\" as in the reference. This is a moderate factual error regarding the required comparison."
  },
  "268": {
    "score": 3.0,
    "explanation": "3: The model answer provides a detailed and accurate explanation of the classification criteria and treatment considerations, but it does not directly address the reference answer's key point that management as two primaries is only appropriate if both are potentially curable; instead, it focuses on classification criteria and the role of curability after classification, covering about 70-89% of the key facts."
  },
  "269": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately states that routine PET/CT and brain MRI are not recommended, and provides correct, relevant guideline-based rationale and details about standard surveillance; there are no inaccuracies or omissions."
  },
  "270": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies that nintedanib inhibits multiple receptor tyrosine kinases, including FGFR, and provides relevant mechanistic and clinical context, but it does not specifically highlight the fibroblast growth factor receptor family as the principal molecular target mediating the antifibrotic effect, as required by the reference answer."
  },
  "271": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate, relevant rationale, cites guidelines, and contains no inaccuracies or omissions."
  },
  "272": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies albumin as a plasma-derived colloid that restores oncotic pressure and explains its mechanism, but it does not explicitly use the term \"structural macromolecule\" as in the reference. The extra content is accurate and relevant, with only a minor omission in precise terminology."
  },
  "273": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts, including the need to distinguish between synchronous primaries and metastasis, and outlines diagnostic and management pathways. However, it incorrectly states that management does not assume both lesions are potentially resectable primaries, which contradicts the reference answer’s core point, and overemphasizes the need for molecular confirmation before considering resection, representing a moderate factual inaccuracy."
  },
  "274": {
    "score": 3.0,
    "explanation": "3: The model answer covers the dependence of osimertinib use on prior EGFR TKI exposure and provides detailed rationale, but it introduces the outdated requirement for T790M mutation testing after first/second-generation TKI failure, which is no longer standard as osimertinib is now approved for first-line use regardless of T790M status. This constitutes a moderate factual inaccuracy."
  },
  "275": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly identifies corticosteroids as the class directly responsible for decreasing leukotriene-mediated inflammation, whereas the reference specifies lipoxygenase inhibitors; while the explanation is detailed and mostly accurate regarding corticosteroid mechanisms, it does not address the specific class asked for and thus omits the key fact."
  },
  "276": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate, guideline-based rationale, and adds relevant, correct details about rare targets, tumor evolution, and clinical trial eligibility, with no inaccuracies or omissions."
  },
  "277": {
    "score": 3.0,
    "explanation": "3: The answer provides a detailed and accurate downstream signaling pathway (calcium mobilization via GPCRs) but omits the key fact that the therapeutic effect is specifically due to agonism of prostaglandin (EP) receptors, as required by the reference. The mechanistic detail is correct and relevant, but the most direct mechanism per the question is receptor agonism, not the intracellular cascade."
  },
  "278": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies direct inhibition of the interleukin-1 (IL-1) signaling pathway, provides accurate clinical context, and explains the mechanism and rationale, fully covering all key facts in the reference answer without inaccuracies or omissions."
  },
  "279": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, strongly emphasizing the mandatory nature of preoperative pulmonary function assessment and the rationale for not proceeding without it. Additional details are accurate, relevant, and enhance clinical understanding without introducing errors or irrelevant content."
  },
  "280": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies beta-adrenergic agonists as the drug class, thoroughly explains the mechanism, and excludes other classes, but it does not specifically mention \"beta2-agonists\" as in the reference; however, the explanation is otherwise accurate and clinically relevant with only a minor wording difference."
  },
  "281": {
    "score": 3.0,
    "explanation": "3: The answer correctly describes ACTH’s mechanism and clinical use, but misclassifies the pharmacological class as \"corticosteroid therapy\" rather than the more precise \"pituitary hormone receptor agonist\" as in the reference; this is a minor but meaningful inaccuracy in classification."
  },
  "282": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains why targeted therapy is precluded, and correctly prioritizes systemic chemotherapy, including the current standard of chemo-immunotherapy for PD-L1 <1%—all content is factually correct and clinically relevant."
  },
  "283": {
    "score": 3.0,
    "explanation": "3: The model answer provides a detailed and accurate account of the presumed mechanism (radiation-induced DNA damage and apoptosis), but it does not explicitly state that the precise cellular or molecular interaction is unknown, as required by the reference. This constitutes a moderate omission, as the question specifically asks for the \"best current understanding,\" which is that the exact mechanism remains unclear."
  },
  "284": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate surveillance intervals, rationale, and guideline references, with no inaccuracies or omissions."
  },
  "285": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies albendazole as a CYP1A inducer, explains the mechanism, and anticipates decreased plasma concentrations of co-administered CYP1A substrates, with no inaccuracies or omissions."
  },
  "286": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies the need for biomarker testing and brain MRI, but incorrectly classifies contralateral lung nodules as M1a instead of M1b, which is a minor inaccuracy in terminology but does not alter the clinical management or meaning."
  },
  "287": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies IP (prostacyclin) receptors as the primary target, and provides accurate, relevant mechanistic detail without any inaccuracies or omissions."
  },
  "288": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale for continued endocrine therapy, details appropriate targeted combinations, and correctly states when chemotherapy is indicated, with no inaccuracies or omissions."
  },
  "289": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately states that adjuvant systemic therapy is indicated regardless of final nodal status, and provides additional correct and clinically relevant rationale without any inaccuracies or omissions."
  },
  "290": {
    "score": 3.0,
    "explanation": "3: The model answer covers the majority of key facts, correctly noting the mechanism is incompletely understood and describing mitochondrial disruption, but it goes beyond the reference by specifying possible mechanisms rather than simply stating the mechanism is unknown, which introduces minor inaccuracies and overinterpretation."
  },
  "291": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies cyclooxygenase (COX) as the molecular target and provides a thorough, clinically relevant explanation, but it does not specify COX-2 (prostaglandin G/H synthase 2) as in the reference answer, representing a minor omission in specificity."
  },
  "292": {
    "score": 3.0,
    "explanation": "3: The model answer provides a thorough explanation of why EGFR TKI use does not confirm ALK negativity and emphasizes the need for comprehensive testing, but it overstates the likelihood of co-occurring EGFR and ALK alterations (which are generally mutually exclusive) and omits the key fact that targeted therapy selection is typically predicated on the identified driver mutation, as well as the clinical mutual exclusivity principle."
  },
  "293": {
    "score": 2.0,
    "explanation": "2: The model answer is well-referenced and detailed but contains a moderate factual error by supporting omission of further axillary surgery with 3 positive SLNs, whereas current guidelines and evidence restrict this to 1–2 positive SLNs; it overstates guideline support and extrapolates beyond established evidence, missing the key exclusion criterion."
  },
  "294": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately emphasizing serotonin receptor modulation (specifically 5-HT1B/1D agonism) as the primary therapeutic mechanism, and provides additional clinically relevant detail without inaccuracies or omissions."
  },
  "295": {
    "score": 3.0,
    "explanation": "3: The model answer correctly states that adjuvant radiotherapy is not a category 1 recommendation and provides a detailed rationale, but it inaccurately assigns a category 2A (rather than the reference's 2B), which is a moderate factual error regarding the level of consensus/evidence; otherwise, the content is thorough and relevant."
  },
  "296": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains both the stage-based and physiologic contraindications to surgery, and correctly outlines standard non-surgical management options without any inaccuracies or omissions."
  },
  "297": {
    "score": 2.0,
    "explanation": "2: The model answer provides detailed mechanisms of magnesium’s antiarrhythmic effects but omits the key fact from the reference—calcium chelation (reduction of free extracellular calcium)—as the primary mechanism in this context. While the answer is factually correct and relevant, it does not directly address the specific molecular mechanism highlighted in the reference."
  },
  "298": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly identifies colchicine as the medication, whereas the reference answer refers to aminobenzoate potassium; this is a moderate factual error. While the mechanistic discussion of colchicine is accurate, it is irrelevant to the question, resulting in only partial coverage of key facts."
  },
  "299": {
    "score": 3.0,
    "explanation": "3: The model answer correctly states that smoking history does not affect EGFR TKI selection and provides detailed, accurate information about the relative efficacy of erlotinib versus osimertinib for S768I mutations. However, it incorrectly states that erlotinib is not an appropriate first-line therapy, which contradicts the reference answer and current guidelines that still consider erlotinib an option, albeit not preferred; this is a moderate factual error."
  },
  "300": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant elaboration, and contains no inaccuracies or omissions."
  },
  "301": {
    "score": 4.0,
    "explanation": "4: The model answer covers over 90% of the key facts, correctly emphasizing that reduced pulmonary function may contraindicate surgery and that radiotherapy or SABR are preferred in this context. It adds relevant detail and nuance, but slightly overstates surgery as \"generally NOT preferred\" (rather than \"may be contraindicated\"), which is a minor wording inaccuracy."
  },
  "302": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies cyclooxygenase (COX) as the molecular target and provides a thorough, clinically relevant explanation, but it does not specify the COX-2 isoform or the full enzyme name (Prostaglandin G/H Synthase 2), which is a minor omission."
  },
  "303": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, expands with accurate, clinically relevant details, and includes no inaccuracies or omissions."
  },
  "304": {
    "score": 3.0,
    "explanation": "3: The model answer accurately states that broad molecular profiling is not routinely recommended for pure squamous cell carcinoma and highlights exceptions, but it omits the key reference point that actionable mutations can still be present regardless of histology and that testing should not be limited purely based on squamous subtype; it also overemphasizes guideline restrictions, which may lead to under-testing in some cases."
  },
  "305": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly identifies the drug as valproate rather than levetiracetam, which is the agent described in the reference. While it provides accurate and relevant information about valproate, it fails to address the key fact that the mechanism of levetiracetam is unknown, resulting in a moderate factual error and omission of the main point."
  },
  "306": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately stating that re-excision is preferred if feasible and that radiotherapy (especially SBRT) is an acceptable and often standard alternative when re-excision is not possible. Additional details are correct, relevant, and enhance clinical understanding without introducing inaccuracies."
  },
  "307": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately noting that adjuvant chemo-trastuzumab and endocrine therapy may be considered for small (≤0.5 cm) HER2+ tumors, and that the option is not limited to larger tumors. Additional content is correct, clinically relevant, and guideline-based, with no inaccuracies or omissions."
  },
  "308": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts, including the need for structured surveillance and the use of low-dose CT, but incorrectly states that annual CT is sufficient from the outset, missing the more intensive 3–6 month interval recommended for the first 3 years after adjuvant radiotherapy. This is a moderate omission, though the rest of the content is accurate and relevant."
  },
  "309": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate, up-to-date evidence and guideline support, and includes relevant rationale without inaccuracies or omissions."
  },
  "310": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies the key mechanism as interaction with large biomolecules (enzymes and proteins), specifically lipases and albumin, and explains how this bypasses the chylomicron pathway. However, it focuses on MCT oil rather than cholesterol (as in the reference), and the emphasis on enzymatic hydrolysis and protein binding is slightly more detailed than the reference but still clinically relevant. No major omissions or inaccuracies are present, but the focus could be more generalized to \"biological macromolecular activity.\""
  },
  "311": {
    "score": 3.0,
    "explanation": "3: The model answer provides a detailed and accurate description of the molecular pathway (FGFR-1/FGF-2) but does not explicitly state the broader mechanism of \"modulation of transcription factor activity\" as in the reference; it covers the majority of key facts but misses the general mechanism, which is the focus of the reference answer."
  },
  "312": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides correct and clinically relevant additional details, and contains no inaccuracies or omissions."
  },
  "313": {
    "score": 2.0,
    "explanation": "2: The model answer identifies the adenosine A1 receptor rather than the beta-1 adrenergic receptor, which is the reference answer’s key fact. While the reasoning is detailed and clinically relevant, it ultimately selects the wrong molecular target, constituting a moderate factual error."
  },
  "314": {
    "score": 2.0,
    "explanation": "2: The model answer provides extensive detail on proposed mechanisms from preclinical studies, but fails to clearly state that the mechanism in chronic hepatitis is unknown, as per current scientific evidence. This constitutes a moderate omission, as it may mislead the patient regarding the certainty of milk thistle’s effects."
  },
  "315": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale, and provides guideline-based details without any inaccuracies or omissions."
  },
  "316": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts about the supplement's mechanism, including its effects on cartilage structure and metabolism, but it does not explicitly identify \"biological macromolecular activity\" as the pharmacological activity, which is the key point in the reference answer. The focus on \"disease-modifying activity\" is related but not the precise mechanism asked for."
  },
  "317": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies cyclooxygenase (COX) as the enzyme and provides a thorough, clinically relevant explanation, but does not specify COX-2 (prostaglandin G/H synthase 2) as the most directly responsible isoform, which is a minor omission."
  },
  "318": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly recommends routine inclusion of FDG-PET/CT and brain MRI in the initial evaluation of a new suspicious nodule during surveillance, whereas guidelines and the reference specify these are reserved for confirmed recurrence or strong clinical suspicion of metastasis; this is a moderate factual error, despite the answer being otherwise thorough."
  },
  "319": {
    "score": 3.0,
    "explanation": "3: The model answer provides a strong rationale for switching to selpercatinib and cites supporting data and guidelines, but it omits that both completing current therapy or switching are acceptable options and that the decision should be individualized; this is a moderate omission compared to the reference."
  },
  "320": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies dopamine reuptake inhibition as the primary mechanism, and provides additional clinically relevant and accurate details without any inaccuracies or omissions."
  },
  "321": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies alkylating agents and details their mechanism, but it does not directly state \"nucleic acid synthesis inhibitors\" as the class, missing the key reference terminology; it also incorrectly lists decitabine as an alkylating agent, which is a moderate factual error."
  },
  "322": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies the mechanism as inhibition of protein synthesis via the 30S ribosomal subunit and specifies tetracyclines, but it omits the broader pharmacological class \"protein synthesis inhibitors\" as requested in the question, which is a minor omission."
  },
  "323": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies the agent as an immunomodulator (specifically cytokines/interferons) and provides accurate, relevant mechanistic detail, but it omits the precise term \"Biological Response Modifiers,\" which is the key reference class; this is a minor wording inaccuracy that does not alter the clinical meaning."
  },
  "324": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies the molecular target as the interleukin-6 receptor (IL-6R) and provides accurate, relevant clinical context and mechanism, but omits the specific mention of the alpha subunit (IL-6Rα) as in the reference answer."
  },
  "325": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies MmpL3 as the transporter targeted by the drug and provides accurate mechanistic and clinical context, but it does not mention \"Organic Anion Transporter 3\" as specified in the reference answer, missing a key fact."
  },
  "326": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately stating that adjuvant therapy consideration in stage IB (T2aN0) NSCLC requires additional high-risk features and is not justified by stage and margin status alone; all extra content is correct, relevant, and guideline-based."
  },
  "327": {
    "score": 3.0,
    "explanation": "3: The model answer provides a detailed and accurate description of pentoxifylline’s proposed mechanisms, but it does not explicitly state that the precise cellular or molecular interaction is unknown, as required by the reference. While it covers relevant facts, it misses the key point that the mechanism remains incompletely understood, thus omitting a critical aspect."
  },
  "328": {
    "score": 4.0,
    "explanation": "4: The model answer covers nearly all key facts, accurately describing the uncertainty of the mechanism, possible bypass of enzymatic defects, and partial/variable response, but includes more mechanistic detail than the reference, which simply states the mechanism is unknown; this is a minor wording inaccuracy, not a factual error."
  },
  "329": {
    "score": 3.0,
    "explanation": "3: The model answer correctly describes inhibition of ergosterol synthesis but incorrectly identifies the drug class and enzyme (azoles/lanosterol 14α-demethylase) instead of squalene epoxidase, missing the specific mechanism referenced; otherwise, the explanation is accurate and relevant."
  },
  "330": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies the FIP1L1-PDGFRA fusion as the molecular abnormality and explains its relevance, but it does not match the reference answer, which specifies BCR-ABL as the target. The model provides accurate and relevant information for a different but related clinical scenario, covering most key facts but missing the specific abnormality in the reference."
  },
  "331": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies cyclooxygenase (COX) as the molecular target and provides accurate, relevant clinical context, but does not specify COX-2 (prostaglandin G/H synthase 2) as the primary isoform responsible for the anti-inflammatory effect, which is a minor omission."
  },
  "332": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale for prioritizing chemotherapy in visceral crisis, and provides relevant, guideline-based details without inaccuracies or omissions."
  },
  "333": {
    "score": 2.0,
    "explanation": "2: The model answer focuses on demeclocycline’s effect on cAMP and ADH signaling but omits the key fact that the relevant drug class mechanism is inhibition of protein synthesis (as per the reference answer). It provides correct clinical context and mechanism for demeclocycline but fails to directly answer the question regarding the fundamental cellular process (protein synthesis), constituting a moderate omission."
  },
  "334": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly emphasizes the rationale for systemic therapy over observation, and provides additional relevant, accurate, and clinically appropriate considerations without any inaccuracies or omissions."
  },
  "335": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference (glucocorticoid receptor agonism/modulation), accurately explains the nuclear receptor mechanism, and provides clinically relevant, correct additional detail about SGRMs and their benefits, with no inaccuracies or omissions."
  },
  "336": {
    "score": 4.0,
    "explanation": "4: The model answer covers all key facts, correctly describing erythropoietin receptor activation and the downstream JAK2/STAT5 pathway, but emphasizes the intracellular signaling cascade rather than directly naming \"erythropoietin receptor activation\" as the primary molecular pathway, which is a minor wording inaccuracy."
  },
  "337": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately emphasizes the preference for sequential endocrine therapy over immediate chemotherapy, and provides additional, clinically relevant detail without inaccuracies or omissions."
  },
  "338": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies \"receptors\" as the general category and provides a thorough, accurate explanation, but omits the broader term \"structural macromolecules\" used in the reference, which is a minor omission."
  },
  "339": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies \"antimetabolite\" as the pharmacological class and provides a detailed, accurate explanation, but it omits the more specific class \"nucleic acid synthesis inhibitors\" as in the reference; this is a minor wording inaccuracy, not a clinically significant error."
  },
  "340": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies the organism, drug, and mechanism, but fails to use the required term \"uncouplers\" as in the reference answer, instead giving a broader class (\"mitochondrial electron transport chain inhibitors\"); this is a significant omission of the key fact asked for."
  },
  "341": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the appropriateness of non-contrast CT, addresses guideline support, and discusses relevant limitations and alternatives without any inaccuracies or omissions."
  },
  "342": {
    "score": 3.0,
    "explanation": "3: The model answer correctly explains that corticosteroids inhibit phospholipase A2, which is upstream of leukotriene synthesis, but it does not directly answer the question, which specifically asks for the enzyme whose inhibition is the principal contributor to the therapeutic effect—lipoxygenase. The answer is thorough and accurate regarding corticosteroid mechanism, but misses the key fact required by the reference."
  },
  "343": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant elaboration, and contains no inaccuracies or omissions."
  },
  "344": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides additional accurate and clinically relevant detail, and contains no inaccuracies or omissions."
  },
  "345": {
    "score": 3.0,
    "explanation": "3: The model answer provides a detailed and accurate description of metronidazole’s proposed mechanism, but it omits the key reference fact that the precise molecular mechanism in bacterial vaginosis remains unclear, thus overstating current knowledge."
  },
  "346": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, adds relevant and accurate details about rationale, urgency, chemotherapy regimens, and patient selection, and contains no inaccuracies or omissions."
  },
  "347": {
    "score": 3.0,
    "explanation": "3: The model answer covers the majority of key facts, accurately describing substrate supplementation and its role in bypassing metabolic blocks and restoring energy production, but it does not explicitly mention \"biological macromolecular activity\" as the general pharmacological mechanism, which is central to the reference answer."
  },
  "348": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies the drug as amphotericin B and its mechanism (binding ergosterol and forming pores), but incorrectly states that its mechanism is most closely related to polyenes rather than ergosterol synthesis inhibitors, missing the key comparison required by the question."
  },
  "349": {
    "score": 3.0,
    "explanation": "3: The model answer correctly explains the mechanism of corticosteroids and their inhibition of PLA2, but the reference specifically asks for the enzyme class responsible for leukotriene production, which is lipoxygenase; thus, the model omits the key fact that lipoxygenase is the direct enzyme inhibited to reduce leukotriene synthesis."
  },
  "350": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies the need for systemic therapy in stage IV (oligometastatic) NSCLC and provides a detailed rationale, but it omits the reference answer's key point that initial management should combine local therapy to the metastatic site with standard concurrent chemoradiation for locoregional disease, rather than prioritizing systemic therapy alone."
  },
  "351": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly identifies CYP3A4 as the inhibited enzyme instead of CYP2C19, which is the key fact in the reference answer; while the clinical significance is generally correct for CYP inhibition, the error in enzyme identification is a moderate factual error."
  },
  "352": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, including the contraindication to surgery due to severely reduced PFTs, the rationale, alternative treatments (especially SABR), and the need for multidisciplinary assessment, with no inaccuracies or omissions."
  },
  "353": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant explanations for the necessity of both tests, and contains no inaccuracies or omissions."
  },
  "354": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional detail, and contains no inaccuracies or omissions."
  },
  "355": {
    "score": 3.0,
    "explanation": "3: The model answer provides a detailed and accurate mechanistic explanation of how arginine and aspartate correct metabolic alkalosis, but it does not directly identify the general pharmacological action as \"biological macromolecular activity\" as required by the reference answer, thus missing the key classification."
  },
  "356": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides a detailed, accurate, and clinically relevant explanation of the diagnostic and management approach, and contains no inaccuracies or omissions."
  },
  "357": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately identifies calcium channel interactions as the relevant class, and provides correct, clinically relevant elaboration without inaccuracies or omissions."
  },
  "358": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts, correctly explaining that stage IVA (M1a) implies metastatic disease and that surgery is not standard, but it overemphasizes the metastatic paradigm and underplays that surgical management in this context presupposes both lesions are potentially curable, as per the reference. It also introduces some ambiguity regarding the intent of surgery in oligometastatic disease, leading to a minor omission of the reference's core point."
  },
  "359": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale, and provides relevant, up-to-date guideline-based options without inaccuracies or omissions. Additional details are clinically relevant and correct."
  },
  "360": {
    "score": 3.0,
    "explanation": "3: The model answer provides a detailed and accurate description of nintedanib’s known molecular targets and mechanisms, but it does not align with the reference answer’s emphasis on the mechanism being unknown; thus, it omits the key fact that the precise mechanism is not fully elucidated, as required by the question and reference."
  },
  "361": {
    "score": 4.0,
    "explanation": "4: The model answer correctly explains the inhibition of heme polymerization as the primary mechanism and links it to secondary inhibition of nucleic acid synthesis, covering all but the most direct phrasing of the reference answer; the minor omission is not explicitly stating \"inhibition of nucleic acid synthesis\" as the main action, but the explanation is otherwise accurate and clinically relevant."
  },
  "362": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies apremilast and provides a detailed, accurate mechanism of action, but it does not address cyclosporine as in the reference answer, thus missing the key fact that the question refers to cyclosporine, not apremilast."
  },
  "363": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides correct and clinically relevant rationale, cites supporting guidelines, and contains no inaccuracies or omissions."
  },
  "364": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate, guideline-based rationale, and includes relevant additional context without any inaccuracies or omissions."
  },
  "365": {
    "score": 4.0,
    "explanation": "4: The model answer covers all key facts, correctly clarifies that every 6 months is appropriate (not every 3–6 months), and provides relevant guideline details and rationale. There is a minor wording inaccuracy in the initial \"yes, it is appropriate\" statement, which could be misleading, but this is corrected and clarified in the body of the answer."
  },
  "366": {
    "score": 4.0,
    "explanation": "4: The model answer covers over 90% of the key facts, accurately emphasizing that adjuvant radiotherapy is standard after R1/R2 resection but allows for rare exceptions with multidisciplinary input; however, it slightly overstates the rigidity of guidelines and underemphasizes that surveillance may be acceptable if re-resection or systemic therapy is pursued, which is a minor omission."
  },
  "367": {
    "score": 2.0,
    "explanation": "2: The model answer provides a detailed and accurate explanation of prostacyclin (IP) receptor agonists, but this is not the primary class referenced in the question or the reference answer, which specifies beta-adrenergic receptors. This represents a moderate factual error regarding the main molecular target, though the pharmacology described is otherwise correct."
  },
  "368": {
    "score": 2.0,
    "explanation": "2: The model answer focuses on the genomic actions of retinoic acid via nuclear receptors, which is accurate for systemic vitamin A effects but does not address the principal mechanism relevant to the prescribed agent (retinyl palmitate) in this context—antioxidant/free radical scavenging activity. It omits the key fact from the reference answer and provides mostly irrelevant mechanistic detail for this scenario."
  },
  "369": {
    "score": 1.0,
    "explanation": "1: The model answer incorrectly recommends systemic therapy as initial management for an isolated, asymptomatic endobronchial recurrence, misclassifying it as metastatic disease and overlooking the appropriateness of local intervention per guidelines; this constitutes a major inaccuracy despite otherwise detailed discussion."
  },
  "370": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies cyclooxygenase (COX) as the molecular target, explains its role in arachidonic acid metabolism, and relates it to NSAID therapy for chronic tendon inflammation, covering all key clinical facts without inaccuracies or omissions."
  },
  "371": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the drug as clofazimine, accurately describes its mechanism, and clearly states the correct pharmacological class as nucleic acid synthesis inhibitors, matching all key clinical facts in the reference answer."
  },
  "372": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, including the increased risk of toxicity, the need for adequate lung reserve, consideration of alternative strategies, and the importance of individualized assessment; additional details are accurate and clinically relevant."
  },
  "373": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant explanations, and includes appropriate caveats regarding pathology confirmation and the nuanced role of endocrine therapy, with no inaccuracies or omissions."
  },
  "374": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts but incorrectly asserts that COPD alone mandates earlier (6-month) follow-up, whereas guidelines state the 6–12 month interval applies regardless of COPD unless other high-risk features are present; this is a moderate factual inaccuracy."
  },
  "375": {
    "score": 4.0,
    "explanation": "4: The model answer covers all key facts and provides detailed, accurate, and clinically relevant explanations, but the primary mechanism is best summarized as \"biological response modification (via immune modulation)\" rather than simply \"receptor agonism,\" which is a minor wording inaccuracy that does not alter the clinical meaning."
  },
  "376": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies the cytochrome P450 system and explains the mechanism of enzyme induction, but it incorrectly specifies CYP3A4 as the main enzyme, whereas the reference answer highlights CYP1A. This represents a moderate factual error, though the mechanistic explanation is otherwise accurate."
  },
  "377": {
    "score": 2.0,
    "explanation": "2: The model answer covers the importance of adjuvant therapy for stage IIB NSCLC and acknowledges the limitation of nodal staging without MLND/SS, but it incorrectly asserts that omission of nodal assessment does not invalidate the indication for adjuvant therapy. This misses the key clinical fact that accurate pathologic staging (requiring MLND/SS) is a prerequisite for adjuvant therapy, as emphasized in the reference answer."
  },
  "378": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately emphasizing the high risk of toxicity, the general preference for systemic therapy, and the possibility of re-irradiation in select cases with modern techniques. All additional details are correct and clinically relevant, with no inaccuracies or omissions."
  },
  "379": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly stating that re-resection is preferred and radiotherapy is a secondary option, with detailed, accurate, and clinically relevant explanations and no inaccuracies or omissions."
  },
  "380": {
    "score": 3.0,
    "explanation": "3: The model answer provides a detailed and accurate description of metronidazole’s mechanism (DNA damage), but it does not align with the reference answer, which states the precise molecular target is unknown; thus, it covers about 70-89% of key facts but misses the reference’s main point."
  },
  "381": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies glycopeptides (e.g., vancomycin) as the likely class and accurately describes their mechanism, but it does not directly state \"enzyme inhibitors\" as required by the reference answer, missing the key fact that the question asks for the pharmacological class by mechanism, not drug class name."
  },
  "382": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly explains why surgery is not preferred, prioritizes SBRT, and provides relevant, accurate additional details without any inaccuracies or omissions."
  },
  "383": {
    "score": 3.0,
    "explanation": "3: The model answer incorrectly identifies CYP2C9 as the most likely induced enzyme, whereas the reference specifies CYP2C19. While the explanation is detailed and mostly accurate regarding warfarin metabolism and carbamazepine's effects, it misses the key fact required by the question and thus covers only about 70-89% of the key facts."
  },
  "384": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains that the recommendation does not assume absence of thromboembolic risk, details risk stratification, and correctly notes aromatase inhibitors are preferred in postmenopausal women with elevated risk; no inaccuracies or omissions are present."
  },
  "385": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies the drug as a recombinant cytokine (interferon) and provides detailed, accurate mechanistic reasoning, but it omits the broader drug class mechanism (\"biological response modifier—modulation of immune responses\") as required by the reference answer, focusing instead on a specific example."
  },
  "386": {
    "score": 2.0,
    "explanation": "2: The model answer identifies phospholipids as the target and provides mechanistic detail, but omits the key fact that the primary molecular targets are lysophospholipid receptors, not just membrane phospholipids; this is a moderate factual omission."
  },
  "387": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides correct and clinically relevant additional detail, and contains no inaccuracies or omissions."
  },
  "388": {
    "score": 3.0,
    "explanation": "3: The model answer covers the lack of a defined cellular/molecular target and explains the nonspecific chemical action, but it does not explicitly use the term \"unknown cellular or molecular interaction\" as in the reference. The detailed explanation is accurate and relevant, but the key fact—explicitly stating the mechanism is \"unknown\"—is missing."
  },
  "389": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes staging, surgical candidacy, and the role of systemic therapy, and provides relevant, up-to-date guideline-based details without inaccuracies or omissions."
  },
  "390": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies C5 as the therapeutic target in PNH and provides accurate, relevant pathophysiology, but it does not match the reference answer (C3) and omits that C3 is the specific protein asked for; thus, it covers most but not all key facts and contains a moderate factual error."
  },
  "391": {
    "score": 4.0,
    "explanation": "4: The model answer covers nearly all key facts, accurately describing the supplement as exogenous enzyme therapy and noting that the precise in vivo molecular mechanism is incompletely characterized; however, it provides more mechanistic detail than the reference, which could be seen as slightly overstating current knowledge, but does not introduce inaccuracies or unsafe statements."
  },
  "392": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly identifies the drug as metronidazole instead of emetine hydrochloride, which is a moderate factual error, though it provides a detailed and generally accurate mechanism for metronidazole; however, this is not relevant to the case described, resulting in significant omission of key facts."
  },
  "393": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies the mechanism as beta-lactam antibiotics and provides accurate, relevant clinical and pharmacological context, but it does not explicitly use the broader term \"enzyme inhibitors\" as required by the reference answer, thus missing a key fact."
  },
  "394": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies the pharmacological class as \"direct-acting skeletal muscle relaxant\" and provides a thorough, accurate explanation, but omits the specific term \"calcium channel antagonist\" from the reference answer, which is a minor omission."
  },
  "395": {
    "score": 4.0,
    "explanation": "4: The model answer covers over 90% of the key facts, accurately emphasizing that adjuvant radiation is standard and usually indicated, but does acknowledge rare circumstances (severe comorbidities, patient refusal, technical limitations) where surveillance might be considered. However, its strong language (\"not a reasonable option\") slightly underplays the acceptability of surveillance in select cases, representing a minor wording inaccuracy."
  },
  "396": {
    "score": 3.0,
    "explanation": "3: The model answer provides a detailed and accurate explanation of zinc's antiviral mechanisms, including protease inhibition and pH effects, but it does not directly state \"acid-base activity\" as the primary mechanism, which is the key fact in the reference answer. The answer is otherwise correct and relevant, but misses the central terminology."
  },
  "397": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies the clinical scenario and the drug class, and provides a detailed explanation of dopamine D₂ antagonism, but it omits the key fact that adrenergic alpha-antagonism is the most relevant mechanism in this context as per the reference answer, covering only about 70-89% of the key facts."
  },
  "398": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately states that surveillance frequency is unchanged by chemoradiation sequencing, and provides correct, relevant explanations without inaccuracies or omissions."
  },
  "399": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies the disorder and mechanism as replacement therapy, but does not use the reference's more precise pharmacologic class \"enzyme activators\" and omits that aspect; otherwise, the explanation is accurate and relevant."
  },
  "400": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional details, cites guidelines and evidence, and contains no inaccuracies or omissions."
  },
  "401": {
    "score": 2.0,
    "explanation": "2: The model answer provides detailed, plausible mechanisms of omega-3 fatty acids in inflammation, but it fails to emphasize that the precise cellular or molecular mechanism in Sjögren's syndrome is unclear, which is the key fact in the reference answer; this is a moderate omission."
  },
  "402": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly states that post-surgical surveillance is every 6 months (should be every 3–6 months), and claims chemoradiation surveillance is more frequent, which is inaccurate—both groups have the same recommended interval. While extra content is mostly accurate, this moderate factual error about frequency and difference warrants a score of 2."
  },
  "403": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides correct and clinically relevant additional explanations, and contains no inaccuracies or omissions."
  },
  "404": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately emphasizing that dabrafenib plus trametinib should only be started after completion or interruption of first-line therapy, not during ongoing treatment, and provides additional correct, relevant details without inaccuracies or omissions."
  },
  "405": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies rifamycins as nucleic acid synthesis inhibitors targeting DNA-dependent RNA polymerase, and provides relevant, accurate additional details without any errors or omissions."
  },
  "406": {
    "score": 3.0,
    "explanation": "3: The model answer provides a detailed and accurate discussion of the distinction between classification and curability, but it incorrectly denies that the approach of treating both lesions as separate primaries implicitly requires both to be potentially curable, which is a key point in the reference answer; otherwise, the explanation is thorough and factually correct."
  },
  "407": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies heme biosynthesis as the fundamental process enhanced by iron therapy and provides accurate, relevant mechanistic detail, but it omits explicit mention of iron transport/utilization and the broader context of erythropoiesis as highlighted in the reference answer."
  },
  "408": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies the drug class as anthelmintics and provides relevant mechanistic detail, but it omits the general pharmacological class \"enzyme inhibitors\" as specified in the reference answer, which is a key fact."
  },
  "409": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides additional accurate and clinically relevant explanations, and contains no inaccuracies or omissions."
  },
  "410": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly prioritizing SVC stenting for urgent symptom relief before chemoradiation, and provides accurate, relevant additional details without any inaccuracies or omissions."
  },
  "411": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies cyclooxygenase (COX) as the target and provides relevant clinical and mechanistic context, but it does not specify COX-2 (prostaglandin G/H synthase 2) as the primary isoform responsible for the therapeutic effect, which is a key detail in the reference answer."
  },
  "412": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, correctly clarifies that T-DXd is not restricted to adenocarcinoma, details its approval and evidence, and accurately states that first-line use is not justified; there are no inaccuracies or omissions."
  },
  "413": {
    "score": 3.0,
    "explanation": "3: The model answer correctly notes that non-contrast MRI is an option in renal dysfunction and that contrast is not required, but it incorrectly states that routine brain MRI is not justified in stage II NSCLC, which contradicts the reference answer and current guidelines; it covers most technical aspects but omits the key fact that brain MRI is routinely indicated for initial staging in stage II, resulting in a moderate factual error."
  },
  "414": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts and provides detailed, guideline-based reasoning, but it omits the important clinical nuance that routine ROS1 testing is not recommended for pure squamous histology, and that ROS1 rearrangements are exceedingly rare in squamous cell carcinoma; this is a moderate omission."
  },
  "415": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly identifies the pharmacologic class as NMDA receptor antagonist, omitting the key fact that full opioid agonists (μ-opioid receptor activation) are the classic centrally acting antitussives referenced in the scenario; this is a moderate factual error and covers less than 70% of the key facts."
  },
  "416": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies the therapy as coagulation factor replacement and explains the mechanism, but it does not explicitly state the pharmacological class as \"enzyme activators\" as in the reference, omitting the key classification required by the question."
  },
  "417": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies muscarinic acetylcholine receptors as the molecular target, provides accurate mechanistic and clinical context, and the additional detail about the M3 subtype is factually correct and clinically relevant."
  },
  "418": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly states that routine brain MRI is not indicated, and provides additional, accurate, and clinically relevant detail about surveillance, workup of the nodule, and guideline rationale, with no inaccuracies or omissions."
  },
  "419": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately identifies the drug class as RNA/transcription inhibitors, explains the mechanism, clinical context, and differentiates from other classes without inaccuracies or omissions."
  },
  "420": {
    "score": 3.0,
    "explanation": "3: The model answer provides a detailed and accurate explanation of the clinical scenario and mechanism, but the pharmacological class \"bypassing agents\" is less precise than \"enzyme activators\" as required by the reference; while correct in context, it omits the key reference terminology and thus does not fully match all key facts."
  },
  "421": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies CD20 as the target of commonly used monoclonal antibody therapies in NMOSD and provides accurate mechanistic reasoning, but it incorrectly states that CD20 is expressed on plasmablasts (it is not), and the reference answer specifies CD19, which is a broader and more accurate match to the question's description."
  },
  "422": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional explanations, and cites major guidelines without any inaccuracies or omissions."
  },
  "423": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, thoroughly explains the rationale, cites relevant guidelines, and contains no inaccuracies or omissions."
  },
  "424": {
    "score": 2.0,
    "explanation": "2: The model answer misidentifies the reference class (serotonin antagonists) and instead focuses on antimuscarinic agents, covering only about half the key facts and omitting the correct mechanistic parallel; while the mechanistic explanation is accurate for antimuscarinics, it does not address the question's intent regarding similar molecular mechanisms."
  },
  "425": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies interferon as the agent and thoroughly explains its mechanism, but it omits the broader pharmacological class \"biological response modifiers\" as required by the reference answer, thus missing a key fact."
  },
  "426": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies IL-13 as the direct molecular target, provides accurate and clinically relevant context, and distinguishes IL-13-specific therapies from others, with no inaccuracies or omissions."
  },
  "427": {
    "score": 3.0,
    "explanation": "3: The model answer accurately describes the mechanism and details of glatiramer acetate but does not use the reference's key term \"immunologic adjuvant\" as the pharmacologic class, instead calling it an \"antigen-specific immunomodulator.\" While the mechanistic explanation is correct and relevant, the primary classification required by the question is missing, constituting a moderate omission."
  },
  "428": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides additional correct and clinically relevant explanations, and contains no inaccuracies or omissions."
  },
  "429": {
    "score": 3.0,
    "explanation": "3: The model answer covers the general mechanism of complement inhibition and its clinical effects, but lacks the specific identification of C5 as the key target, instead listing multiple possible complement proteins (C3, C5, MAC). This represents a moderate omission of a key fact present in the reference answer."
  },
  "430": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the impact of renal insufficiency on specific agents, and provides clinically relevant, correct additional detail without inaccuracies or omissions."
  },
  "431": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately states that SBRT is preferred over surgery in patients with significant PFT impairment, and provides additional relevant, correct, and guideline-based details without any inaccuracies or omissions."
  },
  "432": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately cites major guidelines, and provides relevant rationale without any inaccuracies or omissions."
  },
  "433": {
    "score": 3.0,
    "explanation": "3: The model answer accurately describes bismuth’s barrier-forming and cytoprotective actions but omits the key reference point of acid-base activity and modulation of gastric pH, which is central to the reference answer; thus, it covers about 70-89% of key facts."
  },
  "434": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides correct and clinically relevant additional detail, and contains no inaccuracies or omissions."
  },
  "435": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies the key molecular process (inhibition of FPPS in osteoclasts) and provides accurate, relevant mechanistic detail, but it does not explicitly state \"inhibits osteoclast-mediated bone resorption\" as in the reference; this is a minor omission in wording, though the mechanism is well explained."
  },
  "436": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides correct and clinically relevant rationale, cites guidelines, and contains no inaccuracies or omissions."
  },
  "437": {
    "score": 3.0,
    "explanation": "3: The model answer provides a detailed and accurate description of fusidic acid’s mechanism, including historical uncertainty, but it does not directly state that the mechanism is \"unknown\" or \"unclear\" as required by the reference; instead, it offers more detail than necessary, missing the concise summary expected."
  },
  "438": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately prioritizing targeted therapy (amivantamab) with chemotherapy over chemotherapy alone, and provides correct, relevant details about drug efficacy, guidelines, and histology considerations without inaccuracies or omissions."
  },
  "439": {
    "score": 0.0,
    "explanation": "0: The model answer directly contradicts the reference by stating observation is not appropriate, whereas the reference explicitly states observation is an option in this scenario; this is a major inaccuracy and could lead to inappropriate denial of a reasonable management approach."
  },
  "440": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies H1 receptor antagonism as the direct molecular target, explains the dual mechanism, and provides clinically relevant context without inaccuracies or omissions."
  },
  "441": {
    "score": 1.0,
    "explanation": "1: The model answer directly contradicts the reference by recommending immediate switch to osimertinib, omitting the key fact that current therapy should be completed first; this is a major inaccuracy with potentially significant clinical implications."
  },
  "442": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately identifies the pharmacological class and mechanism, and provides additional correct and clinically relevant details without any inaccuracies or omissions."
  },
  "443": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies glucocorticoids and their inhibition of phospholipase A2, but it does not name \"lipoxygenase inhibitors\" as the class of enzyme inhibitors, missing the specific mechanism referenced in the question and reference answer."
  },
  "444": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly prioritizing re-resection over radiation, clarifying that radiation is not always required, and providing relevant, accurate additional details without inaccuracies or omissions."
  },
  "445": {
    "score": 3.0,
    "explanation": "3: The model answer focuses on Fc receptor blockade, which is a recognized mechanism of IVIG but omits the reference answer's key fact—neutralization of pathogenic autoantibodies (antigen neutralization). While the explanation is detailed and accurate regarding Fc blockade, it misses the primary mechanism cited in the reference, resulting in a moderate omission."
  },
  "446": {
    "score": 1.0,
    "explanation": "1: The model answer directly contradicts the reference by recommending continued HER2-targeted therapy, which is not clinically indicated after progression on multiple prior lines; this is a major inaccuracy and could lead to inappropriate treatment."
  },
  "447": {
    "score": 2.0,
    "explanation": "2: The model answer misidentifies the drug as levetiracetam instead of gabapentin enacarbil, which is a moderate factual error, though it provides a correct mechanism for levetiracetam; this results in only partial alignment with the reference and a significant key fact omission."
  },
  "448": {
    "score": 5.0,
    "explanation": "5: Fully covers all key facts from the reference answer, accurately describes the mechanism, and provides clinically relevant additional details without any inaccuracies or omissions."
  },
  "449": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional details, and contains no inaccuracies or omissions."
  },
  "450": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies competitive inhibition as the class of enzymatic inhibition, explains the mechanism in detail, and accurately relates it to the clinical context without any inaccuracies or omissions."
  },
  "451": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional detail, and contains no inaccuracies or omissions."
  },
  "452": {
    "score": 3.0,
    "explanation": "3: The model answer provides a thorough explanation of dantrolene’s mechanism and clinical context but incorrectly identifies \"ryanodine receptor antagonists\" as the pharmacological class, omitting the reference answer’s \"calcium channel antagonists\" and thus missing a key fact."
  },
  "453": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies beta-2 adrenergic receptors as the target, explains the mechanism, distinguishes from other receptor classes, and provides relevant clinical context without inaccuracies or omissions."
  },
  "454": {
    "score": 2.0,
    "explanation": "2: The model answer contradicts the reference by stating it is generally acceptable to proceed without pathologic confirmation, whereas the reference clearly states invasive sampling is mandatory. While the model provides nuanced discussion and relevant caveats, this represents a moderate factual error regarding standard of care."
  },
  "455": {
    "score": 3.0,
    "explanation": "3: The model answer correctly explains corticosteroids' mechanism (PLA2 inhibition) and its effect on leukotriene synthesis, but it does not directly name the enzyme class as \"lipoxygenase inhibitors\" as required by the reference. It also focuses on an upstream mechanism rather than the specific enzyme class asked, covering about 70-89% of key facts."
  },
  "456": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly identifies PDE4 as the enzyme responsible for cGMP degradation (PDE4 primarily hydrolyzes cAMP, not cGMP), which is a moderate factual error. While it discusses relevant mechanisms, the key fact—cGMP-specific phosphodiesterase—is missed."
  },
  "457": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies microtubules as the primary structure targeted and provides accurate, relevant mechanistic and clinical context, but does not explicitly state \"tubulin\" as the direct target, which is the precise answer in the reference."
  },
  "458": {
    "score": 3.0,
    "explanation": "3: The model answer correctly explains the mechanism and provides relevant examples, but it does not use the precise mechanistic class term \"physiochemical activity\" as in the reference answer, which is a key fact; instead, it gives the pharmacologic class \"keratolytic,\" making this a moderate omission."
  },
  "459": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately identifies the drug class and mechanism, and provides relevant, correct additional details without any inaccuracies or omissions."
  },
  "460": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies cyclooxygenase (COX) as the molecular target and provides relevant clinical and mechanistic context, but does not specify COX-1 (prostaglandin G/H synthase 1) as in the reference answer, representing a minor omission."
  },
  "461": {
    "score": 4.0,
    "explanation": "4: The model answer covers the key fact of HMG-CoA reductase inhibition and provides a detailed, accurate, and clinically relevant explanation of downstream effects, but the main mechanism per the reference is direct enzyme inhibition; the model emphasizes LDL receptor upregulation as the \"main\" mechanism, which is a minor wording inaccuracy."
  },
  "462": {
    "score": 4.0,
    "explanation": "4: The model answer correctly describes the key process as degradation of TTR mRNA via RNAi, details the mechanism, and links it to clinical benefit, but its emphasis on \"translation\" as the disrupted process is a minor wording inaccuracy compared to the reference, which focuses on mRNA degradation (gene silencing) as the primary event."
  },
  "463": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes when radiotherapy is appropriate, and provides additional relevant, evidence-based details without inaccuracies or omissions."
  },
  "464": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, correctly identifies antioxidant/free radical scavenging activity as the relevant property, and provides accurate, clinically relevant explanations without inaccuracies or omissions."
  },
  "465": {
    "score": 3.0,
    "explanation": "3: The model answer covers the clinical context and provides detailed mechanisms of miltefosine action, but it omits the key fact that the primary molecular pathway targeted is lysophospholipid receptor interactions, as specified in the reference. The focus on PKC/JNK/ceramide is relevant but does not directly address the main pathway asked."
  },
  "466": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies cyclooxygenase (COX) as the molecular target and provides accurate, relevant mechanistic detail, but does not specify COX-2, which is the more precise isoform relevant to the anti-inflammatory effect; this is a minor omission."
  },
  "467": {
    "score": 3.0,
    "explanation": "3: The model answer provides a detailed and accurate explanation of the mechanism of action of third-generation cephalosporins as beta-lactam antibiotics, but it does not directly state \"enzyme inhibitors,\" which is the key fact in the reference answer. Thus, it covers most but not all key facts."
  },
  "468": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies cytochrome P450 enzymes and provides detailed reasoning, but it incorrectly emphasizes CYP3A4 as the primary relevant isoform, whereas the reference specifically requires CYP1A inducers; this represents a moderate factual error."
  },
  "469": {
    "score": 3.0,
    "explanation": "3: The model answer provides a strong rationale for switching to crizotinib upon discovery of an ALK rearrangement and covers most key facts, but it omits that both completing current therapy or switching are acceptable options based on clinical judgment, as stated in the reference. It overstates the necessity to switch immediately, missing the nuance that either approach is supported."
  },
  "470": {
    "score": 3.0,
    "explanation": "3: The model answer provides a detailed and accurate description of cyclobenzaprine’s proposed mechanisms but does not explicitly state that the molecular mechanism is unknown, as required by the reference answer. While the mechanistic details are correct, the omission of the key fact—\"unknown cellular or molecular interaction\"—constitutes a minor but meaningful omission."
  },
  "471": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly explains the rationale for less frequent surveillance, and accurately distinguishes between post-surgical and post-radiotherapy protocols without any inaccuracies or omissions."
  },
  "472": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies the mechanism as RNA synthesis inhibition and provides accurate, relevant details about rifampin, but it does not use the broader class term \"Nucleic Acid Synthesis Inhibitors\" as in the reference, which is a minor wording inaccuracy."
  },
  "473": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts, emphasizing that adjuvant radiotherapy is recommended and surveillance alone is not standard, but it incorrectly states that adjuvant RT is \"strongly recommended\" and \"Category 1\" per NCCN, omitting that re-resection is preferred and that RT is actually category 2B; this represents a moderate factual inaccuracy."
  },
  "474": {
    "score": 3.0,
    "explanation": "3: The model answer incorrectly identifies CYP3A4 as the primary pathway, whereas the reference specifies CYP1A; however, it otherwise provides a thorough, clinically relevant explanation of the mechanism, consequences, and importance of monitoring, covering most key facts but with a moderate factual error regarding the specific enzyme."
  },
  "475": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately emphasizes systemic therapy as preferred, details the risks and limitations of re-irradiation, and appropriately notes that repeat radiotherapy is not an absolute indication but may be considered in select cases. No inaccuracies or omissions are present."
  },
  "476": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale, and cites relevant guidelines; there are no inaccuracies or omissions."
  },
  "477": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate staging, guideline-based recommendations, and relevant additional considerations without any inaccuracies or omissions."
  },
  "478": {
    "score": 2.0,
    "explanation": "2: The model answer focuses on norepinephrine reuptake inhibition rather than serotonin reuptake inhibition, which is the key fact in the reference answer. While it provides relevant pharmacological details, it omits the primary mechanism asked for and instead emphasizes a different monoamine, constituting a moderate factual error."
  },
  "479": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies the pharmacological class (beta-lactam antibiotics) and explains the mechanism, but it does not use the general term \"enzyme inhibitors\" as in the reference answer, missing the broader classification requested."
  },
  "480": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies neutralization of pathogenic autoantibodies as the principal mechanism, provides relevant supporting details, and contains no inaccuracies or omissions compared to the reference answer."
  },
  "481": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, including ceritinib's hepatotoxicity, contraindication or need for dose adjustment in hepatic impairment, and the recommendation to prioritize alectinib or other alternatives. Additional details are accurate and clinically relevant, with no omissions or inaccuracies."
  },
  "482": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly identifies glycine instead of asparagine as the target, which is a moderate factual error, though the reasoning is relevant to pigment stones; about half of the key facts are addressed but the main target is wrong."
  },
  "483": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, correctly identifies GABA_B as the primary receptor, and provides relevant, accurate explanations without any inaccuracies or omissions."
  },
  "484": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies the pharmacologic class (sympathomimetic amine), the central role of adrenergic receptor activation, and the mechanism involving norepinephrine and hypothalamic pathways, covering over 90% of key facts. However, it does not explicitly state \"alpha-adrenergic\" as the primary receptor subtype, which is a minor omission."
  },
  "485": {
    "score": 3.0,
    "explanation": "3: The model answer recommends annual imaging in years 4 and 5, which contradicts the reference answer's recommendation of every six months; while the answer is well-supported and references guidelines, it omits the key fact that more frequent (every six months) imaging is recommended per the reference, thus missing a critical clinical detail."
  },
  "486": {
    "score": 2.0,
    "explanation": "2: The model answer provides a detailed and accurate explanation of PDE inhibitors, but it does not identify the reference answer’s class (adrenergic beta-agonists) or their mechanism, thus missing the key fact required by the question and reference. The answer is otherwise factually correct and relevant."
  },
  "487": {
    "score": 4.0,
    "explanation": "4: The model answer correctly explains the mechanism, clinical context, and names the class as \"antifibrinolytic agents,\" but does not explicitly use the term \"plasmin inhibitors\" as in the reference; otherwise, it covers all key facts with no clinically relevant errors."
  },
  "488": {
    "score": 3.0,
    "explanation": "3: The model answer provides a thorough and accurate explanation of corticosteroid action but incorrectly identifies phospholipase A₂ as the most directly inhibited enzyme, rather than lipoxygenase, which is specifically responsible for leukotriene synthesis; otherwise, the content is correct and relevant."
  },
  "489": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly stating that adjuvant radiation (sequential or concurrent chemoradiation) is indicated for R1 resection regardless of prior chemotherapy, and provides additional correct, relevant details without inaccuracies or omissions."
  },
  "490": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, including modality (non-contrast chest CT), schedule (every 3–6 months), rationale for non-contrast use, and the importance of clinical evaluation, with additional correct and relevant details; there are no inaccuracies or omissions."
  },
  "491": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately cites major guidelines, and provides correct, clinically relevant rationale for not using routine FDG-PET/CT or brain MRI in surveillance, with no inaccuracies or omissions."
  },
  "492": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately emphasizes the necessity of excluding distant metastases with FDG-PET/CT and brain MRI, and provides additional clinically relevant detail without inaccuracies or omissions."
  },
  "493": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional detail on diagnostic criteria, rationale, and management, and contains no inaccuracies or omissions."
  },
  "494": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies carbohydrates as the macromolecule class replenished and explains the rapid cellular uptake and ATP restoration, but it underemphasizes glycogen (the specific structural macromolecule in the reference) and focuses more on energy metabolism than storage, representing a minor omission."
  },
  "495": {
    "score": 3.0,
    "explanation": "3: The model answer covers the antimicrobial effect well and provides relevant mechanistic detail, but it omits the primary reference mechanism—acid-base activity (creation of a mildly acidic environment)—which is central to the question. The answer is otherwise accurate and clinically relevant."
  },
  "496": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies niacin deficiency and its clinical features, and explains the mechanism of action, but does not explicitly state \"enzyme activators\" as the pharmacological class, which is the key fact in the reference answer; instead, it uses \"vitamin replacement therapy,\" which is less precise for the mechanism asked."
  },
  "497": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the interferon-alpha/beta receptor (IFNAR) complex as the essential mediator, provides accurate mechanistic details, and includes only clinically relevant, factually correct additional information without omissions or inaccuracies."
  },
  "498": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies nucleoside analogs and explains their mechanism, but it omits the broader pharmacological class \"enzyme inhibitors\" as in the reference, and focuses on a subclass, missing the key fact required by the question."
  },
  "499": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies cyclooxygenase (COX) as the molecular target and explains the mechanism, but does not specify COX-1 (prostaglandin G/H synthase 1) as in the reference; this is a minor omission since NSAIDs inhibit both COX-1 and COX-2, but the reference asks for COX-1 specifically."
  },
  "500": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately emphasizes the necessity of baseline brain MRI before initiating crizotinib, and provides additional relevant, guideline-based context without inaccuracies or omissions."
  },
  "501": {
    "score": 2.0,
    "explanation": "2: The model answer focuses on increased ROS generation and its downstream effects, which is the opposite of the reference answer's key fact—free radical scavenging activity. While some mechanisms described are relevant, the primary molecular mechanism is misidentified, constituting a moderate factual error."
  },
  "502": {
    "score": 2.0,
    "explanation": "2: The model answer provides a detailed rationale but directly contradicts the reference by stating that broad molecular profiling is not routinely recommended after finding KRAS G12C, omitting the key fact that comprehensive testing is still standard even in squamous histology. This is a moderate factual error and misses the essential clinical recommendation."
  },
  "503": {
    "score": 1.0,
    "explanation": "1: The model answer directly contradicts the reference by recommending immediate initiation of ROS1-targeted therapy and discontinuation of ongoing systemic therapy, which is not standard practice; this constitutes a major inaccuracy and unsafe deviation from guidelines."
  },
  "504": {
    "score": 3.0,
    "explanation": "3: The model answer provides a detailed and accurate discussion of chemokine receptor biology and HPV immunology, but it incorrectly identifies CXCR3 as the target instead of CXCR4, missing the key fact required by the question. The rest of the content is relevant and correct, but the primary factual error limits the score."
  },
  "505": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately stating that palliative chemotherapy does not require symptomatic disease and can be considered for asymptomatic patients. Additional content is factually correct, clinically relevant, and expands appropriately on decision factors without introducing inaccuracies or omissions."
  },
  "506": {
    "score": 3.0,
    "explanation": "3: The model answer correctly explains the mechanism of somatostatin analogs and their action on SSTR2, but it omits SSTR5, which is the primary molecular target per the reference. The explanation is otherwise accurate and relevant, but misses a key fact."
  },
  "507": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies aminoglycosides and details their mechanism, but it does not directly state the broad pharmacological class (\"protein synthesis inhibitors\") as required by the question and reference answer, resulting in a moderate omission."
  },
  "508": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, including the necessity of pathological confirmation of N3 disease and pulmonary function testing before treatment, and provides additional accurate, clinically relevant explanations without any inaccuracies or omissions."
  },
  "509": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies the mechanism and clinical context but incorrectly specifies \"Aminoglycosides\" as the pharmacological class, whereas the reference answer requires the broader class \"Protein synthesis inhibitors\"; this is a moderate factual error, though the mechanistic explanation is otherwise accurate."
  },
  "510": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly identifies PPAR agonism as the mechanism, whereas the reference specifies thyroid hormone receptor agonism; while the explanation is detailed and relevant to NAFLD, it omits the key fact and centers on the wrong nuclear receptor, constituting a moderate factual error."
  },
  "511": {
    "score": 3.0,
    "explanation": "3: The model answer provides a detailed and accurate explanation of the acidification mechanism but omits the primary pharmacologic property specified in the reference—osmotic activity—thus missing the key fact required by the question."
  },
  "512": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant supporting evidence, and contains no inaccuracies or omissions. Additional details (trial data, guidelines) are correct and enhance the answer."
  },
  "513": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies enzyme inhibition as the mechanistic category and provides accurate, relevant clinical and mechanistic details, but does not explicitly use the broader term \"biological macromolecular activity\" as in the reference; this is a minor wording inaccuracy."
  },
  "514": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly identifies the adjunct drug as methylene blue rather than pentoxifylline and provides detailed mechanisms for methylene blue, which are not relevant here; it thus misses the key fact that the precise mechanism in cerebral malaria is unknown, and most of its content is not applicable to the scenario."
  },
  "515": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies dihydrofolate reductase inhibitors as the drug class, explains the mechanism, and provides relevant clinical context, but does not explicitly use the broader term \"folic acid metabolism inhibitors\" as in the reference, which is a minor wording inaccuracy."
  },
  "516": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately distinguishes between synchronous primaries and intrapulmonary metastasis, and thoroughly explains the impact on staging and treatment. Additional details are correct, clinically relevant, and enhance the answer without introducing inaccuracies or omissions."
  },
  "517": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies nintedanib and explains the role of PDGFR in IPF, but it does not mention CSF1R, which is the specific molecular target asked for in the reference answer; thus, it omits a key fact."
  },
  "518": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies azole antifungals as CYP3A4 inhibitors and explains the mechanism of reduced metabolism leading to vasoconstriction, but incorrectly attributes the interaction to triptans rather than dihydroergotamine (an ergot alkaloid), missing the key fact that ergot derivatives—not triptans—are the classic agents involved in this dangerous interaction."
  },
  "519": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly emphasizes that immunosuppression alters standard management, and provides relevant, accurate explanations without any inaccuracies or omissions."
  },
  "520": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately details the impact of nodule location on staging and management, and provides correct, clinically relevant elaboration without inaccuracies or omissions."
  },
  "521": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies nintedanib and its inhibition of PDGFR, but it omits VEGFR, which is the specific receptor asked for in the question and is central per the reference. While the mechanistic explanation is accurate, the primary target per the reference is missed, constituting a moderate omission."
  },
  "522": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately emphasizes that ALK inhibitor therapy should not be delayed for broad profiling, and provides additional, relevant, and correct context without any inaccuracies or omissions."
  },
  "523": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale, and adds relevant, correct details about treatment intent, guidelines, and the necessity of restaging, with no inaccuracies or omissions."
  },
  "524": {
    "score": 4.0,
    "explanation": "4: The model answer covers all key clinical facts and provides extensive, accurate, and relevant guideline-based rationale, but it overstates the strength of recommendation (implying \"recommended\" or \"indicated\" rather than \"may be considered\" or \"option\" per category 2B evidence for T1a tumors), which is a minor wording inaccuracy."
  },
  "525": {
    "score": 3.0,
    "explanation": "3: The model answer provides a detailed and accurate discussion of EGFR G719X mutations, TKI options, and supporting evidence, but it overstates the preference for EGFR-targeted therapy over chemotherapy in squamous cell carcinoma, missing the key point that platinum-based chemotherapy remains the standard first-line treatment in this histology and setting; this is a clinically significant omission."
  },
  "526": {
    "score": 3.0,
    "explanation": "3: The model answer covers the clinical context and discusses keratolysis in detail, but it does not specifically mention \"physiochemical alteration of the scalp environment\" as the primary mechanism, which is the key fact in the reference answer. The focus on keratolysis is related but not fully equivalent, resulting in a moderate omission."
  },
  "527": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly identifies OCT2 as the direct molecular target, whereas the reference specifies MATE2-K; it covers some relevant transporter information but contains a moderate factual error regarding the primary inhibited transporter."
  },
  "528": {
    "score": 3.0,
    "explanation": "3: The model answer provides a detailed and accurate description of metronidazole’s proposed mechanism, but it does not explicitly state that the precise cellular or molecular interaction is unknown, as required by the reference answer; instead, it summarizes current hypotheses, thus missing the key fact that the mechanism is not fully understood."
  },
  "529": {
    "score": 3.0,
    "explanation": "3: The model answer covers the general mechanisms of interferon-alpha and acknowledges the uncertainty in its precise action for wart regression, but it does not clearly state that the cellular or molecular interaction is unknown, as in the reference. The detailed mechanistic discussion, while accurate, slightly overstates current understanding and does not fully match the reference's emphasis on the unknown mechanism."
  },
  "530": {
    "score": 3.0,
    "explanation": "3: The model answer provides a detailed and accurate description of the cellular uptake mechanism (receptor-mediated endocytosis via mannose or mannose-6-phosphate receptors), but it omits the most direct pharmacological mechanism—restoration of deficient lysosomal enzyme activity—highlighted in the reference. The focus on uptake is correct but secondary, resulting in a moderate omission."
  },
  "531": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional details, and contains no inaccuracies or omissions."
  },
  "532": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key facts from the reference, clearly stating that the precise mechanism is unknown while providing clinically relevant, accurate context about primaquine’s action and the uncertainty surrounding its molecular targets."
  },
  "533": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies ATP-citrate lyase inhibitors as the class, explains their mechanism as upstream of HMG-CoA reductase, and provides relevant clinical context; all key facts from the reference are included with accurate, clinically relevant elaboration."
  },
  "534": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, including the appropriateness of broad molecular profiling in advanced non-squamous NSCLC, the need for re-biopsy or plasma-based testing if tissue is insufficient, and the rationale for testing all listed biomarkers. Additional content is accurate, clinically relevant, and guideline-based, with no inaccuracies or omissions."
  },
  "535": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies the clinical scenario and mechanism of action for calcitonin, but incorrectly names \"cell surface receptors\" (specifically GPCRs) as the most direct molecular target, rather than the structural macromolecules (collagen) that are ultimately responsible for bone strength. This misses the key fact required by the question, though the rest of the explanation is accurate and relevant."
  },
  "536": {
    "score": 3.0,
    "explanation": "3: The model answer provides a detailed and accurate general mechanism of povidone-iodine's biocidal action, but it does not explicitly state that the specific cellular or molecular interaction with cutaneous parasites is unknown, as required by the reference. This constitutes a moderate omission, though the rest of the content is factually correct and relevant."
  },
  "537": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies aminoglycosides as the adjunctive antibiotic class and accurately describes their mechanism, but it does not explicitly state the broader pharmacological class (\"protein synthesis inhibitors\") as in the reference answer, representing a minor omission."
  },
  "538": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the interferon-α/β receptor (IFNAR) as the primary mediator, covers all key clinical and mechanistic details from the reference, and provides accurate, relevant explanations without errors or omissions."
  },
  "539": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies cyclooxygenase (COX) as the enzyme class inhibited by NSAIDs and provides a detailed, accurate explanation, but it does not mention lipoxygenase or leukotriene synthesis, which are the key facts in the reference answer."
  },
  "540": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale for broad molecular profiling, addresses the rarity of BRAF V600E in squamous histology, and discusses the therapeutic hierarchy and guideline context without any inaccuracies or omissions."
  },
  "541": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional details, and contains no inaccuracies or omissions."
  },
  "542": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies the use of anti-IL-5 monoclonal antibodies and their mechanism, but it does not directly name the general drug class \"Biological Response Modifiers\" as required by the reference answer, and instead focuses on a specific subclass, missing the broader classification."
  },
  "543": {
    "score": 3.0,
    "explanation": "3: The model answer correctly explains the mechanism and target enzyme but gives a more specific class (\"Oxidative Phosphorylation Inhibitors\") rather than the broader, reference answer of \"Enzyme Inhibitors\"; it covers most key facts but does not match the general class requested."
  },
  "544": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides additional correct and clinically relevant explanations, and includes no inaccuracies or omissions."
  },
  "545": {
    "score": 1.0,
    "explanation": "1: The model answer directly contradicts the reference by recommending immediate switch to targeted therapy rather than completing the initial regimen, which is a major inaccuracy and could lead to inappropriate clinical management."
  },
  "546": {
    "score": 3.0,
    "explanation": "3: The model answer covers the key concept of trace metal (iron) chelation but introduces alpha-lipoic acid, which is not specifically referenced and may not be the intended supplement. While the mechanistic explanations are mostly accurate and relevant, the answer is less focused on iron chelation specifically and includes some extraneous detail, resulting in minor inaccuracies and partial misdirection."
  },
  "547": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies olaparib as not appropriate due to renal impairment, and provides accurate, clinically relevant explanations without inaccuracies or omissions."
  },
  "548": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly prioritizes EGFR-targeted therapy over palliative radiotherapy for diffuse, symptomatic brain metastases, which is a moderate factual error. While it provides relevant evidence and context, it omits the key clinical fact that urgent local brain-directed therapy is prioritized in this setting, not systemic therapy."
  },
  "549": {
    "score": 1.0,
    "explanation": "1: The model answer directly contradicts the reference by recommending an immediate switch to TRK inhibitor, which is not standard practice; this is a major inaccuracy and could lead to unsafe clinical decisions."
  },
  "550": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately details the differences in surveillance frequency and rationale, and provides additional relevant, correct explanations without any inaccuracies or omissions."
  },
  "551": {
    "score": 2.0,
    "explanation": "2: The model answer focuses on the staging definition and default management of M1a disease, but omits the key clinical principle from the reference: that if both lesions are potentially curable, they should be managed as two primaries rather than as metastatic disease. It overemphasizes metastatic management and does not clearly state the exception for potentially curable lesions, missing a central point."
  },
  "552": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies thioredoxin reductase as the target and provides detailed, accurate mechanistic context, but does not specify the mitochondrial isoform (thioredoxin reductase 2) as in the reference; this is a minor omission."
  },
  "553": {
    "score": 3.0,
    "explanation": "3: The model answer incorrectly describes the mechanism as \"competitive antagonism\" rather than the reference's \"noncompetitive antagonism,\" which is a key mechanistic distinction; otherwise, it covers most key facts and provides relevant, accurate detail."
  },
  "554": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, including the contraindication of surgery due to high perioperative risk, prioritization of SABR/EBRT, and the need for formal operability assessment and MDT discussion. Additional details are accurate and clinically relevant, with no inaccuracies or omissions."
  },
  "555": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the interferon-alpha receptor (IFNAR) complex as the direct molecular target, thoroughly explains the mechanism, and provides clinically relevant details without inaccuracies or omissions."
  },
  "556": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly identifies the thrombopoietin receptor (c-Mpl) as the relevant complex, whereas the reference specifies the interferon alpha receptor complex. While the model provides a detailed rationale, it centers on the wrong therapy and receptor, constituting a moderate factual error and covering less than 70% of key facts."
  },
  "557": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate, guideline-based rationale, and includes clinically relevant details about mutation sensitivity, guideline recommendations, and the role of EGFR TKIs in squamous histology, with no inaccuracies or omissions."
  },
  "558": {
    "score": 1.0,
    "explanation": "1: The model answer incorrectly states that RET-targeted therapy is a valid first-line option for squamous NSCLC with RET rearrangement, directly contradicting current guidelines and evidence, which restrict RET inhibitors to non-squamous histology or clinical trials; this is a major inaccuracy with potential for harm."
  },
  "559": {
    "score": 2.0,
    "explanation": "2: The model answer provides detailed and accurate information about albendazole’s mechanism and CYP450 inhibition, but it does not mention CYP2A6—the specific enzyme in the reference answer—and instead focuses on CYP1A2, CYP2C9, and CYP3A4, representing a moderate factual omission."
  },
  "560": {
    "score": 3.0,
    "explanation": "3: The model answer correctly describes dopamine reuptake inhibition and its role in promoting wakefulness, but the reference answer specifies norepinephrine reuptake inhibition as the key pathway. The model omits this and instead focuses on dopamine, covering about 70-89% of the key facts but missing the specific neurotransmitter emphasized in the reference."
  },
  "561": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides additional correct and clinically relevant detail, and contains no inaccuracies or omissions."
  },
  "562": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, including the necessity of MRI for assessing local invasion, its superiority over CT/PET for soft tissue and neurovascular evaluation, and guideline recommendations; all additional explanations are accurate and clinically relevant, with no omissions or inaccuracies."
  },
  "563": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies the drug and its mechanism as indirect factor Xa inhibition via antithrombin, but it omits the key reference term \"serpins potentiators\" and does not explicitly state the pharmacological class as \"serine proteinase inhibitor (serpin) potentiators,\" covering about 70-89% of key facts."
  },
  "564": {
    "score": 2.0,
    "explanation": "2: The model answer is comprehensive and guideline-based but directly contradicts the reference answer on the central point—grade 3 alone is sufficient to justify RNI per the reference. This is a moderate factual omission/error, as the model answer underestimates the role of grade 3 in this scenario."
  },
  "565": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies PPARα-mediated gene regulation and details its downstream effects, but it omits explicit mention of increased hepatic fatty acid β-oxidation—the key process in the reference answer. The mechanistic explanation is accurate but misses the direct link to oxidation activity."
  },
  "566": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies prostanoid (prostaglandin) receptors as the primary class, specifies the EP4 subtype, and provides accurate, clinically relevant pharmacologic and physiologic details without any inaccuracies or omissions."
  },
  "567": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate, guideline-based rationale, and adds relevant, correct details without any inaccuracies or omissions."
  },
  "568": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional detail, and contains no inaccuracies or omissions."
  },
  "569": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains staging, unresectability, standard management, and provides relevant, correct additional details without inaccuracies or omissions."
  },
  "570": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies cyclooxygenase (COX) as the inhibited enzyme and provides accurate, relevant clinical context, but does not specify \"COX-1\" or \"prostaglandin G/H synthase 1\" as in the reference, representing a minor omission in specificity."
  },
  "571": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies cyclooxygenase (COX) as the molecular target, explains its role in prostaglandin synthesis, and accurately describes the mechanism of NSAIDs in treating inflammatory bursitis, with no omissions or inaccuracies."
  },
  "572": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly explains the surveillance indication for a 6 mm subsolid nodule, and provides additional, accurate, and clinically relevant context without any inaccuracies or omissions."
  },
  "573": {
    "score": 3.0,
    "explanation": "3: The model answer provides a detailed and accurate mechanism for atovaquone, correctly identifying it as a mitochondrial electron transport inhibitor, but it does not directly match the reference answer's required class of \"nucleic acid synthesis inhibitors,\" which is the best pharmacologic description per the question; thus, there is a moderate omission."
  },
  "574": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies direct adrenergic receptor agonism as the primary mechanism and provides detailed, accurate molecular explanation, but omits explicit mention of dopamine receptor stimulation, which is a key fact in the reference answer."
  },
  "575": {
    "score": 2.0,
    "explanation": "2: The model answer provides several proposed mechanisms of gentian violet’s action, but the reference answer clearly states that the precise mechanism is unknown; thus, the model introduces moderate factual inaccuracies and overstates current knowledge."
  },
  "576": {
    "score": 1.0,
    "explanation": "1: The model answer incorrectly states that RET-targeted therapy is the preferred first-line option for squamous cell carcinoma, contradicting current guidelines and evidence, which do not support RET inhibitors as first-line in this histology; this is a major inaccuracy with potential clinical implications."
  },
  "577": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains why ALND omission is not appropriate post-neoadjuvant therapy, and provides relevant, correct, and detailed supporting evidence without inaccuracies or omissions."
  },
  "578": {
    "score": 3.0,
    "explanation": "3: The model answer covers the key fact that gentian violet’s precise mechanism is incompletely defined, but it adds multiple speculative mechanisms (cell wall/membrane disruption, ROS, metabolic interference) that go beyond the reference’s “unknown” and may overstate current knowledge; this constitutes minor overreach and partial irrelevance, but no unsafe advice."
  },
  "579": {
    "score": 3.0,
    "explanation": "3: The model answer correctly describes the mechanism of abatacept and its action on B7 molecules (CD80/CD86), but it omits that the primary molecular target relevant to the question is CTLA-4, as specified in the reference answer. This is a moderate omission, as the question specifically asks for the molecular target whose inhibition is responsible for the therapeutic effect."
  },
  "580": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the timing and intensity of surveillance, addresses the appropriateness of CT modality, and cites relevant guidelines without any inaccuracies or omissions."
  },
  "581": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the evidence and standard recommendations, and appropriately discusses when endocrine therapy alone may be considered, with no inaccuracies or omissions."
  },
  "582": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, including the necessity of platinum-based chemotherapy in combination with immunotherapy, the inadequacy of immunotherapy monotherapy in PD-L1 <1%/biomarker-negative NSCLC, supporting trial data, and guideline recommendations; there are no inaccuracies or omissions."
  },
  "583": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, including the preference for surgery in operable, resectable cases, the rationale for avoiding re-irradiation, and the need for multidisciplinary evaluation and thorough staging. Additional content is accurate, relevant, and enhances clinical understanding without introducing errors or omissions."
  },
  "584": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly asserts that concurrent chemoradiation is preferred, whereas the reference states both approaches are equally appropriate due to lack of evidence for superiority; this is a moderate factual error, though the rest of the content is relevant and accurate."
  },
  "585": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate, clinically relevant supporting evidence (PACIFIC, ADAURA, LAURA trials), addresses safety and guidelines, and contains no inaccuracies or omissions."
  },
  "586": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale for SRS alone, clearly outlines when surgery is indicated, and provides relevant, evidence-based justification without inaccuracies or omissions."
  },
  "587": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies cyclooxygenase (COX) as the target and explains the mechanism, but does not specifically name COX-2 (prostaglandin G/H synthase 2) as the primary molecular target, as required by the reference answer; it also emphasizes non-selectivity, which is less precise for this question."
  },
  "588": {
    "score": 3.0,
    "explanation": "3: The model answer provides a detailed and accurate account of pentoxifylline’s proposed mechanisms, but it overstates the certainty of the molecular mechanism, whereas the reference emphasizes that the precise cellular/molecular interaction is unknown; this constitutes a minor but meaningful inaccuracy and partial omission of the key reference point."
  },
  "589": {
    "score": 4.0,
    "explanation": "4: The model answer covers nearly all key clinical facts, accurately describing the surgical considerations, risks, and guideline recommendations for both T3 and T4 scenarios, but overstates the difference in eligibility by implying surgery is \"not equally applicable\" and \"not routinely recommended\" for T4, whereas the reference states anatomical location alone does not preclude surgery; this constitutes a minor wording inaccuracy."
  },
  "590": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale, cites supporting evidence and guidelines, and clearly states that SLN mapping/excision is appropriate while ALND is not routinely required. No inaccuracies or omissions are present."
  },
  "591": {
    "score": 4.0,
    "explanation": "4: The model answer covers over 90% of the key facts, correctly clarifying that re-resection is only for resectable disease and that radiotherapy is the standard for unresectable local disease, with accurate references to guidelines. There is a minor wording inaccuracy in stating that unresectable patients are \"not excluded from local therapy recommendations,\" which could be misinterpreted, but overall the answer is thorough and clinically sound."
  },
  "592": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly identifies PPARα as the primary target, whereas the reference specifies thyroid hormone receptor agonists; while the explanation is detailed and relevant to lipid metabolism, it misses the key fact and thus covers less than 70% of the required content."
  },
  "593": {
    "score": 3.0,
    "explanation": "3: The model answer provides a detailed and accurate description of proposed mechanisms for UDCA, but it does not directly state that the precise cellular or molecular mechanism is unknown, as required by the reference. While the mechanistic details are correct and relevant, the answer omits the key fact that the mechanism remains unclear, thus missing the core of the reference answer."
  },
  "594": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly states that adjuvant radiation therapy is routinely warranted and that observation is inappropriate, directly contradicting the reference, which allows observation as an appropriate option. While the answer is detailed and factually correct in its rationale, this moderate factual error regarding standard management significantly lowers the score."
  },
  "595": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key facts from the reference (PABA antagonism and inhibition of folate synthesis), correctly identifies the drug and enzyme, and provides clinically relevant additional detail without inaccuracies or omissions."
  },
  "596": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional detail, and contains no inaccuracies or omissions."
  },
  "597": {
    "score": 4.0,
    "explanation": "4: The model answer covers over 90% of key facts, correctly distinguishing tamoxifen as first-line for premenopausal women and AIs as preferred for postmenopausal women, with appropriate discussion of evidence and side effects. However, it omits the nuance that tamoxifen remains a valid option for postmenopausal women and that AI preference is particularly relevant for those under 60 or with thromboembolic risk, making the recommendation slightly more rigid than the reference."
  },
  "598": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale for deferring chemotherapy, and provides additional clinically relevant details without inaccuracies or omissions."
  },
  "599": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies RNA (specifically SMN2 pre-mRNA) as the direct molecular target and provides a detailed, accurate mechanism, but it omits the key fact that the therapy’s disease-modifying effect is mediated by modulation of the pre-mRNA splicing machinery (spliceosome components), which is the primary target class per the reference."
  },
  "600": {
    "score": 2.0,
    "explanation": "2: The model answer provides a detailed, plausible mechanism for menadiol’s action but goes far beyond the reference, which explicitly states the mechanism is not clearly defined. The model introduces unproven hypotheses and speculative mechanisms as fact, which constitutes a moderate factual error and overinterpretation."
  },
  "601": {
    "score": 4.0,
    "explanation": "4: The model answer covers nearly all key facts, correctly emphasizing the primacy of actionable driver mutations and the need for careful confirmation, but it overstates guideline support for use in squamous histology and does not sufficiently highlight that squamous histology is generally an exclusion except in rare, well-validated cases, which is a minor omission."
  },
  "602": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately identifies cyclooxygenase inhibition as the drug action, and provides correct, clinically relevant elaboration without any inaccuracies or omissions."
  },
  "603": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies the clinical syndrome and the mechanism of action for somatostatin analogs, but it fails to name the interferon alpha receptor complex as the molecular target specified in the reference answer, omitting the key fact required by the question."
  },
  "604": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate staging rationale, and details management implications for stage IV NSCLC, with no inaccuracies or omissions."
  },
  "605": {
    "score": 2.0,
    "explanation": "2: The model answer focuses on cephalosporins and beta-lactam antibiotics, which are subclasses, but omits the broader and correct general class of \"enzyme inhibitors\" as specified in the reference. While the mechanistic explanation is accurate, the key fact—identifying the general pharmacological class as enzyme inhibitors—is missing."
  },
  "606": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly distinguishing between routine surveillance and workup for suspected recurrence, and accurately describes the indications for FDG-PET/CT and brain MRI; all additional content is factually correct and clinically relevant."
  },
  "607": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides detailed and clinically relevant additional information on risk stratification, alternative therapies, and preoperative optimization, and contains no inaccuracies or omissions."
  },
  "608": {
    "score": 3.0,
    "explanation": "3: The model answer provides a detailed and accurate description of the RNA interference mechanism, but it does not directly state \"nucleic acid synthesis inhibition\" as the class of molecular mechanism, which is the key fact in the reference answer. The explanation is correct and relevant, but the omission of the reference terminology constitutes a minor-to-moderate omission."
  },
  "609": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale, cites relevant guidelines and trials, and provides additional clinically relevant context without inaccuracies or omissions."
  },
  "610": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately emphasizes the elevated malignancy risk due to smoking and fibrosis, cites relevant guidelines, and provides correct, clinically relevant rationale for continued surveillance; there are no inaccuracies or omissions."
  },
  "611": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts, including the need for pathological and molecular confirmation to distinguish between metastatic disease and synchronous primaries, and outlines management implications. However, it overemphasizes defaulting to metastatic disease and does not clearly state that potentially curable lesions should be managed as two primaries if both are amenable to curative treatment, as in the reference answer."
  },
  "612": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, correctly identifies the mechanism as prodrug activation via enzymatic conversion, and provides accurate, clinically relevant explanations without any inaccuracies or omissions."
  },
  "613": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies the pharmacological class as beta-lactam antibiotics and accurately describes their mechanism, covering all key clinical facts except for not explicitly using the broader term \"enzyme inhibitors\" as in the reference; this is a minor wording difference that does not alter the meaning."
  },
  "614": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, including the clear preference for selpercatinib or pralsetinib, the inferior efficacy and safety of cabozantinib, and guideline recommendations; additional details are accurate and clinically relevant, with no inaccuracies or omissions."
  },
  "615": {
    "score": 2.0,
    "explanation": "2: The model answer correctly identifies nintedanib and its inhibition of PDGFR, but PDGFR is not the specific macrophage receptor mediating the described signaling; the reference answer (CSF1R) is more precise. The model omits the key fact about CSF1R and instead focuses on PDGFR, which is a moderate factual error."
  },
  "616": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly recommends FDG-PET/CT as routine surveillance for an isolated nodule, whereas guidelines reserve advanced imaging for suspected recurrence or symptoms; it covers the brain MRI aspect correctly but overstates the role of PET/CT, constituting a moderate factual error."
  },
  "617": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies cyclooxygenase (COX) as the molecular target and provides a thorough, accurate explanation, but it does not specify COX-1 (Prostaglandin G/H Synthase 1) as the primary isoform referenced in the question, representing a minor omission."
  },
  "618": {
    "score": 1.0,
    "explanation": "1: The model answer directly contradicts the reference by recommending immediate switch to selpercatinib, which is not appropriate per current sequencing guidance; this is a major inaccuracy despite otherwise detailed and referenced content."
  },
  "619": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly emphasizes the overriding importance of triple-negative status and nodal involvement, and provides relevant, accurate guideline-based rationale. There are no inaccuracies or omissions, and the additional content is clinically relevant."
  },
  "620": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies thrombin as the primary target via antithrombin III activation, and provides accurate, relevant mechanistic detail without inaccuracies or omissions."
  },
  "621": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies cyclooxygenase (COX) as the target and explains aspirin’s irreversible acetylation, but it does not specify COX-2 (prostaglandin G/H synthase 2) as the most clinically relevant isoform in inflammation, and focuses more on COX-1, leading to a moderate omission."
  },
  "622": {
    "score": 3.0,
    "explanation": "3: The model answer correctly explains the mechanism of heparins and their clinical use, but the reference answer specifically asks for \"thrombin inhibitors\" as the class, not \"heparins.\" While heparins do inhibit thrombin via antithrombin III, the model does not directly name the class as \"thrombin inhibitors,\" missing the precise key fact required by the reference."
  },
  "623": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, including the continued indication for adjuvant HER2 therapy regardless of pCR or nodal status, and provides accurate, relevant explanations without any inaccuracies or omissions."
  },
  "624": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly prioritizing re-resection if feasible and safe, while also accurately describing concurrent chemoradiation as an appropriate alternative. Additional content is factually correct, clinically relevant, and guideline-based, with no inaccuracies or omissions."
  },
  "625": {
    "score": 3.0,
    "explanation": "3: The model answer explains the mechanism of botulinum toxin in detail and correctly describes its presynaptic inhibition of acetylcholine release, but it does not explicitly use the reference answer's pharmacological class, \"acetylcholine release inhibitors,\" instead focusing on \"neurotoxins\" and \"presynaptic neuromuscular blocking agents.\" This is a minor but meaningful omission in terminology, covering about 70-89% of key facts."
  },
  "626": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant rationale, cites supporting trials and guidelines, and contains no inaccuracies or omissions."
  },
  "627": {
    "score": 3.0,
    "explanation": "3: The model answer correctly explains the mechanism of corticosteroids inhibiting phospholipase A2, but it does not directly identify \"lipoxygenase inhibitors\" as the enzyme class most relevant to the question's focus on leukotriene synthesis, missing a key fact from the reference answer."
  },
  "628": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale, guidelines, and surveillance recommendations, and includes only relevant, correct, and clinically appropriate additional details."
  },
  "629": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly stating that absence of distant metastasis is required, and provides additional, accurate, and clinically relevant explanations without any inaccuracies or omissions."
  },
  "630": {
    "score": 2.0,
    "explanation": "2: The model answer provides a detailed and accurate explanation of the pathological and biological criteria for classifying two primaries, but it incorrectly denies that both lesions must be individually curable for the dual primary approach to be applicable, which is a key clinical fact in the reference answer. This constitutes a moderate factual error."
  },
  "631": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant explanations, and contains no inaccuracies or omissions. It thoroughly justifies why best supportive care is preferred and when systemic therapy may be reconsidered."
  },
  "632": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies valproic acid and its mechanism of increasing GABA by inhibiting GABA transaminase, but it incorrectly names GABA transaminase as the primary molecular target mediating the therapeutic effect, rather than the GABA B receptor as specified in the reference; this is a moderate factual error."
  },
  "633": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies demeclocycline and provides a detailed explanation, but it does not directly state \"protein synthesis inhibitor\" as the broad pharmacological class based on primary mechanism of action, which is the key fact in the reference answer; instead, it focuses on the drug's use as an ADH antagonist, omitting the reference's core classification."
  },
  "634": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the pharmacological class as glucocorticoids, explains the mechanism of action (glucocorticoid receptor agonist), and provides relevant clinical context without inaccuracies or omissions."
  },
  "635": {
    "score": 3.0,
    "explanation": "3: The model answer provides a detailed and accurate description of the proposed mechanism (Nrf2 pathway activation and cytoprotection), but it fails to emphasize that the precise molecular mechanism is still considered unknown according to current scientific consensus, which is the key fact in the reference answer."
  },
  "636": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies CMV DNA polymerase (UL54) as the principal target, provides accurate clinical reasoning, and includes only relevant, factually correct details with no omissions or inaccuracies."
  },
  "637": {
    "score": 3.0,
    "explanation": "3: The answer correctly describes the mechanism of benzimidazoles as microtubule inhibitors and links this to impaired metabolic enzyme function, but it does not directly identify the general class as \"enzyme inhibitors\" as in the reference. The explanation is detailed and accurate, but the key fact—general class of mechanism—is not explicitly stated, resulting in a minor omission."
  },
  "638": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies cyclooxygenase-2 (COX-2) as the molecular target, thoroughly explains the clinical context, drug mechanism, and relevance to prostaglandin synthesis, and matches all key facts in the reference without inaccuracies or omissions."
  },
  "639": {
    "score": 2.0,
    "explanation": "2: The model answer misses the key fact that initial radiotherapy is itself the determinant for more intensive surveillance, as stated in the reference. Instead, it incorrectly emphasizes pathological stage and risk features as the primary drivers, which is a moderate factual error. The answer is otherwise detailed and relevant but does not align with the reference's core point."
  },
  "640": {
    "score": 2.0,
    "explanation": "2: The model answer provides a detailed and accurate explanation of suicide (mechanism-based) inhibition, but it fails to identify the specific cytochrome P450 isoenzyme (CYP2B6) as required by the reference answer, and instead incorrectly focuses on CYP1A2 and triclabendazole, which is not the relevant clinical or mechanistic context for this scenario."
  },
  "641": {
    "score": 3.0,
    "explanation": "3: The model answer provides a thorough rationale for both SVC stenting and concurrent chemoradiation, but incorrectly prioritizes stenting as the universal first step, whereas the reference recommends chemoradiation as initial management with stenting reserved for rapidly worsening symptoms. This represents a moderate factual inaccuracy regarding the sequence of interventions."
  },
  "642": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies cyclooxygenase inhibition and its relevance but incorrectly names NSAIDs as the drug class responsible, rather than cyclooxygenase inhibitors as in the reference; this is a minor but meaningful inaccuracy, though most key facts are covered."
  },
  "643": {
    "score": 3.0,
    "explanation": "3: The model answer provides a detailed and accurate account of thalidomide’s best-supported mechanism (TNF-α inhibition) but does not align with the reference answer’s emphasis that the precise cellular or molecular mechanism is unknown; thus, it omits the key fact that the mechanism remains uncertain."
  },
  "644": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale, and adds relevant, correct, and up-to-date details (e.g., consolidation durvalumab) without any inaccuracies or omissions."
  },
  "645": {
    "score": 3.0,
    "explanation": "3: The model answer accurately describes the mechanism of pyrantel pamoate (nicotinic receptor activation and depolarizing neuromuscular blockade), but it does not mention cholinesterase inhibition, which is the specific molecular mechanism referenced in the key. Thus, it covers most but not all key facts."
  },
  "646": {
    "score": 0.0,
    "explanation": "0: The model answer does not mention enzyme modulation, instead focusing on nuclear receptor-mediated gene transcription, which is a different mechanism; this is a major factual error relative to the reference."
  },
  "647": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key facts from the reference, accurately identifies antifolate inhibition as the mechanism, and provides correct, clinically relevant context without inaccuracies or omissions."
  },
  "648": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly states that broad molecular profiling is routinely required for all advanced NSCLC regardless of histology, which contradicts current guidelines for pure squamous cell carcinoma without atypical features; this is a moderate factual error. While the answer is detailed and references guidelines, it misses the key fact that routine testing is not indicated in standard-risk pure squamous cases."
  },
  "649": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the glucocorticoid receptor pathway, and provides relevant, correct additional detail without any inaccuracies or omissions."
  },
  "650": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately emphasizes tumor size >5 cm as the indication for PMRT, and provides additional correct, clinically relevant guideline-based details without any inaccuracies or omissions."
  },
  "651": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate, clinically relevant additional details (trial data, biological rationale, guidelines), and contains no inaccuracies or omissions."
  },
  "652": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts, including the universal need for molecular profiling and its impact on systemic therapy, but incorrectly states that local therapy should not be delayed for profiling results even in asymptomatic patients, which contradicts the reference's clear prioritization of profiling before local therapy regardless of symptoms; this represents a moderate omission."
  },
  "653": {
    "score": 3.0,
    "explanation": "3: The model answer correctly describes the mechanism of polyene antifungals (binding to ergosterol and increasing membrane permeability), but does not mention disruption of ergosterol synthesis as in the reference; instead, it describes direct binding, which is a related but distinct mechanism."
  },
  "654": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly states that the recommendation for systemic therapy implicitly assumes absence of severe comorbidities, whereas the reference clarifies that such comorbidities are absolute contraindications but not an implicit assumption; while the model provides relevant details, this key conceptual error constitutes a moderate factual inaccuracy."
  },
  "655": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies interferon-alpha and its immunomodulatory effects, but it does not use the reference term \"biological response modifiers\" and instead focuses on \"immunomodulation,\" which is related but less precise for the mechanistic class asked. The explanation is detailed and accurate, but the key reference terminology is missing, constituting a minor omission."
  },
  "656": {
    "score": 4.0,
    "explanation": "4: The model answer covers nearly all key facts, correctly stating that observation is not automatically excluded and remains an option, especially in asymptomatic patients, but emphasizes that guidelines favor intervention after progression. It provides relevant, accurate detail but slightly overstates that observation is a deviation from standard guidelines, which could be interpreted as a minor wording inaccuracy rather than a substantive error."
  },
  "657": {
    "score": 3.0,
    "explanation": "3: The model answer provides a detailed and accurate description of the nuclear receptor-mediated genomic effects of retinoids, but it does not explicitly mention modulation of epithelial and mucin-related enzymes as the reference answer highlights; instead, it focuses on gene transcription, which is related but not identical, resulting in a minor omission of the specific enzyme interaction emphasis."
  },
  "658": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies the clinical scenario and mechanism but incorrectly names muscarinic (cholinergic) receptors instead of adrenergic beta2 receptors as the primary target, covering most but not all key facts and including a moderate factual error."
  },
  "659": {
    "score": 1.0,
    "explanation": "1: The model answer directly contradicts the reference by recommending routine FDG-PET/CT for all asymptomatic patients with new radiographic findings, which is not guideline-supported and could lead to unnecessary testing; this is a major inaccuracy."
  },
  "660": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly recommends low-dose non-contrast CT at every surveillance interval for the first five years, omitting the guideline-based preference for standard (with or without contrast) CT every 3–6 months for the first three years, then every six months for two years, and only then transitioning to annual low-dose CT. This is a moderate factual error regarding imaging modality and schedule."
  },
  "661": {
    "score": 4.0,
    "explanation": "4: The model answer correctly explains the mechanism and lists relevant drugs, but uses the term \"antiherpetic nucleoside analogues\" rather than the broader \"DNA polymerase inhibitors\" as in the reference; this is a minor wording inaccuracy but does not alter the essential meaning."
  },
  "662": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts, including the default classification as metastatic disease and the exception for proven synchronous primaries, but it overemphasizes the metastatic approach and underplays that, if both lesions are independently curable, management as two primaries is appropriate—resulting in a minor but clinically relevant omission."
  },
  "663": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly identifies EGFR as the primary molecular target, whereas the reference specifies IGF-1R. While the answer is detailed and relevant to actinic keratosis, this represents a moderate factual error regarding the specific receptor, warranting a score of 2."
  },
  "664": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant supporting evidence, and contains no inaccuracies or omissions."
  },
  "665": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies beta-1 adrenergic receptors as the primary target, provides accurate clinical reasoning, and includes only relevant, factually correct information with no omissions or inaccuracies."
  },
  "666": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale for adjuvant chemotherapy in pT1bN0 triple-negative breast cancer, cites relevant guidelines, and provides additional clinically relevant context without inaccuracies or omissions."
  },
  "667": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies cyclooxygenase (COX) as the principal target and provides accurate, relevant mechanistic detail, but it does not specifically name \"Prostaglandin G/H Synthase 1 (Cyclooxygenase-1)\" as required by the reference, and instead discusses both COX-1 and COX-2, leading to a moderate omission."
  },
  "668": {
    "score": 2.0,
    "explanation": "2: The model answer provides a detailed and accurate explanation of LSD1 inhibition, but it does not identify histone deacetylase—the reference answer's key fact—as the primary target. While the mechanistic discussion is correct for LSD1 inhibitors, the question and reference specify HDAC as the expected answer, making this a moderate factual omission."
  },
  "669": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately cites major guidelines, and provides relevant, correct rationale without any inaccuracies or omissions."
  },
  "670": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate, guideline-based rationale, and includes relevant, correct additional details without any inaccuracies or omissions."
  },
  "671": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes iron chelation by deferoxamine, its molecular mechanism, and clinical relevance, with no inaccuracies or omissions."
  },
  "672": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate, up-to-date, and clinically relevant detail, and includes no inaccuracies or omissions. All additional content is correct and enhances the answer."
  },
  "673": {
    "score": 1.0,
    "explanation": "1: The model answer directly contradicts the reference by recommending immediate initiation of ALK inhibitor and discontinuation of current therapy, which is not standard and could be unsafe; this is a major inaccuracy with potentially harmful implications."
  },
  "674": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies cyclooxygenase (COX) as the enzyme inhibited by NSAIDs and explains the mechanism and clinical relevance, but does not specifically name COX-2 (prostaglandin G/H synthase 2) as required by the reference answer; this is a minor omission."
  },
  "675": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies SNAP-25 as the direct molecular target, and provides accurate, clinically relevant explanations without any inaccuracies or omissions."
  },
  "676": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the impact of N2 disease on staging and management, and provides additional relevant, correct, and clinically useful detail without inaccuracies or omissions."
  },
  "677": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, correctly identifies inhibition of nucleic acid synthesis as the mechanism, and provides accurate, clinically relevant elaboration without any inaccuracies or omissions."
  },
  "678": {
    "score": 3.0,
    "explanation": "3: The model answer correctly explains the mechanism of heparin and its effect on thrombin and factor Xa, but incorrectly identifies \"serine proteases\" as the primary class of molecular targets, rather than the more specific \"thrombin inhibitors\" required by the reference; this is a moderate factual inaccuracy."
  },
  "679": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly identifies cryotherapy as the topical agent, whereas the scenario describes a topical therapy with an unknown molecular mechanism—matching salicylic acid, not cryotherapy. This is a moderate factual error, as the question context points to a chemical, not physical, modality."
  },
  "680": {
    "score": 2.0,
    "explanation": "2: The model answer focuses on CYP3A4 inhibitors, not CYP2D6 inhibitors as specified in the reference answer, representing a moderate factual error. While the explanation is detailed and relevant to many CFTR modulators, it misses the key fact required by the question."
  },
  "681": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional explanations, and contains no inaccuracies or omissions."
  },
  "682": {
    "score": 3.0,
    "explanation": "3: The model answer covers the key fact that the exact molecular mechanism of gold compounds in RA is undetermined, but adds multiple plausible, mechanistic details that are not definitively established and go beyond current understanding, introducing minor inaccuracies by overstating certainty; however, no unsafe or clinically dangerous advice is present."
  },
  "683": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant explanations, cites guidelines, and contains no inaccuracies or omissions."
  },
  "684": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately distinguishing the follow-up schedules and providing correct, clinically relevant explanations for the differences, with no inaccuracies or omissions."
  },
  "685": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, including the criteria for considering two primaries, the clinical significance regarding treatment and prognosis, and relevant diagnostic tools, with additional accurate and clinically relevant detail. No inaccuracies or omissions are present."
  },
  "686": {
    "score": 3.0,
    "explanation": "3: The model answer provides a detailed and accurate explanation of the presumed mechanism of ethosuximide but does not clearly state that the precise cellular or molecular mechanism remains unknown, as in the reference. It covers most key facts but overstates the certainty of the mechanism, missing the emphasis on the lack of definitive knowledge."
  },
  "687": {
    "score": 2.0,
    "explanation": "2: The model answer provides a detailed, textbook mechanism of vitamin K action but fails to acknowledge that the precise cellular or molecular mechanism in premature infants is currently unknown, which is a moderate omission relative to the reference answer."
  },
  "688": {
    "score": 4.0,
    "explanation": "4: The model answer covers over 90% of the key facts, accurately stating that use of capmatinib or tepotinib is not strictly predicated on brain metastasis status, but adds nuanced, guideline-based considerations about intracranial efficacy and agent preference. The extra detail is correct and relevant, though the reference answer is more direct; the model's emphasis on \"preference\" for capmatinib in active CNS disease is a minor interpretive addition, not a factual error."
  },
  "689": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately states that routine FDG-PET/CT and brain MRI are not indicated, provides correct and relevant rationale, and outlines appropriate surveillance per guidelines with no inaccuracies or omissions."
  },
  "690": {
    "score": 3.0,
    "explanation": "3: The model answer provides a detailed and accurate description of the presumed mechanism (oxidative damage by free iodine), but it does not explicitly state that the precise cellular or molecular mechanism is unknown, as required by the reference answer. This constitutes a minor but important omission, as the question specifically asks for the current state of scientific understanding."
  },
  "691": {
    "score": 4.0,
    "explanation": "4: The model answer covers over 90% of the key facts, correctly emphasizes that broad molecular profiling is standard of care, and notes that isolated HER2 testing is technically sufficient for drug eligibility; however, it slightly overstates that isolated testing suffices for prescribing without clarifying that broad profiling is required to meet the standard of care, which is the main point of the reference."
  },
  "692": {
    "score": 4.0,
    "explanation": "4: The model answer covers nearly all key facts, including the indication for brain MRI, the risks of gadolinium in severe CKD, and alternative strategies, but it initially states that contrast-enhanced MRI is still indicated without immediately clarifying that non-contrast MRI is preferred, which could be a minor wording inaccuracy."
  },
  "693": {
    "score": 4.0,
    "explanation": "4: The model answer covers nearly all key facts, correctly emphasizes the low absolute benefit of chemotherapy in this scenario, and appropriately highlights the increased cardiac risk. However, it slightly overstates the general recommendation against chemotherapy in all such cases, whereas the reference allows for individualized consideration of non-anthracycline regimens; this is a minor wording inaccuracy rather than a clinically significant omission."
  },
  "694": {
    "score": 4.0,
    "explanation": "4: The model answer covers nearly all key facts, correctly identifying psoralen, its activation by UVA, and the resulting DNA photoaddition as the direct molecular process, with accurate downstream mechanistic detail. However, it does not explicitly use the term \"photoabsorption\" as in the reference, and the mention of \"cyclobutane pyrimidine dimers\" is a minor inaccuracy (these are typically UVB-induced, not psoralen/UVA), which slightly detracts from precision."
  },
  "695": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly stating that ECOG 2 is not an exclusion criterion and that fam-trastuzumab deruxtecan-nxki remains appropriate; additional content is accurate, relevant, and provides useful clinical context without introducing errors."
  },
  "696": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts, including the importance of distinguishing between metastatic disease and synchronous primaries, and the need for histologic/molecular confirmation. However, it overemphasizes the metastatic paradigm and underplays that current practice does allow for curative intent if both lesions are deemed independent primaries, as per the reference. This constitutes a moderate omission and a slight misrepresentation of the clinical nuance."
  },
  "697": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately affirms T-DXd as an appropriate option post-platinum therapy in ECOG 2 patients, and provides clinically relevant, correct elaboration on guidelines, evidence, and necessary clinical considerations without any inaccuracies or omissions."
  },
  "698": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly identifies muscarinic acetylcholine receptor antagonism as the primary mechanism for antiemetic efficacy in this context, omitting the key fact that dopamine receptor antagonism is responsible, as stated in the reference. While the explanation is detailed and mostly accurate for motion sickness, it misses the specific link to dopamine receptor antagonism and thus covers less than 70% of the key facts."
  },
  "699": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies nucleoside analogues as the class and thoroughly explains the mechanism, but the reference answer specifically uses \"DNA polymerase inhibitors,\" which is a more direct answer; the model's terminology is accurate but slightly less precise per the question's wording, constituting a minor wording inaccuracy."
  },
  "700": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant elaboration, and contains no inaccuracies or omissions."
  },
  "701": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies cyclooxygenase (COX) as the primary molecular target and provides accurate, relevant clinical context, but does not specify COX-2 (prostaglandin G/H synthase 2) as the main isoform responsible for the anti-inflammatory effect, representing a minor omission."
  },
  "702": {
    "score": 3.0,
    "explanation": "3: The model answer overstates the routine indication for adjuvant radiotherapy, presenting it as standard for all R1/R2 cases regardless of other factors, whereas the reference emphasizes individualized, multidisciplinary decision-making based on clinicopathological features. While the model provides detailed, accurate technical information, it misses the nuance that RT is not automatically indicated for every patient with positive margins, resulting in a moderate omission."
  },
  "703": {
    "score": 2.0,
    "explanation": "2: The model answer identifies protein tyrosine phosphatase (PTP) as the primary target, which is incorrect; the reference specifies protein kinase C iota type. While the mechanistic explanation is detailed and relevant, the key fact (the specific enzyme) is wrong, constituting a moderate factual error."
  },
  "704": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately emphasizing that significant PFT impairment generally precludes perioperative therapy and surgery, and that definitive chemoradiation is the standard alternative. Additional details are clinically relevant and correct, with no inaccuracies or omissions."
  },
  "705": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately emphasizes the necessity of pathologic confirmation, cites relevant guidelines, and provides correct rationale without any inaccuracies or omissions."
  },
  "706": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies enzyme inhibition as the general mechanism, and provides additional accurate, relevant mechanistic and clinical context without inaccuracies or omissions."
  },
  "707": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies the clinical context, drug class, and mechanism, but incorrectly states SSTR2 as the primary target instead of SSTR5, which is the key fact in the reference answer; otherwise, the explanation is accurate and relevant."
  },
  "708": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies hydroxyapatite as the binding target of bisphosphonates and provides a detailed, accurate mechanism, but it misses the reference answer's focus on structural macromolecules like collagen, which is a key fact. The answer is otherwise clinically sound and relevant."
  },
  "709": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, correctly identifies the drug class as prostacyclin analogs (prostanoids), explains the mechanism via GPCRs (IP receptors), and relates the effects to vasodilation and platelet inhibition. All additional details are accurate and clinically relevant, with no omissions or inaccuracies."
  },
  "710": {
    "score": 3.0,
    "explanation": "3: The model answer provides a detailed and accurate explanation of the keratolytic action of salicylates, but it does not directly address that the specific cellular or molecular mechanism for magnesium salicylate tetrahydrate in this indication is unknown, as required by the reference answer."
  },
  "711": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly stating that surveillance alone is insufficient and additional local treatment is always indicated. It provides accurate, relevant elaboration on management options and rationale, with no inaccuracies or omissions."
  },
  "712": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies tryptophan hydroxylase (TPH) as the inhibited enzyme and provides detailed, relevant clinical and mechanistic context, but does not explicitly specify the isoform \"TPH1\" (tryptophan 5-hydroxylase 1) as in the reference answer, which is a minor omission."
  },
  "713": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, including the necessity of broad molecular profiling (with all relevant targets), rationale, guideline support, and practical considerations; all additional content is accurate and clinically relevant, with no omissions or inaccuracies."
  },
  "714": {
    "score": 3.0,
    "explanation": "3: The model answer provides a detailed and accurate explanation of how oxygen therapy mitigates hypoxia-induced ROS production, but it does not mention the key reference mechanism—free radical scavenging activity—thus missing the central point required by the reference answer."
  },
  "715": {
    "score": 2.0,
    "explanation": "2: The model answer omits the key fact that residual or new radiographic abnormalities after chemoradiation in stage III NSCLC warrant closer or more frequent imaging, regardless of symptoms, as they may indicate recurrence; instead, it incorrectly advises standard surveillance unless progression is confirmed, which is a moderate factual omission."
  },
  "716": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies thioredoxin reductase as the target and provides a detailed, accurate mechanistic explanation, but it does not specify the mitochondrial isoform (thioredoxin reductase 2) as in the reference answer, which is a minor omission."
  },
  "717": {
    "score": 1.0,
    "explanation": "1: The model answer directly contradicts the reference by recommending adjuvant systemic therapy despite significant pulmonary impairment, which the reference states is a contraindication; this is a major inaccuracy and could be unsafe for patients with poor pulmonary reserve."
  },
  "718": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, including the need for broad molecular profiling (listing all relevant targets), the irrelevance of prior radiotherapy to testing indications, and the importance of concurrent PD-L1 testing. Additional explanations are accurate, clinically relevant, and guideline-based, with no inaccuracies or omissions."
  },
  "719": {
    "score": 3.0,
    "explanation": "3: The model answer accurately describes the clinical scenario, mechanism, and examples of the drug class, but it names \"hypomethylating agents\" rather than the reference answer's \"nucleoside synthesis inhibitors,\" omitting the broader class and focusing on a subclass; this is a moderate omission."
  },
  "720": {
    "score": 1.0,
    "explanation": "1: The model answer incorrectly assumes the drug is a calcineurin inhibitor (tacrolimus/pimecrolimus) rather than clioquinol, and provides an extensive, detailed mechanism for the wrong class of medication, missing the key fact that the mechanism of clioquinol in lichenoid dermatitis is unknown."
  },
  "721": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately states that surveillance is sufficient and adjuvant therapy is not routinely indicated, and provides relevant, correct supporting evidence and guideline references without any inaccuracies or omissions."
  },
  "722": {
    "score": 3.0,
    "explanation": "3: The model answer accurately describes the recent approval of T-DXd for HER2-mutant NSCLC regardless of histology or PD-L1 status, but it overstates the standard-of-care status for squamous cell carcinoma and does not sufficiently emphasize that targeted therapy for ERBB2 mutations in squamous NSCLC remains investigational and is not yet standard practice, as highlighted in the reference."
  },
  "723": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, thoroughly explains the rationale, and provides additional clinically relevant details without inaccuracies or omissions."
  },
  "724": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate, clinically relevant additional details, and contains no inaccuracies or omissions."
  },
  "725": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains why surgery is contraindicated, details the rationale for SBRT as the preferred alternative, and provides relevant, correct additional information without inaccuracies or omissions."
  },
  "726": {
    "score": 3.0,
    "explanation": "3: The model answer covers the main point that the drug’s mechanism is incompletely defined at the molecular level, but it adds extensive, mostly correct background about metronidazole that, while relevant, goes beyond the reference. However, it does not clearly and concisely state \"unknown cellular or molecular interaction\" as in the reference, and the detailed explanation could be seen as partially contradicting the reference’s emphasis on the mechanism being unknown, thus representing a minor inaccuracy in focus."
  },
  "727": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides correct and clinically relevant additional rationale, and contains no inaccuracies or omissions."
  },
  "728": {
    "score": 4.0,
    "explanation": "4: The model answer covers over 90% of the key facts, accurately describing the genomic mechanism of glucocorticoid action and its clinical effects, but it underemphasizes direct mineralocorticoid receptor agonism, which is also a key therapeutic mechanism in primary adrenal insufficiency."
  },
  "729": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts and provides detailed, guideline-based rationale, but it incorrectly states that dual HER2-targeted therapy is standard for cT2N0M0 disease regardless of nodal status, which contradicts the reference answer that restricts pertuzumab use to pN+ cases; this represents a moderate factual inaccuracy."
  },
  "730": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies calcium channel blockers and explains their mechanism, but does not specify \"L-type\" as in the reference answer, which is a minor omission. All other content is accurate and clinically relevant."
  },
  "731": {
    "score": 2.0,
    "explanation": "2: The model answer overstates the impact of pulmonary fibrosis by claiming it fundamentally alters surveillance strategy, which contradicts the reference; while it correctly recommends 3–6 month follow-up and multidisciplinary review, it introduces moderate factual errors regarding guideline applicability and necessity for more aggressive management."
  },
  "732": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, adds relevant and accurate clinical context, and includes no inaccuracies or omissions."
  },
  "733": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies type II 5α-reductase as the enzyme targeted, explains its role in DHT production and hair loss, and provides accurate, clinically relevant details about the medication, mechanism, and supporting evidence, with no omissions or inaccuracies."
  },
  "734": {
    "score": 4.0,
    "explanation": "4: The model answer covers nearly all key facts, emphasizing the urgency of starting chemotherapy in symptomatic, PS 2 patients and the need for concurrent biomarker testing, with a plan to switch to targeted therapy if indicated. However, it overstates the appropriateness of initiating therapy \"without delaying for molecular results\" as a general rule, rather than reserving this for cases of urgent clinical need, which is a minor wording inaccuracy."
  },
  "735": {
    "score": 3.0,
    "explanation": "3: The model answer incorrectly identifies GABA_A instead of GABA_B as the receptor mediating the effect of the centrally acting muscle relaxant (baclofen) described in the vignette, but provides a mostly accurate and relevant explanation for benzodiazepines; however, this represents a moderate factual error and covers about 70-89% of the key facts."
  },
  "736": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies metronidazole and its general mechanism (DNA damage via reduced intermediates), but it fails to directly address that the precise molecular or cellular interaction responsible for its effectiveness in deep tissue abscesses is unknown, as stated in the reference. The answer overstates the certainty of the mechanism in this specific context, missing the key nuance."
  },
  "737": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately states that routine brain MRI is not indicated, and provides additional correct and clinically relevant rationale and guideline references without any inaccuracies or omissions."
  },
  "738": {
    "score": 4.0,
    "explanation": "4: The model answer covers all key clinical facts, including the necessity of confirmed NTRK1 fusion via adequate profiling and the appropriateness of larotrectinib as first-line therapy. However, it introduces a minor inaccuracy by stating that larotrectinib is \"preferred\" and \"recommended\" first-line, whereas guidelines allow but do not always prefer it over other options; also, the statement about \"no satisfactory alternative treatments\" is not strictly required in the first-line setting if an actionable fusion is present. These are minor wording inaccuracies, so a score of 4 is appropriate"
  },
  "739": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant elaboration, and contains no inaccuracies or omissions."
  },
  "740": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale, cites supporting evidence and guidelines, and appropriately details what should guide therapy choice, with no inaccuracies or omissions."
  },
  "741": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains why monotherapy is not appropriate, and correctly identifies platinum-based chemotherapy (with or without immunotherapy) as standard care; all additional details are clinically relevant and factually correct."
  },
  "742": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant explanations, cites guidelines and evidence, and contains no inaccuracies or omissions."
  },
  "743": {
    "score": 2.0,
    "explanation": "2: The model answer directly contradicts the reference by stating that preoperative systemic therapy does not affect the recommendation, missing the key nuance that the standard recommendation for PMRT in this setting is specifically for patients who have not received preoperative systemic therapy. While the answer is detailed and references guidelines, this central omission constitutes a moderate factual error."
  },
  "744": {
    "score": 4.0,
    "explanation": "4: The model answer covers all key facts about the mechanism (calcium channel interaction, increased Ca²⁺ influx, paralysis), correctly identifies praziquantel, and provides relevant extra detail. However, the reference answer specifically names \"calcium channel interactions\" as the molecular interaction, while the model answer uses the broader term \"ligand-receptor interaction,\" which is slightly less precise, constituting a minor wording inaccuracy."
  },
  "745": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, including prioritizing NTRK inhibitors for their systemic and intracranial efficacy, exceptions for urgent radiotherapy in symptomatic cases, and provides accurate, relevant additional details without inaccuracies or omissions."
  },
  "746": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly explains the risks of repeat chemoradiation, prioritizes systemic therapy, and provides relevant, evidence-based alternative management without inaccuracies or omissions."
  },
  "747": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies DNA methyltransferase (DNMT) as the enzyme inhibited by azacitidine, which is the clinically relevant target in MDS therapy, but it omits the more specific reference answer (tRNA (Cytosine(38)-C(5))-Methyltransferase), which is a precise molecular target; thus, it covers most but not all key facts."
  },
  "748": {
    "score": 3.0,
    "explanation": "3: The model answer accurately states that adjuvant chemotherapy is standard and provides detailed, evidence-based rationale against routine PORT in N1 disease, but it directly contradicts the reference answer by stating sequential chemo-radiotherapy is NOT appropriate, omitting that radiotherapy can still be considered, thus missing a key clinical nuance."
  },
  "749": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies insulin as the drug and accurately describes its clinical context and mechanism, but it fails to specify \"insulin receptor agonists\" as the pharmacologic mechanism, instead giving the broader and less precise \"Hormone Replacement Therapy,\" which does not directly answer the question about the mechanism of action."
  },
  "750": {
    "score": 2.0,
    "explanation": "2: The model answer overstates the evidence and guideline support for routine EGFR-targeted therapy in squamous cell carcinoma with EGFR exon 20 insertion, failing to note the rarity, potential diagnostic pitfalls, and that most guidelines and approvals are based on non-squamous histology; this is a moderate factual error and omits key cautions present in the reference."
  },
  "751": {
    "score": 3.0,
    "explanation": "3: The model answer provides a thorough rationale for prioritizing chemoradiation in a clinically stable patient and cites guidelines, but it incorrectly states that CRT should be prioritized over stenting, whereas the reference emphasizes stenting for rapid symptom relief even in stable patients with symptomatic SVC obstruction. This represents a moderate factual inaccuracy regarding the initial management sequence."
  },
  "752": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional details, and contains no inaccuracies or omissions."
  },
  "753": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies \"melatonin receptor agonists,\" explains the mechanism, and provides relevant clinical context, but does not use the more general class term \"hormone receptor agonists\" as in the reference; this is a minor wording inaccuracy."
  },
  "754": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies that the precise molecular target is incompletely characterized and describes general mechanisms (membrane disruption, metabolic interference), but it incorrectly identifies the agent as benzoic acid rather than clioquinol, missing a key fact from the reference."
  },
  "755": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly identifies Janus kinase (JAK) as the primary target, whereas the reference specifies the glucocorticoid receptor. While the mechanistic explanation is accurate for JAK inhibitors, this represents a moderate factual error regarding the drug class described, covering less than 70% of key facts."
  },
  "756": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly asserts that concurrent chemoradiation is universally preferred and the standard of care, whereas guidelines recognize both concurrent and sequential approaches as valid without a default priority; this represents a moderate factual error and overstatement, despite providing relevant rationale and evidence."
  },
  "757": {
    "score": 4.0,
    "explanation": "4: The model answer covers all key clinical facts, correctly prioritizing urgent SVC stenting for rapid symptom relief followed by concurrent chemoradiation, and explains why EBRT alone or chemoradiation without stenting are suboptimal. However, it slightly overstates the necessity of stenting in all cases (the reference allows chemoradiation with or without stenting), making this a minor wording inaccuracy."
  },
  "758": {
    "score": 4.0,
    "explanation": "4: The model answer covers nearly all key facts, correctly explains the lack of efficacy and increased toxicity of ICIs in EGFR-mutant NSCLC, and accurately describes the current first-line role of amivantamab-vmjw plus chemotherapy. However, it slightly overstates amivantamab-vmjw's approval as first-line (recent but not yet universal standard) and calls ICI monotherapy \"contraindicated,\" which is stronger than guideline language; these are minor wording inaccuracies."
  },
  "759": {
    "score": 4.0,
    "explanation": "4: The model answer covers all key facts and provides detailed, accurate explanations, but it slightly overstates the universality of broad molecular profiling in squamous cell carcinoma with a known BRAF V600E mutation, as guidelines primarily recommend testing in non-squamous histologies and only selectively in squamous cases; however, this is a minor nuance and does not alter the overall clinical meaning."
  },
  "760": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly states that adjuvant systemic therapy is routinely recommended for all stage IIA (T2b, N0) patients, regardless of high-risk features, which contradicts the reference answer that specifies adjuvant therapy is typically considered only in the presence of high-risk recurrence features; this represents a moderate factual error, despite the otherwise thorough and accurate discussion."
  },
  "761": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies the mechanism as DHFR inhibition (antifolate/antimetabolite), which is a subset of nucleic acid synthesis inhibitors, and provides accurate, relevant mechanistic detail. However, it does not explicitly use the broader class term \"nucleic acid synthesis inhibitors\" as in the reference, representing a minor wording inaccuracy."
  },
  "762": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies NSAIDs as the pharmacological class and thoroughly explains the mechanism involving cyclooxygenase inhibition, covering over 90% of key facts. However, it does not explicitly state \"cyclooxygenase inhibitors\" as the class, which is the precise answer in the reference, representing a minor wording inaccuracy."
  },
  "763": {
    "score": 2.0,
    "explanation": "2: The model answer identifies JAK1/2 as the molecular target, not TNF (the reference answer's key fact), and focuses on ruxolitinib rather than a TNF inhibitor; while the explanation is relevant and accurate for JAK inhibition, it omits the reference's required target, covering less than 70% of key facts."
  },
  "764": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies cyclooxygenase (COX) as the primary molecular target and provides accurate, relevant explanation, but does not specify COX-1 (prostaglandin G/H synthase 1) as in the reference, representing a minor omission in precision."
  },
  "765": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts, including the TAILORx trial data and the importance of shared decision-making, but incorrectly states that endocrine therapy alone is standard and appropriate, omitting that current guidelines recommend chemotherapy for premenopausal women with RS 16–25. It also introduces confusion regarding tumor staging, which, while relevant, detracts from the main clinical recommendation."
  },
  "766": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly states that ALK inhibitor selection does not presuppose negative results for other actionable mutations, contradicting the reference, and introduces moderate factual inaccuracies regarding guideline recommendations and management, though it covers some relevant background."
  },
  "767": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, accurately explains the mechanism (inhibition of nucleic acid synthesis), and provides relevant, correct mechanistic detail without any inaccuracies or omissions."
  },
  "768": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately prioritizing re-resection and correctly describing the limited role of adjuvant radiotherapy. Additional details are clinically relevant and evidence-based, with no inaccuracies or omissions."
  },
  "769": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional detail, and contains no inaccuracies or omissions."
  },
  "770": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies the estrogen receptor pathway and provides detailed, accurate mechanistic reasoning, but it misses the key fact from the reference answer that the question specifically asks about progestational (progesterone) receptor agonists, not estrogen. This is a moderate factual error, as it misidentifies the primary receptor pathway targeted by the prescribed agent."
  },
  "771": {
    "score": 1.0,
    "explanation": "1: The model answer incorrectly asserts that only surgical patients qualify for the described surveillance schedule, directly contradicting the reference answer, and provides misleading information about surveillance eligibility; while detailed, this is a major inaccuracy."
  },
  "772": {
    "score": 3.0,
    "explanation": "3: The model answer provides a detailed and accurate explanation of beta-lactam antibiotics as cell wall synthesis inhibitors, but it does not explicitly use the term \"enzyme inhibitors\" as required by the reference answer, missing the key pharmacological class specified."
  },
  "773": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts, including the need for both tumors to be amenable to definitive local therapy and the absence of nodal/distant spread, but it incorrectly states that both tumors do not inherently need to be independently curable, which contradicts the reference. This represents a moderate factual inaccuracy, though the rest of the content is detailed and clinically relevant."
  },
  "774": {
    "score": 5.0,
    "explanation": "5: The model answer accurately explains that mediastinal (N2) lymph node involvement excludes Stage IIB, details the impact of a separate pulmonary nodule on staging, and correctly concludes that perioperative therapy in this scenario assumes Stage IIIA or higher, thus matching all key clinical facts in the reference."
  },
  "775": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies isavuconazole as a triazole and OCT2 inhibitor, and clearly explains the clinical significance regarding drug interactions and monitoring, with no inaccuracies or omissions."
  },
  "776": {
    "score": 4.0,
    "explanation": "4: The model answer covers nearly all key facts, correctly notes the need for dose adjustment with larotrectinib and avoidance of entrectinib, and emphasizes monitoring, but slightly overstates the appropriateness of larotrectinib (calling it \"preferred and appropriate\") without sufficient emphasis on the need for careful risk assessment; otherwise, content is accurate and relevant."
  },
  "777": {
    "score": 3.0,
    "explanation": "3: The model answer covers the key point that a synchronous ipsilateral lesion does not automatically upstage to stage IV and provides detailed discussion on distinguishing separate primaries from metastases, but it introduces a factual inaccuracy by stating that intrapulmonary metastasis in a different ipsilateral lobe is M1a (stage IV), when according to the AJCC 8th edition, this scenario is T4, not M1a; this is a moderate error."
  },
  "778": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate, guideline-based rationale, and includes relevant, correct additional details without any inaccuracies or unsafe statements."
  },
  "779": {
    "score": 5.0,
    "explanation": "5: All key facts from the reference are included—covalent (irreversible) binding to PBPs, inhibition of transpeptidation, and clinical relevance to beta-lactam allergy. Additional details are accurate and clinically relevant. No errors or omissions."
  },
  "780": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant supporting evidence, and includes no inaccuracies or omissions. It thoroughly explains the rationale for prioritizing concurrent chemoradiation and appropriately addresses the limited role of surgery."
  },
  "781": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies beta-lactam antibiotics and thoroughly explains their mechanism, but it does not directly state the general pharmacological class as \"enzyme inhibitors\" as in the reference answer, missing the broader classification required by the question."
  },
  "782": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly identifies glutamate-gated chloride channels as the main target, whereas the reference specifies GABA A receptors; it also misattributes the mechanism of action for common pinworm treatments, resulting in a moderate factual error and partial coverage of key facts."
  },
  "783": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, correctly explains why SABR is inappropriate for stage IIIB (N2) disease, and accurately prioritizes definitive concurrent chemoradiation (with Durvalumab) as standard of care. There are no inaccuracies or omissions."
  },
  "784": {
    "score": 4.0,
    "explanation": "4: The model answer covers over 90% of the key facts, correctly emphasizing that orthopedic stabilization is prioritized for imminent fracture risk and provides relevant details about risk assessment and multidisciplinary care. However, it introduces nuanced scenarios (moderate/low risk) not mentioned in the reference, which could be seen as a minor deviation from the reference's more absolute stance."
  },
  "785": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the drug class (azoles), the specific enzyme inhibited (lanosterol 14α-demethylase), and accurately explains that the mechanism is competitive inhibition, covering all key clinical facts in the reference answer with relevant, accurate elaboration and no errors."
  },
  "786": {
    "score": 4.0,
    "explanation": "4: The model answer covers nearly all key clinical facts, accurately emphasizing that surgery remains standard if operability criteria are met, but adds detailed, guideline-based thresholds and alternative options. There is a minor omission in not explicitly stating that surgery is prioritized unless contraindicated, but this is implied; all extra content is relevant and correct."
  },
  "787": {
    "score": 4.0,
    "explanation": "4: The model answer covers all key facts and provides detailed, accurate, and relevant explanations, but it overstates the exclusivity of concurrent chemoradiation as \"preferred\" and claims sequential therapy is \"not recommended,\" whereas the reference states both are options with concurrent often preferred. This is a minor wording inaccuracy that does not alter the overall clinical meaning."
  },
  "788": {
    "score": 2.0,
    "explanation": "2: The model answer focuses on 5-HT1B/1D receptor agonism, omitting the reference answer's emphasis on dopamine receptor interactions, which is the key fact. While the explanation is detailed and mostly accurate for triptans/ergots, it misses the most directly relevant receptor per the reference, constituting a moderate omission."
  },
  "789": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies the drug (metolazone) and its primary target (NCC in the DCT), but does not name the potassium channel as in the reference answer; it also clarifies the distinction between cotransporters and ion channels, which is accurate but diverges from the question's focus. Most key facts are covered, but the specific channel named in the reference is omitted."
  },
  "790": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, including the standard indication for chemotherapy, the need to avoid anthracyclines, consideration of alternative regimens (TC), and the importance of individualized risk assessment and shared decision-making. All additional content is accurate, relevant, and enhances clinical understanding."
  },
  "791": {
    "score": 2.0,
    "explanation": "2: The model answer overstates the contraindication of immune checkpoint inhibitors in NYHA class III heart failure and incorrectly claims that ICI monotherapy is not standard for PD-L1 1–49%, which is inaccurate; while it provides detailed reasoning, it omits the key fact that ICI monotherapy remains an appropriate option per guidelines if there is no absolute contraindication, thus missing over 40% of key facts and including moderate factual errors."
  },
  "792": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately identifies the drug class, explains the mechanism, and provides relevant clinical context without inaccuracies or omissions."
  },
  "793": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies cyclooxygenase (COX) as the enzyme inhibited and provides a thorough, accurate explanation, but it does not specify COX-1 (prostaglandin G/H synthase 1) as in the reference; this is a minor omission since most NSAIDs inhibit both COX-1 and COX-2, but the reference asks for the most direct answer."
  },
  "794": {
    "score": 4.0,
    "explanation": "4: The model answer covers over 90% of the key facts, correctly identifies sodium oxybate, and explains its clinical effects and the uncertainty of its precise mechanism, but includes mechanistic details (GABA-B, GHB receptor actions) that, while accurate, go beyond the reference's focus on the unknown mechanism and could be seen as slightly overstating current knowledge."
  },
  "795": {
    "score": 4.0,
    "explanation": "4: The model answer covers all key clinical facts, correctly identifies beta-lactams as the pharmacological class, and explains the mechanism and clinical context. However, it does not explicitly use the broader term \"enzyme inhibitors\" as in the reference, which is a minor wording inaccuracy but does not alter the clinical meaning."
  },
  "796": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies the drug class as RNA polymerase inhibitors and accurately describes the mechanism, but it does not explicitly use the broader class term \"Nucleic Acid Synthesis Inhibitors\" as in the reference answer, which is a minor omission."
  },
  "797": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides correct and clinically relevant rationale, guideline citations, and no inaccuracies or omissions are present."
  },
  "798": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the mechanism (inhibition of nucleic acid synthesis), and provides additional clinically relevant detail without inaccuracies or omissions."
  },
  "799": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies the 26S proteasome, and provides accurate, relevant explanations without inaccuracies or omissions."
  },
  "800": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains current guideline recommendations, addresses the relevance of squamous histology, and provides correct, clinically relevant rationale without any inaccuracies or omissions."
  },
  "801": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately cites guidelines, explains the rationale, and includes no inaccuracies or omissions; additional details are correct and clinically relevant."
  },
  "802": {
    "score": 2.0,
    "explanation": "2: The model answer correctly identifies mast cell stabilizers and explains their mechanism, but it does not use or mention the broader class \"Biological Response Modifiers\" as required by the reference answer, which is a moderate omission."
  },
  "803": {
    "score": 3.0,
    "explanation": "3: The model answer accurately states that follow-up imaging is generally every 6 months for both groups and provides supporting guideline references, but it incorrectly claims there is no difference in frequency, missing the key fact that radiotherapy patients typically require more frequent (every 3–6 months) imaging in the first 3 years."
  },
  "804": {
    "score": 3.0,
    "explanation": "3: The model answer covers the acid-base activity of the agent and its relevance in nephritis, but introduces an incorrect mechanism—sulfate is not metabolized to generate bicarbonate or consume H⁺ in this way. While it correctly identifies the acid-base property as key, the mechanistic explanation is inaccurate, constituting a moderate factual error."
  },
  "805": {
    "score": 3.0,
    "explanation": "3: The model answer provides a well-reasoned argument for 6-monthly CT surveillance and cites supporting guidelines and studies, but it omits that current recommendations allow for more frequent (every 3–6 months) imaging in the first 3 years and incorrectly asserts that 6-monthly imaging is standard, missing the key point that 6-month intervals may be insufficient."
  },
  "806": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional details, and contains no inaccuracies or omissions."
  },
  "807": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, adds relevant and accurate detail about patient selection, risks of re-irradiation, and guideline support, with no inaccuracies or omissions."
  },
  "808": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies the pharmacologic class as protein phosphatase inhibitors and provides accurate, relevant mechanistic detail, but omits explicitly stating \"enzyme inhibitors\" as the broader class, which is the reference answer; this is a minor omission."
  },
  "809": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies the drug class (NSAIDs), explains the mechanism (COX inhibition), and provides relevant clinical context without inaccuracies or omissions."
  },
  "810": {
    "score": 2.0,
    "explanation": "2: The model answer provides detailed reasoning but contains a moderate factual error by incorrectly stating that amivantamab-lazertinib is not appropriate for EGFR exon 19 deletion, when in fact, emerging evidence and guidelines support its use in this setting regardless of KRAS status; it also overstates the impact of KRAS co-mutation and approval status, leading to a significant omission of the reference answer’s key point."
  },
  "811": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly identifies phospholipase A2 as the central enzyme class, rather than lipoxygenase, which is specifically responsible for leukotriene formation from arachidonic acid; while the explanation is detailed and relevant, this constitutes a moderate factual error."
  },
  "812": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides correct and clinically relevant additional detail, and contains no inaccuracies or omissions."
  },
  "813": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional details (trial data, mechanistic rationale, guidelines), and contains no inaccuracies or omissions."
  },
  "814": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly states that switching to a TRK inhibitor is strongly preferred and that completing planned systemic therapy or maintenance is not justified, which contradicts the reference answer's position that both strategies are acceptable and should be individualized; this represents a moderate factual error and overstates guideline recommendations."
  },
  "815": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies glucose transporters as key targets and provides detailed, accurate mechanistic explanation, but it omits the equally important role of metabolic enzymes in mediating the therapeutic response, which is emphasized in the reference answer."
  },
  "816": {
    "score": 4.0,
    "explanation": "4: The model answer covers all key clinical facts and provides additional relevant detail, but it overstates the strength of the recommendation by calling radiotherapy \"recommended\" and \"standard of care,\" whereas guidelines consider it a category 2B option with less robust evidence; this constitutes a minor wording inaccuracy."
  },
  "817": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale for comprehensive molecular profiling regardless of smoking status, and provides relevant, correct additional detail without inaccuracies or omissions."
  },
  "818": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies cyclooxygenase (COX) inhibition as the mechanism and provides relevant clinical context, but does not specify COX-2 (prostaglandin G/H synthase 2) as the primary enzyme, which is a minor omission."
  },
  "819": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly states that adjuvant pembrolizumab is indicated for all eligible TNBC patients regardless of risk, whereas the reference specifies it is only for those considered high-risk. While the answer is detailed and evidence-based, this moderate factual error about the indication criteria warrants a score of 2."
  },
  "820": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly stating that preoperative systemic therapy is indicated for cT1c, cN0 triple-negative breast cancer and not reserved only for HER2-positive or node-positive disease. Additional explanations are accurate, relevant, and guideline-based, with no inaccuracies or omissions."
  },
  "821": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides correct and clinically relevant explanations, and contains no inaccuracies or omissions."
  },
  "822": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies the drug class and mechanism but does not explicitly state the general pharmacological class \"enzyme inhibitors\" as in the reference; it focuses on the antibiotic class rather than the broader mechanism-based classification."
  },
  "823": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts, including the appropriateness of EGFR TKIs for these mutations and the importance of performance status, but overemphasizes avoidance of TKI initiation and best supportive care, underrepresenting the nuance that targeted therapy may still be considered if poor PS is due to tumor burden. It also introduces a preference for afatinib/osimertinib not mentioned in the reference, which, while not incorrect, is not directly relevant to the question."
  },
  "824": {
    "score": 4.0,
    "explanation": "4: The model answer covers nearly all key facts, accurately describing the mechanism (lubrication via a viscous, protective film) and its clinical relevance, but it omits the specific pharmacological term \"demulcent activity\" used in the reference answer, which is a minor wording inaccuracy."
  },
  "825": {
    "score": 3.0,
    "explanation": "3: The model answer correctly explains corticosteroids' inhibition of phospholipase A2 and its upstream effect on leukotriene synthesis, but it does not directly identify the lipoxygenase pathway as the answer, which is the key fact in the reference. The explanation is accurate but misses the most direct pathway targeted for leukotriene reduction."
  },
  "826": {
    "score": 2.0,
    "explanation": "2: The model answer focuses on tyrosine kinases (JAKs) as the primary molecular targets, which is incorrect for the specific mechanism referenced in the question—interferon’s therapeutic effect in this context is primarily via induction of RNA-degrading enzymes (RNA replicases), not JAK kinases. While the clinical reasoning is thorough, the key fact about the molecular target is moderately incorrect."
  },
  "827": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies beta-lactam antibiotics and explains their mechanism, but it does not directly state the general pharmacological class as \"enzyme inhibitors\" as in the reference answer, missing the broader classification required by the question."
  },
  "828": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies the beta-lactam class and provides a thorough, accurate explanation, but it does not directly answer the question's request for the broad pharmacological class (\"enzyme inhibitors\") and instead gives a subclass; this is a minor but meaningful omission relative to the reference."
  },
  "829": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly states that osimertinib is standard and recommended for classic squamous cell carcinoma with EGFR mutation, overlooking the limited benefit and guideline reservations for pure squamous histology; while it provides correct background on EGFR mutations and testing, it omits the key clinical fact that EGFR TKIs are generally not recommended for classic squamous histology, thus missing a critical nuance."
  },
  "830": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately identifies 5-lipoxygenase inhibitors as the relevant class, and provides correct, clinically relevant explanations without any inaccuracies or omissions."
  },
  "831": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale for prioritizing systemic therapy, and provides additional relevant, correct details without any inaccuracies or omissions."
  },
  "832": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately states that routine FDG-PET/CT and brain MRI are not indicated, and provides correct, relevant rationale and surveillance recommendations without inaccuracies or omissions."
  },
  "833": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly identifies CYP3A4 instead of CYP2D6, omitting the key fact that CYP2D6 is the primary enzyme implicated in interactions with certain antidepressants and beta-blockers; while the explanation is detailed, the main answer is a moderate factual error."
  },
  "834": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate, guideline-based rationale, and includes relevant, correct additional details without any inaccuracies or omissions."
  },
  "835": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies imatinib and its inhibition of PDGFRα, which is the true molecular target in this scenario, but it does not match the reference answer's focus on KIT as the direct target. While the model provides accurate and relevant mechanistic detail, it omits the reference's key fact (KIT), covering about 70-89% of the required content."
  },
  "836": {
    "score": 0.0,
    "explanation": "0: The model answer is correct and detailed, but the reference answer (\"Phosphate chelating activity\") is factually incorrect and irrelevant to the clinical context; thus, the model covers all key facts, but since the reference is wrong, the correct score is 0 per rubric."
  },
  "837": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, including the necessity of pathologic confirmation, inadequacy of imaging alone, guideline requirements, and the rare exceptions. Additional content is accurate, clinically relevant, and enhances understanding without introducing errors or omissions."
  },
  "838": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies the agent as an antiseptic and provides relevant clinical context, but it does not explicitly state \"enzyme interactions\" as the general class of pharmacological action, which is the key fact in the reference answer."
  },
  "839": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, thoroughly explains the rationale for requiring pathologic confirmation, details biopsy approaches, and emphasizes the distinction between curative and palliative intent; there are no inaccuracies or omissions."
  },
  "840": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant explanations, and contains no inaccuracies or omissions."
  },
  "841": {
    "score": 3.0,
    "explanation": "3: The model answer incorrectly identifies RAR (retinoic acid receptor) as the direct nuclear receptor, whereas the reference specifies RXR (retinoid X receptor); while the explanation is detailed and mostly accurate, the primary key fact is missed, constituting a moderate factual error."
  },
  "842": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately prioritizing TRK inhibitor therapy over immunotherapy, and provides additional, relevant, and correct explanations regarding efficacy, guidelines, and sequencing. There are no inaccuracies or omissions."
  },
  "843": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describing both the modulation of enzyme-mediated processes and the specific mechanisms (genomic and non-genomic) relevant to vision and epithelial maintenance, with no inaccuracies or omissions."
  },
  "844": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately stating that both adjuvant systemic therapy and observation are appropriate options, and provides additional, relevant, and correct details regarding guidelines, survival benefit, and EGFR status without any inaccuracies or unsafe statements."
  },
  "845": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies interferon as the agent and thoroughly explains its mechanism, but it does not explicitly state the class \"Biological Response Modifiers\" as required by the question, thus missing the key fact that directly answers the mechanism's class."
  },
  "846": {
    "score": 4.0,
    "explanation": "4: The model answer covers over 90% of the key facts, correctly emphasizing that adjuvant systemic therapy is generally indicated and outlining scenarios where surveillance may be considered, but it introduces nuanced factors (e.g., exceptional NAC response, molecular drivers) that, while accurate, slightly broaden the reference's more conservative stance; no clinically unsafe advice is present, but the expanded scenarios represent a minor deviation from standard practice."
  },
  "847": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately details current guideline recommendations, addresses the impact of prior brain metastasis, and provides relevant rationale without any inaccuracies or omissions."
  },
  "848": {
    "score": 4.0,
    "explanation": "4: The model answer correctly explains the mechanism as inhibition of cell wall synthesis and details the role of PBPs, but it omits explicitly stating \"enzyme inhibition\" as the general class, which is the key fact in the reference answer."
  },
  "849": {
    "score": 2.0,
    "explanation": "2: The model answer provides detailed guideline references and rationale but directly contradicts the reference answer by stating brain MRI is not mandatory for stage II NSCLC, omitting the key fact that it is recommended as a mandatory staging assessment. This is a moderate factual omission that significantly alters clinical management."
  },
  "850": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies cyclooxygenase (COX) as the molecular target and provides a thorough, accurate explanation, but it does not specify COX-2 (prostaglandin G/H synthase 2) as in the reference; this is a minor omission since \"COX\" could refer to either isoform."
  },
  "851": {
    "score": 2.0,
    "explanation": "2: The model answer correctly describes zinc's inhibition of IκB kinase and the NF-κB pathway, but it fails to identify interleukin-6 antagonists as the direct molecular target class, omitting the key fact from the reference answer and focusing on a related but distinct mechanism."
  },
  "852": {
    "score": 4.0,
    "explanation": "4: The model answer covers all key mechanistic details and clinical context, but the required answer is \"DNA polymerase inhibitors\" (the broader class), while the model gives \"nucleoside analogues\" (a subclass); this is a minor wording inaccuracy that does not alter the essential meaning."
  },
  "853": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly states that radiotherapy is only indicated if re-resection is not feasible, omitting that radiotherapy can be considered as an alternative even if re-resection is possible (albeit as a less preferred, category 2B option); this is a moderate factual omission that misrepresents guideline nuance."
  },
  "854": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the stage upgrade, its impact on perioperative therapy eligibility, and the shift to definitive chemoradiation, with no inaccuracies or omissions."
  },
  "855": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides correct and clinically relevant additional explanations, and contains no inaccuracies or omissions."
  },
  "856": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies cyclooxygenase (COX) as the molecular target and provides accurate, relevant mechanistic detail, but does not specify COX-1 (Prostaglandin G/H Synthase 1) as in the reference, representing a minor omission."
  },
  "857": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately cites major guidelines, and provides relevant rationale without any inaccuracies or omissions."
  },
  "858": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies CYP2C9, covers all key clinical facts from the reference, and provides accurate, clinically relevant explanations without any inaccuracies or omissions."
  },
  "859": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly distinguishes surveillance intervals and modalities, and provides accurate, relevant guideline-based details without inaccuracies or omissions."
  },
  "860": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly identifies CYP3A4 as the key enzyme system, whereas the reference specifies cytochrome P450 1A enzymes; this is a moderate factual error, though the rest of the explanation is relevant and accurate."
  },
  "861": {
    "score": 3.0,
    "explanation": "3: The model answer focuses primarily on vitamin A’s role in rhodopsin regeneration, which is accurate but does not directly address the reference answer’s emphasis on antioxidant (free radical scavenging) activity as the key mechanism. While it mentions antioxidant effects, the main mechanism described is different, covering about 70-89% of key facts."
  },
  "862": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies proton pump inhibitors as the drug class, provides accurate and clinically relevant explanation, and contains no inaccuracies or omissions."
  },
  "863": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly identifies phospholipase A2 as the directly inhibited enzyme, rather than lipoxygenase, and focuses on indirect inhibition; while mechanistically accurate for corticosteroids' general action, it misses the question's emphasis on direct inhibition relevant to leukotriene synthesis, covering only about half the key facts."
  },
  "864": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies COX inhibition as the primary mechanism, details the molecular pathway, and relates it to the clinical scenario, but does not specifically name \"Prostaglandin G/H Synthase 2 (COX-2)\" as in the reference, representing a minor omission in precision."
  },
  "865": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains why perioperative therapy is unsuitable, and appropriately discusses alternative management options without any inaccuracies or omissions."
  },
  "866": {
    "score": 2.0,
    "explanation": "2: The model answer focuses on CGRP receptor antagonism, which is a modern and effective prophylactic mechanism for migraine, but the reference specifically requires serotonin (5-HT2) receptor antagonism by methysergide. The model omits this key fact and instead provides a detailed, but off-target, explanation, covering less than 70% of the reference's key facts."
  },
  "867": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional detail, and contains no inaccuracies or omissions."
  },
  "868": {
    "score": 2.0,
    "explanation": "2: The model answer provides a detailed and accurate explanation of somatostatin analogs, but it does not identify dopamine agonism as the mechanism asked for in the question, thus missing the key fact from the reference answer."
  },
  "869": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts, correctly describing proposed mechanisms and uncertainties, but it goes beyond the reference by detailing plausible mechanisms rather than simply stating the mechanism is unknown; this introduces minor inaccuracies in emphasis and does not fully align with the reference's focus on the lack of a known molecular interaction."
  },
  "870": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides additional accurate and clinically relevant details, and contains no inaccuracies or omissions."
  },
  "871": {
    "score": 3.0,
    "explanation": "3: The model answer correctly describes the clinical scenario and the mechanism of corticosteroids, but it identifies phospholipase A2 inhibition as the most direct effect, rather than lipoxygenase inhibition as specified in the reference. While the explanation is detailed and accurate for corticosteroid action, it misses the key fact required by the question."
  },
  "872": {
    "score": 3.0,
    "explanation": "3: The model answer provides a thorough rationale for favoring radiotherapy over re-operation in this patient, correctly emphasizing the surgical risks and efficacy of SBRT, but it overstates radiotherapy as \"strongly preferred\" and does not acknowledge that re-operation is generally preferred for positive margins, as in the reference. This represents a moderate omission of the standard approach, though the clinical reasoning is otherwise sound."
  },
  "873": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately stating that M1a disease is metastatic and surgery is generally not indicated, but also correctly notes rare exceptions in highly selected oligometastatic cases, with appropriate caveats and references. There are no inaccuracies or omissions."
  },
  "874": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key facts from the reference (\"chelating activity\"), correctly identifies iron chelation as the principal property, and provides clinically relevant, accurate mechanistic detail without inaccuracies or omissions."
  },
  "875": {
    "score": 2.0,
    "explanation": "2: The model answer overemphasizes concurrent chemoradiation as the standard without adequately highlighting that it is generally contraindicated in patients with severely impaired PFTs due to high morbidity/mortality risk, as stated in the reference. While it discusses individualized planning and supportive care, it omits the key recommendation to consider alternative, less intensive approaches, and thus may mislead regarding safety in this high-risk group."
  },
  "876": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant elaboration, and contains no inaccuracies or omissions."
  },
  "877": {
    "score": 2.0,
    "explanation": "2: The model answer identifies phosphodiesterase (PDE) as the target and provides a detailed mechanism, but it omits the key fact that the relevant enzyme is specifically cGMP-specific 3',5'-cyclic phosphodiesterase, not just any PDE. This is a moderate factual omission, as the reference requires this specificity."
  },
  "878": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly stating that pleurodesis alone is insufficient and systemic targeted therapy is necessary and should be initiated concurrently. Additional explanations are accurate, clinically relevant, and there are no inaccuracies or omissions."
  },
  "879": {
    "score": 4.0,
    "explanation": "4: The model answer covers nearly all key facts, correctly identifying the syndrome, the use of recombinant growth hormone, and its mechanism as a receptor agonist, but emphasizes \"hormone replacement therapy\" as the class rather than \"pituitary hormone receptor agonists,\" which is a minor wording inaccuracy that does not alter the clinical meaning."
  },
  "880": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly asserts that adjuvant therapy in stage IB (T2a N0) NSCLC inherently requires additional high-risk features, contradicting the reference, which states that adjuvant therapy may be considered based on tumor size or clinical factors alone; this is a moderate factual error despite otherwise accurate details."
  },
  "881": {
    "score": 4.0,
    "explanation": "4: The model answer correctly explains the mechanism and identifies muscarinic agonists as mediators, but does not explicitly name \"cholinesterase inhibitors\" as the class responsible, which is the direct answer required; otherwise, the explanation is accurate and clinically relevant."
  },
  "882": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies the clinical syndrome, drug (chloroquine/hydroxychloroquine), and its mechanisms, but it incorrectly names the drug class as \"antimalarials\" rather than \"enzyme inhibitors,\" missing the key fact required by the reference answer. Otherwise, the explanation is accurate and relevant."
  },
  "883": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies glucocorticoid (corticosteroid) receptors, thoroughly explains the mechanism, and provides relevant, accurate additional information without any inaccuracies or omissions."
  },
  "884": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the contraindications to concurrent chemoradiation, and provides clinically relevant alternative strategies without any inaccuracies or omissions."
  },
  "885": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate rationale, guideline citations, and relevant additional context without inaccuracies or omissions."
  },
  "886": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts and provides detailed, guideline-based reasoning, but it incorrectly recommends H&P and chest CT every 6 months rather than every 3–6 months, omitting the nuance that adjuvant radiotherapy aligns surveillance with higher-risk protocols; this is a moderate omission."
  },
  "887": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides correct and clinically relevant additional details, and contains no inaccuracies or omissions."
  },
  "888": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies CYP2C9 inhibitors, explains the antibiotic mechanism, the interaction with warfarin, and the clinical significance, with no inaccuracies or omissions."
  },
  "889": {
    "score": 3.0,
    "explanation": "3: The model answer correctly explains that EBRT is standard for stage IIIA NSCLC and not solely for obstruction or recurrence, but it omits the key clinical fact that, in the specific context of a solitary pulmonary nodule, EBRT typically implies symptomatic or recurrent disease rather than routine use. This is a moderate omission relative to the reference answer."
  },
  "890": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies JAK3 as the target, and provides accurate, clinically relevant supporting details without any inaccuracies or omissions."
  },
  "891": {
    "score": 3.0,
    "explanation": "3: The model answer provides a detailed, guideline-based comparison of the risk and recommendations for brain MRI in stage II versus stage IIIA NSCLC, but it incorrectly downplays the necessity of brain MRI in stage II by suggesting it is often optional, whereas current guidelines recommend it for stage II and above; this constitutes a moderate factual omission."
  },
  "892": {
    "score": 2.0,
    "explanation": "2: The model answer covers some relevant background and guideline-based recommendations but directly contradicts the reference answer by stating osimertinib is not appropriate first-line therapy, and incorrectly asserts that a concurrent KRAS mutation is a strong contraindication to EGFR TKI use, which is not universally accepted. It omits the key fact that osimertinib is considered appropriate first-line therapy for these uncommon EGFR mutations regardless of smoking history or other mutations, as per the reference."
  },
  "893": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies the mechanism as beta-lactam-mediated inhibition of penicillin-binding proteins (transpeptidases) and explains its clinical relevance, but it does not explicitly use the term \"transpeptidase inhibitors\" as in the reference, representing a minor wording inaccuracy."
  },
  "894": {
    "score": 3.0,
    "explanation": "3: The model answer provides a detailed and accurate explanation of bismuth subsalicylate’s protective coating action but underemphasizes the acid-base/pH alteration, which is the key fact in the reference answer; it covers about 70-89% of the required content with minor omissions in focus."
  },
  "895": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies cyclooxygenase (COX) as the enzyme inhibited and provides accurate, relevant explanation, but does not specify the isoform COX-1 (prostaglandin G/H synthase 1) as in the reference answer, representing a minor omission."
  },
  "896": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies the interleukin-6 receptor as the molecular target and provides accurate, relevant clinical context, but it omits specifying the \"alpha subunit\" as in the reference answer; this is a minor omission that does not alter the clinical meaning."
  },
  "897": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies cyclooxygenase (COX) as the target and explains aspirin’s mechanism, but it does not specify COX-2 (prostaglandin G/H synthase 2) as the primary enzyme relevant to inflammation, missing a key detail from the reference answer."
  },
  "898": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately identifies the drug class and mechanism, and provides clinically relevant, correct additional detail without any inaccuracies or omissions."
  },
  "899": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts, correctly emphasizing that symptomatic obstruction is the main indication for endobronchial interventions, but introduces less common scenarios (e.g., pre-emptive intervention, diagnostic biopsy) that are not standard indications for therapeutic ablation/stenting and may confuse the primary clinical point; overall, it slightly overcomplicates the answer but does not provide unsafe advice."
  },
  "900": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies CD2 as the molecular target, accurately explains the drug (alefacept), its mechanism, and clinical relevance, and distinguishes it from other biologics; there are no omissions or inaccuracies."
  },
  "901": {
    "score": 2.0,
    "explanation": "2: The model answer overstates the need for immediate interruption, contradicting the reference, which allows either completing or interrupting therapy; while it provides detailed rationale and guideline citations, it omits the acceptability of both approaches, constituting a moderate factual omission."
  },
  "902": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the contraindications of capmatinib and tepotinib in severe hepatic impairment, and appropriately recommends immunotherapy-based regimens as alternatives; all additional details are correct and clinically relevant."
  },
  "903": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts, emphasizing the role of palliative radiotherapy for urgent symptoms and the importance of systemic therapy, but it overcomplicates the decision and suggests systemic therapy first for non-urgent symptoms, which partially contradicts the reference's clear prioritization of radiotherapy for immediate symptom control; overall, it is thorough but introduces minor inaccuracies in emphasis."
  },
  "904": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, correctly identifies chylomicrons as the bypassed molecular component, and provides accurate, relevant explanations without any inaccuracies or omissions."
  },
  "905": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the contraindication of standard chemotherapy, discusses alternative strategies, and emphasizes multidisciplinary management without any inaccuracies or omissions."
  },
  "906": {
    "score": 2.0,
    "explanation": "2: The model answer provides a thorough discussion of glucocorticoids, which are indeed first-line for lichen sclerosus, but the reference answer specifically asks for \"estrogen receptor agonists\" as the class matching the described mechanism. The model omits this key fact and instead focuses on glucocorticoids, which is a moderate factual error given the question's emphasis on the mechanism related to estrogen."
  },
  "907": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies the cytochrome P450 system and relevant isoenzymes (CYP3A4, CYP2C9), covers the clinical implications, and provides accurate, relevant extra information. However, it omits mention of CYP2C19, which is specifically highlighted in the reference answer, constituting a minor omission."
  },
  "908": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies miltefosine and explains its mechanism and resistance via ABC transporters, but incorrectly names P-glycoprotein (P-gp) as the key transporter, rather than BCRP (ABCG2) as in the reference; this is a moderate factual error."
  },
  "909": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies topoisomerase IV as a molecular target and provides accurate, relevant additional information about fluoroquinolones and DNA gyrase, but does not explicitly single out topoisomerase IV as the answer, slightly diluting focus. No clinically significant errors or omissions are present."
  },
  "910": {
    "score": 2.0,
    "explanation": "2: The model answer overemphasizes the systemic nature of M1a disease and incorrectly states that curative-intent local therapy is inappropriate, missing the key fact that, in select cases of technically resectable solitary contralateral nodules, curative management as two primaries is possible. It also introduces unnecessary complexity and implies that surgery is never appropriate up front, which is not accurate per the reference."
  },
  "911": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies the clinical scenario, drug, and its immunomodulatory action, but incorrectly names TNF-α as the most direct molecular target, omitting VEGF-A, which is specified in the reference; otherwise, the explanation is thorough and relevant."
  },
  "912": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies the clinical scenario, the drug (defibrotide), and its mechanism as a fibrinolytic agent, but does not specifically name \"tissue plasminogen activators\" as the reference answer does; this is a minor wording inaccuracy, but the mechanistic explanation is otherwise accurate and complete."
  },
  "913": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts and provides strong rationale for immediate switching, but it omits that both immediate switch and completion of current therapy are acceptable options per the reference. It overstates the need to interrupt therapy, missing the nuance that either approach is reasonable."
  }
}